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SUMMARY 
Sleep and sex are two fundamental human activities.  The impact of having either chronically poor 
sleep quality from obstructive sleep apnoea (OSA) or impaired sexual function can have 
detrimental effects on physical and mental health, and can result in a significantly reduced quality 
of life.  The presence of either OSA or erectile dysfunction (ED) in men can also be indicative of a 
high risk of developing cardiovascular disease.  The two conditions are more common in 
overweight older men, often co-exist, and have been found to be independently associated.   
Treatments for erectile dysfunction, such as testosterone supplementation or PDE-5 inhibitors, 
and for obstructive sleep apnoea, in terms of Continuous Positive Airways Pressure (CPAP) are 
both readily available.   The sales of supplemental testosterone, PDE-5 inhibitors and CPAP have 
all substantially increased in the last 20 years.  However, there are only scant small uncontrolled 
studies regarding the impact of treatment of one condition (OSA or ED) in the context of the 
other.   
Testosterone prescriptions have increased 500% in the last 20 years.  Given the overlap of many 
symptoms of obstructive sleep apnoea and testosterone deficiency; there is likelihood that men 
with untreated OSA are being provided supplemental testosterone.  The efficacy of testosterone 
in untreated OSA in regards to sexual function and quality of life has not been investigated.   
CPAP use, to treat OSA, has increased substantially since it was first reported in 1981.  
Observational and non-treatment or alternative treatment controlled studies have shown some 
improvement in erectile function in men with OSA; however the majority of these have been in 
men not specifically included on the basis of erectile function.   
 - xiii - 
Since the successful use of PDE-5 inhibitors to treat erectile dysfunction, first patented in 1996, 
sales of PDE-5 inhibitors have substantially increased.  Only two studies by the same author, both 
lacking an adequate placebo control, have specifically assessed the efficacy of a PDE-5 inhibitor, 
administered on demand, in an OSA population.  There remains the possibility through theoretical 
mechanisms that PDE-5 administration may worsen OSA, which was confirmed by a small study.  
Thus the safety and efficacy of daily dose PDE-5 inhibitors in men with OSA are yet to be fully 
studied.   
This thesis aims to investigate and report, through the use of gold-standard and well established 
methods, using randomised controlled protocols, the following 3 unreported questions: 
1. The efficacy of testosterone on sexual function, quality of life, and neurocognition in men with 
OSA. 
2. The effects of CPAP on sexual function, quality of life, mood and relationship in men with OSA 
& ED. 
3. The efficacy and safety of a low daily dose PDE-5 inhibitor (Vardenafil) in men with OSA & ED 
Chapter 1 provides a background and review of current literature on sleep disordered breathing, 
sexual function, and the relationship between the two. 
Chapter 2 describes a randomised controlled study in 67 men with moderate-severe OSA who 
received testosterone injections 3 times over a 12 week period.  In this study, testosterone was 
found to increase libido, but not erectile function nor any other sexual function in men with OSA.  
 - xiv - 
Chapter 3 describes the methodology used in a multi-centre 2x2 factorial double blind double 
placebo trial of 12 weeks treatment with both CPAP and Vardenafil, a PDE-5 inhibitor in 61 men 
with OSA and ED.  The analyses of interactions between the two treatments are reported here. No 
interactions were found, thus the two treatments can be presented separately.  
Chapter 4 reports on the first half of the above mentioned study.  Overall, CPAP, compared to 
Sham CPAP improved overall sexual satisfaction. However, in those who adhered to treatment, 
there were additional improvements in erectile function and libido, accompanied with 
improvements in mental health, sleepiness and several quality of life parameters. 
Chapter 5 reports on the second half of the above study.  This chapter describes the efficacy of 
10mg daily dose Vardenafil in men with OSA and ED as well as the effects on sleep disordered 
breathing.  This dose of Vardenafil did not worsen OSA, but did not improve erectile function at 
the end of the study.  
The thesis concludes with a summary of findings and their implication for clinical applications. 
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REM   Rapid Eye Movement 
ODI3  Oxygen desaturation (minimum 3%) Index  
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TDS  Testosterone Deficiency Syndrome 
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accuracy, all references to AHI and RDI will use the reported nomenclature.   
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1. Literature Review 
1.1. MALE SEXUAL FUNCTION 
Healthy sexual function is not only necessary for reproductive success but is also a contributor 
to a satisfactory quality of life [1, 2].  Male sexual health requires incorporation of biological, 
psychological and social factors in order to shape sexual behaviour, and to maintain sexual 
drive, erectile function, and overall satisfaction [3].  A classic description of sexual response is 
that described by Masters and Johnson, this being a four stage model of sexual desire, sexual 
excitement, orgasm and resolution [4]. All of these phases are required to maintain a healthy 
sexual function. Various aspects of sexual function such as arousal, desire, and behaviour 
intertwine to have influence on one another.  These different facets are driven by a complex 
mix of neurochemical, neuroanatomical, psychological and social factors which can be difficult 
to report in a quantitative research [5].   
1.1.1. Sexual Desire 
Known by various names, including ‘libido’, ‘sex drive’, ‘sexual motivation’, ‘sexual interest’, and 
‘lust’, sexual desire is an important aspect of human existence [6]. The intensity of sexual desire 
can vary between individuals and also within an individual over a given time frame [7]. Defining 
sexual desire and describing its manifestation is difficult, and much of the physiology is 
unknown [7, 8]. A particular area of difficulty is the classification of sexual desire into two 
separate components: dyadic and solitary desire, that is, interest in behaving sexually with a 
partner or by oneself, respectively, which is often not taken into account in clinical quantitative 
research [9]. 
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Clinically, sexual desire can be readily understood, however there is no single accepted method 
used for quantitative measurement [6].   Levels of sexual desire can be difficult to measure due 
to reliance on self-report and self-knowledge in a complicated mix of social and psychological 
processes, particularly when asked retrospectively [5].  There are several questionnaire based 
tools which have been used in the scientific literature, however clinicians often find these 
difficult to accept due to the complexity of contributors to sexual desire [6].  Behavioural 
observations, such as documenting masturbation frequency, has been suggested as a 
measurement of sexual desire, as this activity is less constrained than other sexual behaviours 
by external factors such as partner presence, risk of pregnancy or disease [10].  However, two 
problems exist using this as a measurement technique.  Firstly, masturbation frequency is an 
inferred measurement assuming there is a translation of desire into masturbation, which is not 
always the case, and secondly, engaging in this behaviour may be limited by an individual’s 
social and religious beliefs. 
There are many influences upon the level of sexual desire, which can include hormone levels, 
age, weight, gender, social situation, education, health, and the importance of sex to the 
individual [6, 11-15]. The presence of a relationship may have some influence in sexual desire 
[14], however, the length of the relationship has not been shown to affect sexual desire in 
males, unlike that which occurs in females  [16].  If sexual desire in a relationship differs 
between partners which results in a discrepancy between the desire of one partner and actual 
levels of intercourse, relationship quality can be impacted, particularly over longer relationship 
lengths [17].   
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Suggestion has been made that an ideal method of measuring sex drive is to combine 
questionnaire data, behavioural data and in-depth interview. However, this is not always 
logistically possible in clinical trials [10].  The most available and utilised option in research is to 
use validated questionnaires to quantify sexual desire and related facets of sexual function.  
1.1.2.  Normal Erectile Function 
Erectile function is a complex process, requiring input from the vascular, endocrine, and central 
and peripheral nervous systems.  Two types of erections exist – those occurring due to a 
physical or psychological stimulus of some kind and those occurring without stimulus during 
sleep. An erection occurs when an endogenous release of nitric oxide in the nerve endings of 
the penis and from vascular endothelial cells promotes guanylyl cyclase to produce cyclic 
guanosine monophosphate (cGMP). An increase in cGMP can also occur by inhibiting 
phosphodiesterase type 5 (PDE-5) in the corpus cavernosum via exogenous administration of 
PDE-5 inhibitors. This increase in cGMP allows smooth muscle relaxation, arterial dilatation and 
venous constriction which results in an erection [18].  Testosterone levels also influence this 
function, since testosterone is thought to have effects on nitric oxide release, with insufficient 
amounts associated with a reduction of pressure in penile arteries during erections [19-21].   
1.1.3. Sleep Related Erections 
Long before described in scientific literature, the existence of nocturnal erections was common 
knowledge [22]. The religious community condemned their occurrence, believed to be resulting 
from impure thoughts, and devices were developed to prevent them [22].  Erections during 
sleep have been described in the scientific literature since the 1940’s [23, 24].  These were 
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confirmed to be associated with REM sleep, some thirteen years after the discovery of this 
stage of sleep [25, 26].  Further investigation found that these nocturnal erections correspond 
with about 90% of REM sleep cycles, this being 4 or 5 periods, lasting a total of 1.5-3 hours 
during the sleep period [7].  The nomenclature of this phenomena was coined by Karacan in the 
1960’s as “Nocturnal Penile Tumescence (NPT)”, rather than the phrase “penile erections 
during sleep”, which was considered too explicit for the time [22].  In 1991, the phrase “sleep 
related erections (SRE’s)” was adopted in the International Classification of Sleep Disorders 
[27].  The cause of these predictable and reliable SRE’s which occurred in healthy men was 
found to be due to increased blood flow to the penis and were not found to be related to any 
sexually themed dreams, nor sexual activity [22, 28].  Neither sexual abstinence nor pre-sleep 
sexual activity, either intercourse or sexual arousal affect subsequent erections during sleep 
[22, 29].  Although the neurophysiological basis of these SRE’s is not completely understood, 
these episodes of penile blood engorgement increase corporeal oxygenation and may function 
to protect the morphological integrity of the penis [30, 31]. Without regular oxygenation, 
fibrosis of the smooth muscle may occur leading to atrophy of the corpora cavernosa [32].  
Sleep related erections can be affected by a number of biological influences.  Advancing age has 
been shown to reduce the number of episodes of SRE’s, reducing by about 25% between the 
ages of 13 and 70 years [7].  This reduction is more prominent after age 60 [33].    The presence 
of diabetes has also been shown to reduce SRE’s.  In a study of 100 diabetic and 400 non-
diabetic men, those with diabetes had fewer SRE’s, less tumescence time, diminished penile 
circumference increase, and lower penile rigidity than those without [34].  Similarly, smokers 
have a dose response relationship with increased pack year histories impairing SRE’s [35].  
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1.1.4. Sexual Dysfunction 
Estimates of the broad diagnosis of male sexual dysfunction in the community vary between 10 
to 50%, however, many men are left undiagnosed and untreated due to social discomfort by 
either the patient or physician [36].  Sexual dysfunction, including low sexual desire and erectile 
or ejaculatory difficulties, can have a significant effect on quality of life.  Any of these disorders 
can contribute to difficulty in initiating or maintaining a relationship, and can contribute to 
negative impact on mood, self-esteem and life satisfaction, which can also be bidirectional, by 
creating or worsening the level of sexual dysfunction [37].   
Low desire for sexual activity can cause distress to the individual and create conflict in a 
relationship [38].  The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) defines 
hypoactive sexual desire disorder as “deficient or absent sexual fantasies and desire for sexual 
activity” resulting in significant distress and is not explained by any other disorder [39]. In a 
large (n=1749) cohort of American adults who had been sexually active in the last year, 15% 
reported low sexual desire [1].  Likewise, low dyadic sexual desire found was found in 13.5% of 
community dwelling Australian men aged 35-80 years, whereas 68% reported low solitary 
sexual desire [40].  Australian data collected as part of the Global Study of Sexual Attitudes and 
Behaviours (n=750), found that after adjusting for age, 17% had low sexual desire [41].  In a 
large (n=3714) sexual dysfunction clinic population, low sexual desire was found to occur 
concurrently with other sexual problems of erectile dysfunction, premature and delayed 
ejaculation in 38%, 28% and 50% of participants respectively [13], however, causality and the 
direction thereof cannot be determined. In large population studies of men aged over 50, a 
gradual decline in sexual desire has been seen with increased age [42, 43]. A prominent 
 - 6 - 
physiological association with low sexual desire is low testosterone, found to be in 40% of 
cases, [13] further explained in section 1.2.5. More recent work has also found that low 
estradiol, a metabolite of testosterone, also contributes to a reduction in libido [15]. Other 
medical contributors to low libido include side effects of anti-depressant medication [44], 
hyperprolactinemia [13] and lower urinary tract symptoms [45].  
Erectile dysfunction (ED) is defined by the National Institutes of Health (NIH) Consensus 
Development Conference as the inability to attain and/or maintain penile erection sufficient for 
satisfactory sexual performance [7, 46, 47]. A more recent clarification of the diagnosis specifies 
that symptoms must have been present for at least 3 months, except when trauma or surgically 
induced ED is involved [48].  In the past, nomenclature of erectile dysfunction included the term 
“impotence”, which was derived from Latin meaning “lack of power” [49] which, in a sexual 
sense could relate to either sexual desire or erectile function.  This terminology has been used 
in the past to include all manner of male sexual dysfunction, including erectile dysfunction, as 
well as ejaculatory and orgasmic dysfunction [50, 51]. Usage of the term has changed over 
time, with impotence more recently referring to that of the inability to obtain an erection.  
Since 1992, via a consensus document from the NIH, the more precise term ‘erectile 
dysfunction’ has replaced ‘impotence’ due to confusion about its exact meaning [52].  
Prevalence rates of ED differ between studies due to heterogeneous measurement techniques 
and populations, however, all have found the incidence of erectile dysfunction to increase with 
age. Approximately 10-17% of all men report a degree of ED, with this number increasing to 
approximately 50-60% of men in older age groups [1, 42, 53-57].  The Massachusetts Male 
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Aging study, conducted in the late 1980s on a sample of 1709 community dwelling men aged 40 
to 70 years reported the incidence of at least some level of erectile dysfunction as being 52% 
[54].  Data from this study was used to estimate that in 1995, 150 million men across the world 
experienced some degree of erectile dysfunction, and this prevalence will increase to 320 
million men by 2025 [58].  In a population including younger men in Brazil, overall 17% of men 
reported some degree of ED, ranging from 7.3% in the youngest age group (20-29 years) 
through to 63% in those aged over 60 [57].  Australian data, collected as part of a global study, 
found that of the 750 men surveyed, 21% experienced erectile difficulty [41].  A study 
performed in South Australia based on a community sample, found that overall, 25% of men 
aged over 40 were unable to achieve an erection.  When stratified by age, of those men aged 
40-49, about 3% reported significant erectile dysfunction, with erections being insufficient for 
intercourse, while those in the oldest age bracket, men aged over 90 years, 93% reported such 
difficulties [59]. In a general practice based sample in Perth of 1240 adult men, about 40% of 
men reported some degree of erectile dysfunction [60]. This higher prevalence rate found in 
this latter study may be due to health being slightly lower in general practice than in the 
community. Of those men who report ED, two studies have found that less than 30% are 
receiving treatment [2, 55]. 
Several modifiable risk factors for ED have been identified. Obesity and a sedentary lifestyle 
increases the likelihood of ED [61, 62] as does significant alcohol consumption (>3 drinks per 
day) [63].  In the Massachusetts Male Aging Study, a prospective population study of men aged 
40-70, 513 men had no ED or diabetes at baseline.  When these participants were reassessed 6-
12 years later, those who had smoked or had a BMI greater than 28 at baseline had an 
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increased risk of developing ED [62].  Weight reduction strategies have been shown to improve 
ED [64, 65].  A high proportion (40%) of those with diabetes have ED [66], as do those with low 
testosterone, [67] further explained in section 1.2.5. Chronic periodontitis has also been 
correlated with ED, which may be related to atherosclerosis and its link with dental disease 
[68].  Additionally, the lack of a regular partner has established as a risk factor for ED [40].  
In the first half of the century, prior to 1970, erectile dysfunction was thought to be solely 
psychogenic [22]. Although early reports of the existence of predictable nocturnal erections 
associated with REM sleep were described in the 1940’s [24], it was not until 1970’s that 
impaired nocturnal erections were associated with erectile dysfunction.  At the time, 
suggestion was made that by measuring nocturnal erections, the distinction of the cause of ED 
being a psychological or organic basis could be identified [69].  The assumption was that if 
nocturnal erections are obtainable, then there is evidence that there is erectile capacity [22].  If 
nocturnal erections occur during sleep but not during wakefulness, then there must be 
psychological, behavioural or situational influences, rather than a physiological cause [22, 70]. 
This binary classification of ED being either of psychological or organic origin has since been 
considered an oversimplification, but the concept is still used [22]. Organic ED comprises 60-
80% of all ED and refers to cases that are caused by underlying chronic diseases such as 
Parkinson’s disease, stroke, diabetes, hypertension and atherosclerosis [46], as well as 
endocrine system disorders [71]. Psychogenic causes include performance anxiety, lack of 
sexual excitement, depression and schizophrenia [46]. A large population study (n=1749) found 
the presence of emotional issues or stress increased the risk of developing ED in the order of 
3.5 times [1]. Additionally, higher scores in indexes related to anger and depression, in another 
 - 9 - 
large population study (n=513) was found to increase the risk for developing ED [54].  Since the 
advent of and popularization of Sildenafil, in a complete turnaround from the original thought 
that ED was purely psychological, suggestion has now been made that sexual dysfunction has 
been increasingly attributed to medical causes and overlooks the contribution of psychological 
and social factors [11].   
Several studies have shown that the existence of ED provides an early warning sign that there is 
an increased risk for developing cardiovascular disease (CVD).  CVD has become the main cause 
of death in the developed world. Current estimates from the World Health Organisation predict 
that almost 23.3 million people will die of cardiovascular disease during the year of 2030 [72]. 
ED has been suggested as an early warning sign for cardiovascular disease, even in those men 
without cardiovascular symptoms [73].  Recognition that ED is an important sentinel event for 
CVD is growing among health professionals.  ED and CVD share risk factors including older age, 
obesity, cigarette smoking, diabetes, hyperlipidaemia and hypertension [73, 74]. As a result, 
those men who present with ED should be screened for CVD and associated risk factors [75]. 
Two large prospective studies have shown that baseline coronary risk factors such as age, 
smoking, and being overweight, are associated with subsequent ED in healthy men after 8-10 
[62] and 25 years follow-up [76].  More recent prospective studies [75, 77-79] and two 
retrospective studies [80, 81] provide further evidence that ED can predict subsequent CVD.  
Additionally, a large population-based longitudinal study found that self-reported ED was 
associated with both CVD-mortality and all-cause mortality (hazard ratios 1.43 and 1.26 
respectively) after adjusting for known risk factors [82].  This high predictive association has 
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been shown to be as comparable as smoking or familial history of myocardial infarct as a risk 
factor for developing cardiovascular disease [75, 82, 83].  
1.1.5. Measurement of Sexual Function 
Several questionnaires have been developed to subjectively assess sexual function in the male.  
The European Male Aging Study (EMAS) developed a 20 item questionnaire of particular 
application for the aging male, with questions relating to changes in and distress caused by 
sexual dysfunction, as well as overall sexual functioning  [84, 85].  The Golombok Rust Inventory 
of Sexual Satisfaction (GRISS) questionnaire comprises 28 questions and has domains for 
erectile dysfunction, premature ejaculation, infrequency, avoidance, non-sensuality and 
dissatisfaction [86, 87].  The Brief Sexual Function Inventory (BSFI) was developed for a urology 
based population and comprises 11 items regarding desire, erection, ejaculation and the 
perception of problems related to these domains [88]. The International Index of Erectile 
Function (IIEF) is a series of 16 questions, comprising domains of erectile function, sexual 
desire, orgasmic function, and overall function each rated from 0 or 1 to 5.  Higher scores 
correspond to a higher number of events or satisfaction [89, 90].   This latter questionnaire is 
the recommended methodology to assess erectile function as well as the endpoint of clinical 
trials for ED [89, 91].  This subjective questionnaire, developed by the pharmaceutical company 
Pfizer in conjunction with clinical expertise, was first published in 1997 and has become the 
‘gold standard’ measurement of ED in both clinical and research environments [89-92]. 
Quantification of satisfaction with treatment for ED can be measured using the Erectile 
Dysfunction Inventory of Treatment Satisfaction score [93].   
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Currently there is no accepted method of objectively measuring sexual desire [94].  The closest 
is the measurement of sexual arousal, by penile plethysmography, which measures erectile 
response to audio, visual or emotional cues, more commonly used to assess sex offenders, in 
order to assess patterns of arousal and treatment efficacy [95].   
Several incarnations of objectively measuring erections have been developed. In the early 
1960’s a device which measured penile volume changes was reported, used in the context of 
testing the identification of an individual to homosexual or heterosexual tendencies [96, 97]. 
This device was found to be difficult to use during sleep. Three alternative methods to monitor 
erections during sleep were trialed in the mid 1960’s, including a water filled cuff and a skin 
thermometer.  The third, a mercury strain gauge, was found to be the more superior 
methodology [98].  This technique was further developed and found to be a cheap reliable 
method of monitoring SRE’s [99].  A simpler technique, reported in 1980, involved placing a row 
of easily torn stamps, similar to postage stamps, snugly around the penis.  If these stamps were 
torn along the perforations in the morning, erections were assumed to have occurred during 
sleep [70].  The late 1980’s saw development of the ‘RigiscanTM’ device, using tension cables to 
monitor SRE’s [100].  In a paper by Karacan in 1994, comment was made that monitoring of 
nocturnal erections was being used successfully by physicians around the world to determine 
the cause of erectile dysfunction [101].  Since the advent of successful pharmaceutical 
treatment for ED in the late 1990’s, however, no further development of SRE measurement 
techniques has occurred.  
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Thus the most current technique to measure SRE’s is the Rigiscan device, which monitors the 
frequency and duration of tumescence and rigidity of the penis during sleep [100].  The 
recording device is strapped to the participant’s thigh using a commercially available strap with 
customised pocket to hold the device for the duration of the sleep period.  Two small tension 
cables extend from the device to the penis, which move freely through a conduit and 
disposable loop covers. These loops are placed around the base and tip of the penis which 
gently tighten and release every 15 seconds at a force of 114 grams. After the dilatation of the 
loop, the penile tissue rebounds to the pre-intervention state.  During this rebound, a 
measurement of the erectile tissue engorgement is taken. If an increase in tumescence is 
detected, compared to previous results and has shown at least a 6 millimetre increase, a 
second measurement is taken every 30 seconds.  This second measurement records rigidity by 
tightening the loops to a linear force of 283.5 grams and determines the cross sectional 
response to radial compression [102].  
Measurements obtained from the Rigiscan include the number of erections (defined as a 20% 
increase in tumescence from baseline lasting at least 3 minutes) per night, erection duration in 
both time and per cent of recording, and percentage rigidity (compared to 100% being a hard-
rubber cylinder).  Additionally, calculated variables reported are rigidity activation units (RAU’s) 
which are a product of minutes spent at a given rigidity level in decimal form, summated for the 
duration of the erectile event, for both the base and the tip, as well as tumescence activation 
units (TAU’s), which represent the duration of an erectile event multiplied by the percentage 
increase in circumference, as a decimal, over the baseline tumescence, again for both base and 
tip of the penis [103].  A study conducted in 1996, soon after these latter measurement units 
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were included in the assessment software, concluded that tip TAU’s were the best overall 
measurement correlating with the diagnosis of erectile dysfunction, closely followed by both 
base TAU’s and RAU’s [104].  Repeating this study with a larger sample some 13 years later 
found that the diagnostic accuracy of this device did not go above 75% in any of the 
parameters, due to a large overlap in the RAU and TAU in that of men considered to have 
normal and abnormal erectile function, however, the authors recognised its utility in a research 
context and in documenting treatment efficacy in a clinical setting [105].  The frequency of 
monitoring nocturnal erections has declined since the advent of PDE-5 inhibitors, namely the 
release of Sildenafil in the late 1990’s [22].  Due to the efficacy in treating ED using these 
medications, measurement of nocturnal erections generally only occurs in a clinical setting 
when available medications do not improve erectile function [106].   
1.1.6. Treatment for Erectile Dysfunction 
One of the main first line oral pharmacotherapies for men with ED is the use of PDE-5 
inhibitors.  Erections are normally reversed by the enzyme phosphodiesterase type 5 (PDE-5) by 
breaking down cyclic guanosine monophosphate (cGMP) which relaxes the corpus cavernosum 
muscle allowing blood to fill the muscle and an erection to occur [18].  PDE-5 inhibitors impede 
this process, allowing erections to occur and be maintained.  The efficacy of these medications 
was found accidently during the development process of using PDE-5 inhibitors for the 
treatment of cardiac conditions in the mid 1990’s due to a recurrent unintentional side effect of 
improved erectile function [49]. The most commonly used PDE-5 inhibitors are Sildenafil, 
Tadalafil, and Vardenafil, all of which have been shown to be safe, efficacious and well 
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tolerated [107, 108].  Less available and subsequently less studied are Avanafil, Udenafanil and 
Mirodenafil [109, 110].  Rates of use of PDE-5 inhibitors have substantially increased over the 
last 10 years, without a concomitant increase in diagnostic testing for the cause of ED [111].  
In the few studies comparing PDE-5 inhibitors, the most preferred by patient is reported to be 
Tadalafil, possibly due to the ability to maintain sexual spontaneity [108, 112].  The half-life of 
Tadalafil has been found to have the longest out of the PDE-5 inhibitors, of around 17.5 hours, 
compared to that of Sildenafil (3.8 hours) and Vardenafil (3.9 hours) [113].  Tadalafil also has an 
added benefit of not being affected by food intake, whereas the efficacy of Sildenafil and 
Vardenafil is reduced when a high fat meal is consumed around the same time as dosage [114].  
Traditionally, PDE-5 inhibitors have been taken under an ‘on demand’ regime.  An alternate 
treatment is once daily administration, which can be both advantageous, by restoring the 
spontaneity of sexual activity, as well as disadvantageous due to an increase in burden to the 
patient, resulting in a potential for a reduction in adherence to treatment [110].  Several studies 
have found that daily administration of Tadalafil was more effective than that of an on-demand 
basis [115-117]. Similarly, Vardenafil has been shown to be effective when given daily for 
around 40% of those for whom on-demand administration was ineffective [118].   This is not a 
consistent result, however.  In a study of men with mild to moderate ED, no benefit was found 
with once daily administration of 10mg Vardenafil compared with on demand dosage, with the 
latter regime having a trend toward a higher score in the erectile function domain of the IIEF 
questionnaire [119]. Similarly, in a group of patients post bilateral nerve-sparing radical 
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prostatectomy surgery, on-demand Vardenafil was more effective than daily administration 
[120]. 
Unfortunately, up to 30% of men who are treated with PDE-5 inhibitors for ED do not have an 
improvement in their symptoms [121].  For some of these men, changing the type of PDE-5 
inhibitor, such as from Sildenafil to Vardenafil has been shown to improve erectile function 
[122].  For others, the addition of testosterone therapy has been shown to be efficacious [123-
127].  The expression and function of the enzyme PDE-5 can be modulated by testosterone 
[128], meaning a low endogenous level of testosterone may reduce the number or efficiency of 
these enzymes, reducing the efficacy of PDE-5 inhibitor pharmacotherapy [129]. Testosterone is 
thought to have effects on nitric oxide release, with insufficient amounts associated with a 
reduction of pressure in penile arteries during erections [19].   
The effect of PDE-5 inhibitors on sleep related erections has been inconsistent.  In two studies 
of young healthy men with normal erectile function, a dose of 100mg of Sildenafil increased 
SRE parameters as measured by Rigiscan [130, 131].  In a study of men with ED, no 
improvement was found with Tadalafil on SRE’s when measured by Nocturnal 
Electrobioimpedence Volumetric Assessment, which calculates penis blood flow [132]. Using 
the same SRE monitoring technique, another study found improvements when Sildenafil was 
administered to men with organic, but not psychogenic ED [133].  Also finding improvements 
was a study using a combination of testosterone therapy and PDE-5 inhibitors in hypogonadal 
men. This study found that the combination improved SRE’s greater than the sum of each 
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therapy used on its own [134].  A similar result was found with the addition of on demand PDE-
5 inhibitor for hypogonadal men using testosterone therapy for 6 months [135].  
PDE-5 is the isoform generally expressed in the penile corpus cavernosum, however it is also 
found in other areas of the body, including the pulmonary and systemic vasculature and several 
other smooth muscle structures, which have been shown to be affected by PDE-5 inhibitors 
[136]. The low side effect profile and a greater understanding of cGMP regulated mechanisms 
have prompted many investigations in alternative uses of these medications. The original 
purpose of PDE-5 inhibitors was for cardiac related conditions before the discovery of the 
effects on erectile function.  Since then, Sildenafil has been approved for pulmonary 
hypertension, and has been shown to improve flow mediated dilatation in chronic heart failure 
patients [136].  Additionally, a meta-analysis of PDE-5 inhibitors for Raynaud’s phenomenon, a 
disease of excessive vasoconstriction, found that overall there is a significant but moderate 
effect in reducing the frequency and duration of Raynaud’s exacerbations [137].  Lower urinary 
tract symptoms, continence after prostatectomy and urodynamic function after spinal cord 
injury have also all been shown to improve with PDE-5 inhibitors [138-140].  Therefore the use 
of daily administration of PDE-5 inhibitors may have additional positive effects apart from 
improved erectile function.  
An alternate method of improving erectile function is by the administration of testosterone 
therapy, further described in section 1.2.4. 
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1.2. TESTOSTERONE  
Testosterone is the main androgen which mediates pubertal maturation and preserves sexual 
characteristics and function in men throughout life. It is the main anabolic hormone and has 
wide ranging effects on human physiology.  This hormone contributes toward many aspects of 
well-being and quality of life, including sexual function, strength, vitality, and some 
neurocognitive function. 
The link between the testicles, now known to be the site of testosterone production, and their 
removal, with changes in behaviour and sexual characteristics have been noted by farmers in 
their livestock for at least 6000 years [141].  Historical references to human eunuchs, likewise, 
have noted this connection since at least the time of Ancient Greece [142]. In modern scientific 
literature, one of the first mentions of this phenomena was in 1849 [143]. Chemical 
messengers, first named “hormones” in 1905, were described in the Lancet, after experiments 
finding substances acted upon organs geographically distant from their place of origin [144]. 
Pharmaceutical companies embraced these new developments and in the early twentieth 
century three of these companies competed to isolate the hormone from the testicles [141].  
The first team to succeed in 1935 was supported by Organon, and named the hormone 
“testosterone” [145], with another team, funded by Schering, synthesizing the hormone later 
that same year [146]. The third team published their data one week later, having also 
synthesized testosterone from cholesterol [147].  
Since this early work, significant advances have been made in the understanding of 
testosterone secretion.  Leydig cells within the testes are responsible for the production of the 
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majority of testosterone. The hypothalamus produces gonadatropin releasing hormone (GnRH), 
which binds with the gonadatropins in the anterior pituitary.  This then releases both luteinsing 
hormone (LH) and follicular stimulating hormone (FSH).  The FSH stimulates spermatogenis in 
the testes, while the LH stimulates the Leydig cells to produce testosterone.  The testosterone 
then feeds back to suppress the production of the gonadatrophin [148]. About 2% of total 
testosterone is freely available to perform its functions (“free testosterone”), while the 
remaining is bound to either sex hormone binding globulin (SHBG) or albumin. The levels of 
these two proteins can therefore affect the bioavailability of testosterone [148].     
1.2.1. Normal Testosterone Levels 
Defining clinically normative testosterone levels across the entire adult lifespan has so far been 
elusive, with no clear consensus regarding the level at which a man is considered to have a low 
testosterone concentration. There is wide spread acceptance that there is a gradual decline in 
serum total and free testosterone levels associated with age in healthy adult men [149]. A 
decline of 1-2% per year for those aged over 40 is expected, with a faster decline, in the order 
of 4 nmol/L per year in those aged 61 – 87 years has been described [150, 151].  With an 
increasing life expectancy and a subsequent greater proportion of the older generation, the 
prevalence of low testosterone levels, and its accompanying symptomatology is likely to 
increase [152].  
Extreme cases of intentional testosterone change, such as in athletes and body builders hoping 
for sporting enhancement and male singers castrated to maintain a soprano range, especially 
during the 16th to 18th centuries, as well as transgender individuals undergoing gender 
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reassignment, provide an interesting, but not generalisable, understanding of the effects of 
supraphysiological or complete absence of testosterone.  
1.2.2. Influences on Testosterone Levels 
Many concomitant pharmacotherapies as well as endogenous, situational and lifestyle factors 
can influence testosterone levels.  In addition to age, several endogenous factors controlling 
testosterone exist. A substantial hereditary influence on testosterone levels has been shown in 
the Framingham Heart study [153]. By studying father/son and brother/brother pairs, a 
significant genetic correlation was found for testosterone levels, which included adjustment for 
known risk factors of age, BMI, as well as smoking and diabetic status [153].  The circadian 
rhythm also has a profound effect, with peak values occurring early in the morning and nadirs 
in the early evening [154].  This circadian pattern in the release of testosterone is so well 
established that standard practices require blood samples be taken in the early morning to 
ensure the sample reflects the peak testosterone level achieved throughout the day [155]. This 
diurnal variation, however, may not be as strong in those aged over 40 [156].  The influence of 
sleep on testosterone levels is further discussed in section 1.4.1. 
Several modifiable factors have also been identified to influence testosterone levels.  Firstly, 
increased body weight has been shown to decrease testosterone.  A prospective cohort study 
of 1667 men showed that an increase in BMI of 4-5kg/m2 was comparable to that of the 
expected decline in testosterone over 10 years [157]. Likewise a large (n=890) longitudinal 
study found a decrease in total testosterone levels, but not free testosterone, with increase in 
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BMI [158]. In a large (n=991) long-term (20 year) study, those who gained more weight had 
lower levels of testosterone than those who lost or did not change weight [159].  
Medications can have effects on testosterone levels. Statins, used to lower cholesterol, were 
found to reduce testosterone by 0.7 nmol/L, calculated with a meta-analysis of 6 studies, 
however, the clinical significance of this reduction is difficult to determine [160]. In contrast, a 
recent meta-analysis of 6 studies found statins improved erectile function [161]. Another 
common medication, glucocorticoids, which are often chronically used in the context of 
asthma, have also been shown to reduce testosterone with one small study (n=11) showing an 
inverse dose relationship, resulting in testosterone levels 60% that of the control group [162, 
163].  
A factor which is often overlooked is that of the influence of domestic situations on 
testosterone in men, which has been investigated in many studies with consistent results [164]. 
Relationship factors can alter testosterone, with the loss of a spouse reducing testosterone 
levels by more than 10nmol/L [157].  “Falling in love” in the first six months of a relationship 
can reduce testosterone levels compared to single men or those in long-term relationships 
(14.2 vs 23.6 nmol/L, p> 0.003). These levels were observed to rise after 1-2 years to the level 
previously seen in the control group [165]. A similar reduction in testosterone was found in 
heterosexual men (but not homosexual men) who had long term partners compared to those 
without partners (17.3 vs 27.0nmol/L, p=0.013) [166]. Several studies have documented lower 
testosterone levels in men in committed relationships, compared to single men [167-169].  
There has also been consistent findings that becoming a father and being involved in child 
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rearing, reduces testosterone levels [169-171], suggesting that higher levels are associated with 
mating effort, and inversely correlated with parenting [171].    
Social interactions have also been shown to affect the testosterone levels of men.  In young 
college students, a short conversation with a female increased testosterone, but this was not 
significantly different than after a conversation with a male, however, the degree to which the 
male was trying to impress the female, as rated by the female, correlated with the increase in 
testosterone [172]. A woman’s fertility has also been shown to influence a man’s testosterone 
level, with the scent of premenopausal women who are in their most fertile phase, ovulation,  
producing an increase in testosterone [173].   
Sexual thoughts, in the absence of sexual behaviour, has also been shown to affect 
testosterone levels, however this finding is not consistent.  Watching a sexually explicit film has 
been shown to increase testosterone levels by 35%, compared with a sexually neutral film 
[174], however, a similar study did not find such an increase [175].  Sexual thoughts, elicited by 
imagining and writing about a sexual situation, did not produce an increase in testosterone 
compared to those who wrote about a control non-sexual situation, however an increase in 
cortisol levels was found, prompting a hypothesis that cortisol may facilitate sexual arousal by 
directing efforts toward a sexual situation [176].   
Involvement in competitive sporting events can also influence testosterone levels in men.  
Several studies have shown winning compared to losing, increases testosterone, not only for 
players but for supporters [177-179]. Another study found that the level of participation in the 
game, rather than the outcome, correlated with the level of testosterone [180]. Anticipation for 
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an important match also increases testosterone levels, such as those seen in the supporters of 
the Spanish team participating in the lead up to the 2010 soccer World Cup final [181].   
1.2.3. Testosterone Deficiency 
Clinically, testosterone deficiency is defined as low testosterone levels in conjunction with 
clinical symptoms.  Six such symptoms have been identified as characterising androgen 
deficiency – reduced sexual function, reduced intellectual ability, decreased body mass, 
changes in hair and skin, reduced bone mineral density and increased visceral fat [182].  In the 
older man, late onset hypogonadism can be defined by three or more sexual symptoms (such as 
poor morning erection, ED or low sexual desire) in addition to a total testosterone level of less 
than 11nmol/L and free testosterone level of less than 220pmol/L [183]. There have been 
inconsistent reports of the testosterone levels at which symptoms appear [183], suggesting that 
a significant amount of clinical decision making based on comprehensive medical history taking 
is essential.   
Reported prevalence rates of testosterone deficiency differ. In a longitudinal study of 890 men, 
20% of those over 60, 30% of those over 70 and 50% of those in their 80s have testosterone 
lower than that of a young healthy man [158].   In a large cross sectional study of almost 3000 
men, the European Aging Male Study (EMAS), 2.1% of 40-79 year old males were found to have 
late-onset hypogonadism, and were found to be older and more obese than eugonadal men 
[184].  A population based decline of testosterone levels has been found in the United States, 
independent of age, in a large (n=1532) prospective cohort study, suggesting an unidentified  
health or environmental effect on testosterone levels in the overall population [185].  
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1.2.4. Testosterone Therapy 
Testosterone therapy involves supplementation via transdermal, injected or implanted means 
[186]. Ideally, a sustained consistent release is ideal to avoid fluctuations of symptomatology 
[187].  Testosterone supplementation has been investigated in regard to many different clinical 
outcomes, using a variety of methodologies, and there remains a significant amount of 
conflicting information in regard to its efficacy. Baseline serum testosterone levels below which 
androgen supplementation is suggested varies between 8-17 nmol/L [155, 188, 189]. Although 
official guidelines avoid clearly identifying an exact cut off, reference is made to less than 10 
nmol/L, laboratory dependent, as defining a low testosterone level [105].  There is increasing 
recognition that there is variation between individuals regarding the threshold of testosterone 
concentration and the appearance of or reduction in particular symptoms [190].   The decision 
to commence testosterone therapy must be based on clinical symptoms in the context of the 
risks involved with treatment [155].  Recent reports suggest that younger men, but not older 
men, with classic hypogonadism generally have a positive benefit to risk ratio with testosterone 
therapy [191].    
The rates of prescribed testosterone supplementation in the general Australian community are 
substantially increasing with a nine-fold increase in the last 20 years [192]. This replicates the 
rapid increase in America, of 500% over the same timeframe [105].  The sale of testosterone 
globally has increased from $150 million in 2000 to $1.8 billion in 2011 [193].  This rapid 
increase in testosterone usage has not been associated with any increase in the diagnosis of 
androgen deficiency, and has been speculated to be viewed as a non-specific treatment for 
declining well-being and sexual dysfunction [192, 194].  Indeed, one survey of doctors in 5 
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countries regarding reasons for prescribing testosterone reported that symptoms, rather than 
laboratory values, drove their decision to prescribe testosterone supplementation [195]. 
From a clinical perspective, the effectiveness of testosterone supplementation on sexual 
function is generally accepted via 70 years of experience [191].   This is supported by systematic 
reviews, which report a consistent finding that testosterone treatment increases sexual desire, 
and also erectile function, although to a lesser degree [141, 196].  Separating sexual function 
into its various aspects, these differing facets appear to be affected by differing levels of 
testosterone; however there is not a clear consensus on the exact level of testosterone below 
which a symptom will become apparent. There is also variation between individuals regarding 
the influence of testosterone upon sexual function [197]. Long term observation of 
hypoandrogenic men receiving testosterone pellets (which declined in efficacy with time) 
showed a reproducible return of symptoms (lack of energy, motivation and reduced sexual 
desire) within individuals, however these levels varied markedly between men, suggesting that 
each man has a threshold at which androgen deficient symptoms become apparent [190].  
1.2.5. Testosterone and Sexual Function 
Traditionally, testosterone has long been strongly associated with virility.  Healthy sexual 
function in males comprises sexual desire as well as satisfactory erectile and ejaculatory 
capabilities, and the production of sperm, all of which may be influenced by testosterone [198, 
199].  Low levels of testosterone appear to have an inverse relationship with symptoms of 
sexual problems including poor morning erection, low sexual desire, erectile dysfunction, as 
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well as contributors to the ability to maintain healthy sexual function, including inability to 
perform vigorous activity, depression and fatigue [183].   
Questionnaire data published by various authors regarding sexual functioning, including sexual 
desire, erectile function and orgasmic function have suggested differing threshold levels of 
testosterone to be associated with reduced sexual functioning, ranging from 8nmol/L to 
12nmol/L [105, 183, 190, 200].   Testosterone levels below 8, 11 and 12, nmol/L have all been 
associated with decline in various aspects of functioning [189]. Below 12 nmol/L, less sexual 
activity occurs and there is a reduction in nocturnal erections [105, 141]. Self-reported morning 
erections decrease at testosterone levels below 11 nmol/L [183]. With testosterone 
concentrations under 8 nmol/L, men have been found to have reduced sexual desire and 
erectile function and an increase in depression [183, 201, 202].  
1.2.5.1. Testosterone and Sexual Desire 
Sexual desire has been reported to reduce at a variety of thresholds, including 8, 10, 11, 12 and 
17, 20 nmol/L [183, 203, 204]. Adding to this uncertainty, two separate studies in which 
testosterone levels were artificially adjusted in healthy young eugonadal men found opposing 
results, with one reporting no association with levels of serum testosterone and measurements 
of any sexual function parameter [205] and the other finding a significant reduction in the 
amount of sexual desire, number of fantasies and frequency of sexual encounters [206].  
Although reports regarding the relationship between testosterone levels and sexual desire have 
been inconsistent, the majority point to a link between the two.  Compared to age matched 
controls, for men with testosterone lower than 9 nmol/L, dyadic but not solitary, sexual desire 
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was reduced [207].  In a study of 1632 men, sexual desire measured via self-report on a 14 
point scale, showed a significant association with testosterone, however, the difference in 
mean testosterone between those whom reported low sexual desire (defined as a score less 
than 14) versus those whom did not, was small, with only 0.12 nmol/L difference between unit 
increases of sexual desire [203].   
In the 16th century, young boys, destined to become singers, were castrated prior to their voice 
breaking, in order to maintain voices in the high octave ranges [208].  Depending upon the 
timing of the spermatic cord being severed, these ‘castrati’ were known to have a complete 
lack of sex drive if the procedure was performed prior to puberty [209], and presumably, before 
adult testosterone levels were reached.  
In more recent times, the effects of testosterone therapy on sexual desire have been 
investigated.  Meta-analyses of clinical trials of pharmacotherapy have shown a large effect of 
testosterone supplementation on sexual desire, but only in those with low baseline levels [196, 
210].  In one of the few studies examining both aspects of sexual interest, those with low 
testosterone were found to have lower overall desire  than a matched control group, however, 
there was no difference in solitary sexual desire, that is, interest in behaving sexually by oneself 
[207].  When these men were administered androgen therapy, dyadic sexual desire, the 
interest in behaving sexually with a partner, increased to levels similar to that of the control 
group.  Additionally, solitary desire was increased compared to baseline, but was not different 
than that of the control group [207]. Testosterone replacement, via patch or gel, for those with 
low baseline testosterone has been shown to increase sexual desire.  This increase has been 
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found to occur once a low normal range of testosterone has been reached, and no further 
increase was seen by increasing the serum level to beyond this threshold [211].  In a dose 
finding study, 100 mg/day but not 50 mg/day was found to increase in sexual desire in 
hypogonadal men [204]. 
When men with testosterone within the normal ranges are given supplemental androgens, 
sexual desire has been found to be both unchanged and increased.  In a placebo controlled 
study of eugonadal men presenting with low sexual desire, testosterone was successful in 
increasing desire compared to placebo [212]. A meta-analysis of 7 placebo controlled studies in 
eugonadal men found that testosterone administration slightly increased sexual desire [213]. 
When supraphysiological doses were given to eugonadal men in a study investigating androgen 
use in contraception, an increase in sexual desire without a corresponding change in sexual 
encounters occurred, however this increase was attributed to one individual, without whom 
the result was no longer significant [214]. However, in a randomised controlled study, in which 
eugonadal men with ED received exogenous testosterone, increases in sexual desire were 
reported, but these were not statistically different than placebo [215]. An explanation posed 
regarding the relationship between testosterone and libido is that there is not a linear 
relationship at which there is a threshold level above which desire increases, rather, relative to 
regular levels, a transient increase in circulating hormones may be a more influential factor 
[213]. 
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1.2.5.2. Testosterone and Erectile Function 
The two forms of erection, those occurring as a result of sexual stimulation and those occurring 
during sleep, appear to have differing relationships with testosterone levels, although this is not 
a consistent finding  [71, 216]. In two studies, erections in response to stimuli were not affected 
by levels of testosterone, however those occurring during sleep were [217, 218].  In a case 
series of seven transgender individuals, undergoing male to female gender reassignment, the 
suppression of testosterone through oestrogen therapy was accompanied by a distinct, but 
statistically insignificant, reduction in erections during both wake and sleep [219].    
The relationship with erections during wakefulness due to stimuli with testosterone levels are 
not clear, with studies differing regarding the relationship between erectile function and 
testosterone.  A large population study (n=1071) found there was no difference in serum total 
testosterone levels between groups classified as having or not having ED [220].  Additionally, a 
large population study (n=1195), showed that severe, but not mild, ED, had an increased risk of 
a low testosterone level [221].  
Pharmaceutical studies allow an insight into the relationship of testosterone with erectile 
function.  In a small (n=10) early study of five men with low sexual interest and five men with 
erectile dysfunction, testosterone did not improve erectile function compared with placebo 
[212].  In a systematic review and meta-analysis of placebo controlled trials of testosterone use 
a small improvement in erectile function was found, however, there were several unexplained 
and inconsistent results within these studies [196].  Similarly, a meta-analysis of 17 clinical trials 
showed an inverse relationship between testosterone levels and erectile function, however, 
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they identified several caveats regarding these effects being mediated by baseline levels, 
duration of treatment and identified a lack of information on long-term safety of androgen 
therapy [213].   
For nocturnal erections there appears to be a closer relationship with testosterone levels. In an 
early study reported in 1977, simultaneous measurement of penile tumescence via a mercury 
strain gauge and testosterone by 10-20 minute blood sampling found a relationship between 
the two, although this crude study did not correlate the two using modern methods [222]. A 
few years later, similar measurements were taken in men with lifelong problems with erections, 
and found no relationship between REM cycles, testosterone and tumescence, however,  those 
with erectile difficulties exhibited both reduced testosterone and reduced nocturnal erections 
compared to controls [223]. In a study of five men with epilepsy and low testosterone, and five 
age matched controls, penile activity during sleep was found to be correlated with free 
testosterone levels [224]. Similarly, in a study of hypogonadal men, lower levels of testosterone 
were associated with nocturnal erections that were either absent, or of very low amplitude and 
duration compared to controls [225]. For eight healthy young eugonadal men, a single injection 
of testosterone increased the rigidity but not the duration of nocturnal erections compared to 
placebo [226], however, this is not replicated in another similar study finding no such change 
[227].  Aspects of sleep related erections had varying levels of association with testosterone 
when measured in 201 men including both hypogonadal and eugonadal participants.  This study 
concluded that the testosterone threshold for sleep related erections is less than that of the 
lower end of normal range [228]. In agreement with this concept is a study that found the 
threshold for nighttime erections to be lower than that of sexual intercourse frequency and 
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sexual desire, however this study found a higher threshold, within the normal range, that of 
around 14nmol/L [204].  The effect of testosterone supplementation upon nocturnal erections 
appears to take some time, according to one study, in which, despite a rapid (3 months) 
increase to normalised levels of serum testosterone concentration, nocturnal erections 
increased steadily over 6-12 months of testosterone supplementation [225].  In contrast, the 
association between testosterone levels and nocturnal erections was assessed in hypogonadal 
men immediately after dosage of androgen supplementation and 7-8 weeks later, which found 
that with the declining levels of circulating testosterone, a reduction in nocturnal erections in 
terms of rigidity and duration was seen [229].  In a group of 29 men with COPD, not selected for 
baseline levels of testosterone or erectile function, testosterone supplementation was 
administered in a study examining the effect on body composition and pulmonary function.  
Improvements in overall sexual function as well as erectile function were noted, however, the 
difference between the treatment group and the placebo group was largely due to a decline in 
both testosterone levels and sexual function in the control group, suggesting testosterone may 
prevent decline, rather than improve function in this population [230].   
The pathway between low testosterone and impaired erectile function has not been 
established [200], however, some animal evidence suggests that testosterone may regulate 
nitric oxide mediated validation in the vasculature of the penis [20]. Indeed, one human study 
has found evidence for a relationship between cavernous vasodilation and free testosterone in 
men with ED, using dynamic colour duplex ultrasound to distinguish between arteriogenic or 
corporeal venocclusive or psychogenic erectile dysfunction [21].  Low testosterone may be 
found in conjunction with ED, however, it may not be the only contributing factor, with only 5-
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15% of those with ED having a low testosterone level [216].  Indeed, not all patients with ED 
and a low testosterone level have improvement in symptomatology with exogenous 
testosterone administration [71].  
In summary, the amount of androgen required to maintain sexual function is not well 
established, and has individual variation.  As a result, men with testosterone above or below a 
pre-set threshold value may result in quite different presentations.  
1.2.6. Testosterone and Neurocognitive function 
The role of testosterone in neurocognition is complex and not completely understood [231].  
Various studies, using different methodologies to measure cognitive function under differing 
conditions, age, levels of baseline cognitive functioning, age and duration of treatment, as well 
as a unclear definition of testosterone deficiency, have so far found inconsistent results 
regarding the exact influence that testosterone has upon cognition. Supporting the notion that 
testosterone can have effects on cognition are some observations of brain biology and function.  
Androgen receptors are found in brain regions responsible for learning and memory, which may 
mean that testosterone can influence cognitive processes [231]. Indeed, higher levels of 
testosterone were related to increased amygdala activation in men as measured by brain 
functional magnetic resonance imaging (fMRI) during mental work, which translated to better 
memory performance [232].  An intentional reduction of testosterone in prostate cancer 
patients revealed a reduction in activation of the right parietal-occipital region of the brain, 
compared to baseline, during periods of spatial reasoning and memory tasks on fMRI, in the 
absence of detriments in performance [233].   Additionally, cerebral perfusion has been noted 
 - 32 - 
to be predicted by the level of free testosterone and also to increase with testosterone 
supplementation when measured by single-photon emission computed tomography [234, 235]. 
By artificially adjusting testosterone levels in healthy young eugonadal men, no association was 
found with levels of serum testosterone and measurements of spatial cognition [205].  Very few 
studies have investigated younger, healthy men, rather, the majority of studies regarding the 
association between neurocognition and testosterone have focused on elderly men [231]. In a 
large (n=407) longitudinal study, higher levels of free testosterone were associated with higher 
scores associated with visual and verbal memory, as well as visuospatial functioning [236]. In 
this study, men classified as being hypogonadal had lower scores on memory and visuospatial 
performance than those who were eugonadal [236].  In the Massachusetts Male Aging study, 
there were associations between all measures of cognition with free testosterone; however, 
this effect was not significant once adjusted for age [237].  In another study of 54 men aged 61-
77 years, testosterone was shown to be associated with working memory in but not with spatial 
abilities, verbal memory and visuomotor processing speed, however the influence of age was 
not reported [238].  In men aged 40-80, lower bioavailable levels of testosterone were 
associated with lower scores on processing capacity and speed, whereas executive function and 
memory showed only a weak correlation [239].  After stratification, only those in the oldest age 
group, 71 – 80 years, were found to benefit from higher testosterone levels in processing 
speed, executive and global cognitive function but not memory [239].   
Some studies have found a quadratic (U-shaped) relationship between testosterone and 
cognition, suggesting an optimal hormone range for particular cognitive tasks [240, 241].  Older 
males aged 59 - 89 years were found to have a U-shaped relationship between total 
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testosterone and the World backwards test, as well as free testosterone with the visual 
reproduction test.  Both a linear and a quadratic relationship were found for mental control and 
verbal memory with free, but only a linear relationship with total, testosterone.  The magnitude 
of these relationships may have, however, been affected by a 5 year interval between blood 
sampling and cognitive testing  [240].  
The effect of androgen supplementation on neurocognition has received a reasonable amount 
of attention, with differing results.  Recent work in older men found no change in executive 
function, memory and spatial cognition with physiological or supraphysiological doses of 
testosterone [242, 243].  Similarly, in women with surgically induced menopause, testosterone 
levels were not found to be correlated with cognitive performance as measured by digit symbol 
substitution task, paired and free recall, or the presence of cognitive fatigue [244].  In contrast, 
improvements in spatial memory, special reasoning and verbal fluency were seen with 
testosterone administration compared to placebo in a small (n=25) study [245].  Several other 
small studies have reported improvements in memory and spatial cognition for older men 
treated with androgen supplementation but with only those who had an initial lower level of 
testosterone [246, 247].  Supporting the data showing a U-shaped relationship of testosterone 
and cognition in non-supplemented men, moderate to large increases (11 - 50 nmol/L) in serum 
testosterone were associated with improvements in verbal and partial memory in older men 
from the community given supraphysological doses of testosterone, however, those with either 
very large (>51 nmol/L) or low (<10 nmol/L) increases did not show such change [248]. 
Similarly, higher levels of testosterone in 30 elderly men were associated with a decline in 
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learning in regard to verbal fluency with testosterone treatment, but not in other verbal or 
spatial tasks [249].  
The use of anabolic steroids in those aiming to increase testosterone levels with resultant 
increases in muscle mass or athletic performance has increased in the last 30 years [250, 251].  
Users can reach supraphysiologic testosterone levels at least 50 times the level of normal adult 
male, including a case described having serum testosterone level of over 700 nmol/L [252]. 
These men may be at risk of cognitive deficit, with visuospatial memory of steroid using weight 
lifters in a small study (n = 31) shown to be significantly worse than in their counterparts whom 
did not use steroids. No difference was found for reaction time, rapid visual information 
processing or immediate free recall [252].  Again this may support the theory of a U-shaped 
relationship and an optimal functioning level of testosterone.  
1.2.7. Testosterone and Quality of Life  
Few studies have investigated the relationship between testosterone and quality of life 
measurements such as the SF-36 quality of life assessment tool.  In a population study of 47 
older men, of which 57% had testosterone levels lower than the normal range, no relationship 
was found between testosterone and scores in any domain of the SF-36 [253]. In a study of 
3369 older (age 40-79 years) men, testosterone levels were associated with the Beck 
Depression Inventory and individual questions of the SF-36, although the SF-36 domain scores 
were not reported [183].  The questions reported to be associated with testosterone levels 
were related to vigour, walking more than 1km, bending and stooping, feeling downhearted, 
loss of energy and fatigue.  Further analysis of these individual questions found a threshold of 
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below 13nmol/L to significantly increase the likelihood of having reduced vigour. Similarly, less 
than 160pmol /L of free testosterone increased the probability of feeling down and of having 
increased fatigue. These results suggest that there may be varying thresholds for the 
appearance of androgen deficient symptoms in the general male population.  Several studies of 
pharmaceutical intervention have reported improvements in differing domains of the SF-36 due 
to testosterone replacement [254, 255], however, other studies have found either no or 
minimal improvement in these domains [256-260], again suggesting a heterogeneous 
relationship with testosterone.  
1.2.8. Testosterone and Cardiovascular Disease 
Men have a higher risk of cardiovascular disease than women, suggesting testosterone being a 
mediating factor in this relationship [261-263].  However, this is not a linear, or clear, 
association [19, 148, 263-268].  Both a low level of endogenous testosterone as well as the 
administration of exogenous testosterone appear to have an increase in cardiovascular risk, but 
there is no clear evidence that restoring low testosterone to normal levels increases the 
likelihood of cardiovascular disease [261, 264].  A recent review, has identified testosterone to 
have some protective effects against cardiovascular disease, in regard to the properties of 
being a vasodilator, anti-inflammatory, anti-atherosclerotic, and anti-coagulant agent [269].  
Likewise, a meta-analysis of 19 studies showed older, but not younger, men were weakly 
protected by a higher level of endogenous testosterone [267].  A cross–sectional analysis of 54 
studies showed that those with cardiovascular disease had lower levels of testosterone than 
those without, however, concluded that the association may or may not be that of cause and 
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effect [265].  An often cited study was terminated early due an increase in cardiovascular 
complications in those men randomly assigned to receive testosterone supplementation [270].  
Indeed, a meta-analysis of 27 clinical trials of testosterone found a greater risk of cardiovascular 
events for those taking active testosterone compared to placebo, with a greater risk in non-
pharmaceutical funded clinical trials compared to those funded by pharmaceutical companies 
[271].  A recent retrospective study in men who had undergone coronary angiography found a 
5.8% higher incidence of cardiovascular events in men whom had received testosterone 
therapy [268].  Similar reports of increased cardiovascular events have been described in men 
taking anabolic steroids for sporting enhancement [272].  On the other hand, other authors, 
including those whom have performed meta-analyses, have not shown this relationship and 
reported testosterone replacement therapy as having no or little effect on cardiovascular 
events, but observed that the quality of this data is less than ideal, due to the short duration of 
the studies, lack of allocation concealment, and the small numbers of both events and 
participants  [264, 266, 273].  Several authors consider the current literature, particularly in 
older men, to be inadequate to accurately assess the risks of testosterone therapy on 
cardiovascular outcomes [191, 264, 266, 273]. 
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1.3. OBSTRUCTIVE SLEEP APNOEA 
1.3.1. Description  
Obstructive sleep apnoea (OSA) is a sleep disorder characterised by repetitive periods of 
complete absence (“apnoea”) or reduction (“hypopnoea”) of respiration caused by a narrowing 
of the upper airway.  Periods of apnoea and hypopnoea are accompanied by futile respiratory 
effort against a constricted upper airway [274].  This is terminated by a brief arousal from sleep 
which clears the airway blockage and normal breathing is resumed.  As a result, there are 
repeated disruptions to sleep continuity, drops in blood oxygen levels, momentary increases in 
blood pressure, and numerous other parasympathetic and sympathetic responses.  These 
pauses in breathing can occur up to several hundred times during the sleep period, causing in a 
variety of physiological, psychosocial and psychological outcomes. 
The most common symptoms of OSA are snoring and excessive sleepiness.  Bed partners, family 
members and travelling companions of the patient often observe and report episodes of 
snoring and apnoea [275].  Other features include unrefreshing sleep, nocturia, dry mouth, 
mood disturbance, morning headache, poor concentration, fatigue, choking or gasping, 
recurrent awakenings during sleep and erectile dysfunction [276-278]. 
1.3.2. Diagnosis   
The International Classification of Sleep Disorders defines OSA as, in the absence of any other 
disorder, having more than 5 respiratory events (apnoeas, hypopnoeas and respiratory effort 
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related arousals) per hour was well as clinical symptoms.  If no symptoms are present, more 
than 15 respiratory events per hour are required to make the diagnosis [279] and can be 
referred to as obstructive sleep apnoea syndrome (OSAS). 
The most thorough method to clinically document OSA is full attended in laboratory 
polysomnography [280, 281].  This test involves overnight observation at a sleep laboratory 
while several physiological parameters are concurrently recorded during sleep. Typical 
monitoring configurations to identify sleep stages and arousals from sleep include 
electroencephalography (EEG) and electrooculography (EOG) and electromyography (EMG). 
Respiration parameters are recorded using plethysmography to monitor respiratory effort, 
pressure and temperature changes for nasal and oral respiration and pulse oximetry for blood 
oxygen saturation.  Recordings are analysed and summated to describe sleep efficiency, the 
amount of time in different sleep stages, namely Rapid Eye Movement (REM) and non-Rapid 
Eye Movement (NREM) sleep, degree of hypoxia and the frequency of cortical arousal and 
breathing irregularities per hour of sleep [282].  Monitoring sleep in the home environment is 
becoming increasingly prevalent due to improvements in technology, validation and acceptance 
[283].  
The severity of OSA is generally based on the frequency of apnoeas and hypopnoeas per hour, 
known as the apnoea hypopnoea index (AHI), with less than 5 breathing disturbances per hour 
considered normative, from 5 - 15 mild, 15 - 30 moderate and more than 30 is considered 
severe OSA [276]. The respiratory disturbance index (RDI), is often used interchangeably with 
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AHI, however, this former term should be used when apnoeas, hypopnoeas as well as 
respiratory event related arousals per hour are reported [282]. Prevalence 
The definition of OSA is somewhat inconsistent across studies, which can contribute to 
variation in prevalence rates. Dividing a population into the presence and absence of OSA can 
be influenced by the equipment used, analysis techniques employed, AHI selected and the 
decision to include or exclude associated symptomatology [284-288].   Notwithstanding, by any 
criteria, obstructive sleep apnoea is a relatively common condition with all the hallmarks of a 
chronic condition [289].  
A study commonly cited describing the prevalence of obstructive sleep apnoea is that of Young, 
1993 [286]. In this study, OSA, defined as an AHI of more than 5 per hour as well as concurrent 
excessive daytime sleepiness, occurred in 4% and 2% of middle-aged western men and women 
respectively.  Based on polysomnographic criteria alone, an AHI of greater than 5 exists in 
approximately 24% and 9% of men and women respectively when measured more than 20 
years ago [286].  This prevalence rate is likely to have increased [287].   
1.3.4. Risk Factors 
One of the main risk factors for developing OSA is excessive weight.  Longitudinal data 
regarding obesity showed a dose response relationship, with a 1% increase in weight being 
associated with a 3% increase in the AHI [290], hence, the current obesity epidemic will 
translate into a greater number of individuals with OSA.  A recent study in 400 women from the 
Swedish community (age 48 years, BMI 25kg/m2) found that 50% had an AHI greater than 5, 
with BMI and age being the major contributors to incidence rates  [291].  On average, world-
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wide, body mass index (BMI) has increased by 0.4 kg/m2 per decade over the last 30 years 
[292].  The United States has the highest average BMI of high income countries, with an 
average of 28.4 kg/m2, with 69% of the population classified as being overweight (BMI>25) and 
35% being obese (BMI>30) [292].  Australian body habitus is almost as large, with 60% classified 
as being overweight and 25% obese [293]. This increase in body size is particularly more 
prevalent for men, with a yearly increase in the rate of obesity by 0.8%, with no such change for 
women [294].  Although not currently directly documented, the prevalence rate of OSA is likely 
to increase given the rising rate of obesity and the link between these two conditions [287, 
295].  Incorporating the recent trajectory in obesity, a strong causal factor for OSA, using the 
same AHI and symptomatology criteria as Young’s study, the current estimate of OSA 
prevalence rates  is 14% of men and 5% of women [286, 287].  
Increasing age inflates the incidence of OSA [296, 297].  In a study of 741 men, using a 
definition of an AHI greater than 10, OSA existed in 3.2% of those aged between 20-44 years, 
11.3% of 45-64 year olds, and 18.1% in the oldest category, ages 65-100 [296]. When these 
polysomnographic findings were combined with clinical features of at least one symptom, OSA 
syndrome was prevalent in 1.2%, 4.7% and 1.7% respectively [296]. As this study suggests, as 
does several others, there is a high prevalence of obstructed breathing during sleep in the 
elderly, however, this is not accompanied by clinical symptoms [295, 298].  Possible 
explanations suggested for this incongruence include theories that OSA in older age may be a 
condition distinct from that of middle age, or that those who exhibit symptoms have not 
survived to older age [299].   Indeed, mortality data from the long term Bussleton study shows 
that the presence of OSA is indicative of early death [300]. 
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Physical anatomy can contribute to the narrowing of the upper airway and thus the risk of 
developing OSA. There is an increase in the risk of developing OSA for those with increased 
neck size, enlarged tonsils (particularly in children), anomalies of the craniofacial structure or 
upper airway soft tissue and nasal congestion [301-306]. Alcohol intake can also reduce upper 
airway muscle tone, increasing the likelihood of  OSA [304].  
Hormonal factors have also been suggested to influence the incidence of OSA.  The higher 
prevalence of OSA in males has been suggested to be due to higher testosterone levels [306, 
307].  Women experience many hormonal changes as part of the menstrual cycle, pregnancy, 
menopause and hormone replacement therapy. All of these circumstances have been shown to 
impact upon levels of sleep disordered breathing [307-310].  In a case report,  a woman with a 
testosterone producing tumour with higher than expected levels of testosterone was found to 
have significant OSA, which resolved once the tumour was removed [311].   
1.3.5. Consequences 
Untreated OSA is associated with a number of established outcomes, including excessive 
daytime sleepiness, increased cardiovascular risk, mood disturbance, neurocognitive deficit, 
hormone imbalance and impaired sexual function.  OSA is independently associated with 
increased risk of all-cause mortality [300, 312], cardiovascular mortality [312-314] and 
cardiovascular events [313, 315].  Hypertension, heart failure, coronary heart disease, stroke 
and arrhythmia are all established consequences of OSA [299, 316-318].  Additionally, those 
with OSA may also be at greater risk of diabetes [319], through the increase of glucose 
intolerance and insulin resistance [320, 321] in this population. 
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One of the most common daytime symptoms of OSA is excessive sleepiness.  Those with OSA 
have been shown to be sleepier than well matched controls, however the relationship between 
severity of OSA and sleepiness levels are weak [286, 322].  The level of sleepiness in an 
individual can often be difficult to ascertain through clinical evaluation [323]. Subjective 
methods for quantifying sleepiness are available.  Sleepiness over recent times can be 
subjectively measured in using the Epworth Sleepiness Scale (ESS), first described by Johns 1991 
[324].  This self-reported 8 item scale assesses the likelihood of falling asleep in various 
scenarios commonly encountered in daily life, such as sitting and reading, watching TV and lying 
down in the afternoon. Subjects are asked to rate the chance of falling asleep in each 
circumstance from 0 (no chance of dozing) to 3 (high chance of dozing).  The scores are tallied 
to give a total between 0 – 24, with those above 12 indicating excessive sleepiness [325].  The 
ESS focuses on levels of sleepiness over the preceding two weeks and can be used to 
subjectively quantify sleepiness and assess change due to treatment effects [325]. Two 
measures of ‘present moment’ sleepiness are available for use in the research setting.  The 
Karolinska Sleepiness Scale (KSS), a single item with nine possible responses is presented to 
respondents to assess instantaneous levels of subjective sleepiness from 1 (extremely alert) to 
9 (extremely sleepy – fighting sleep) [326].  Higher scores represent greater subjective 
sleepiness and have been correlated with behavioural and EEG changes [327].  The Stanford 
Sleepiness Scale (SSS) is also a single item measurement of sleepiness with seven possible 
responses ranging from 1 (feeling active and vital; alert; wide awake) to 7 (almost in reverie; 
sleep onset soon; lost struggle to remain awake) [328, 329].  This score assesses momentary 
levels of sleepiness and can be used repeatedly to measure changes across the day [329].   
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1.3.6. Impact on Quality of Life 
Patients with OSA often experience an impaired quality of life [330-332], and this impairment is 
often the reason for seeking and possibly adhering to treatment [331].  General quality of life 
can be measured using the Short Form 36 (SF-36) questionnaire, which can be compared to 
number of reference ranges, including the largest set obtained from over 13,000 subjects from 
the United Kingdom [333, 334].  A large sleep related study (Wisconsin Sleep Cohort) of a 
general population found the entire group to have similar results to that of the English 
reference range, however, those with even mild sleep disordered breathing had much lower 
general health comparable to that experienced with other chronic disease states such as 
arthritis and diabetes [335].  Another study found that, compared to the normative population, 
those with OSA scored lower in all domains of physical function, mental health, role limitation, 
pain, general health, vitality and social function [336]. The latter two domains were noted to be 
the most significantly different [336].  Of all the domains in the SF-36, that of vitality has been 
reported by one study to be the most affected in those with OSA [337].  Likewise, vitality was 
shown to be the only domain correlated with OSA severity in the Sleep Heart Health study 
[330].  Some studies have shown no or minimal correlation of any numerical parameter of OSA, 
such as AHI or minimum oxygen levels, with the scores of any domain of the SF-36 [332, 338], 
which may suggest an interpersonal difference in susceptibility to symptoms.  
A disease specific quality of life measurement, the Functional Outcomes of Sleep Questionnaire 
(FOSQ) has been developed to identify the functional impact of sleep disorders on quality of life 
[339]. This consists of five subscales (Vigilance, Activity, Intimacy and Social Relationships, 
Social Outcome and General Productivity) as well as a total score and can successfully 
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distinguish between those seeking treatment for a sleep disorder and the normal population 
[339].   
More than half of patients with OSA have depression, either doctor diagnosed or via 
questionnaire [340]. This may not be a direct link, however, rather this may be a result of the 
reduced quality of life seen in OSA [338].  Correlation of ESS and quality of life scores with 
depression scores have been documented, but the only parameter of OSA found to have an 
association with levels of depression is hypoxaemia [338, 340].    
Manifestations of OSA, such as sleepiness, mood changes and irritability [341] may collectively 
impact on mental health and interpersonal relationship quality with one’s spouse. Indeed one 
of the earliest descriptions of OSA in a case series of 25 men included marital breakdown as one 
outcome of sleep apnoea [342].  In a study of obese men in Sweden, men with OSA and 
excessive sleepiness were found to be 3 times more likely to be twice (or more) divorced than 
those with neither OSA or sleepiness [343].  A later study showed that men with OSA are almost 
3 times as likely to sleep separately from their wives [344].  In this study there was no 
difference in marital satisfaction between those with and without OSA, and it was speculated 
that by sleeping separately, marital harmony was maintained [344].  
1.3.7. Treatment of OSA with CPAP 
Continuous positive airway pressure (CPAP) is the standard first-line treatment for OSA. CPAP 
delivers pressurised air via a mask which splints the upper airway open during sleep and re-
establishes normal breathing and sleep patterns.  In several reviews focusing on the efficacy of 
CPAP, this treatment is recognised as being effective in eliminating airway obstruction in sleep, 
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thereby improving daytime sleepiness, blood pressure levels and quality of life [345, 346].  In a 
10 year observational study found that, compared to healthy controls, men with untreated 
severe OSA had a higher risk of fatal and non-fatal cardiovascular outcomes, and CPAP use 
reduced this risk [313].  In OSA patients whom have already had a stroke, CPAP has been shown 
in a 5 year follow up study to reduce mortality, compared to those who did not use CPAP [347]. 
Potentially, this reduced risk of cardiovascular disease may be attributable to a reduction in 
blood pressure.  A meta-analysis of 10 pooled randomised controlled trials found a statistically 
significant reduction with CPAP, however, this reduction was small, in the order of 1-2mmHg, 
but was more substantial in subjects with more severe OSA, resulting in a 2-3mmHg reduction 
[348].  Currently, a multicentre, long term study on cardiovascular outcomes (SAVE study) is 
underway to determine the efficacy of CPAP in the prevention of cardiovascular disease [349]. 
Although the efficacy of CPAP on health outcomes is high, adherence to CPAP usage is low. The 
World Health Organisation defines adherence as “the extent to which a person’s behavior … 
corresponds with agreed recommendations from a health care provider”.   In a meta-analysis of 
adherence to recommended medical treatment, categorised by 17 different disease conditions, 
compliance to therapy for sleep disorders was the lowest of all disease categories (65%). 
Complexity of the treatment regimen was suggested as a reason for low adherence [350].    In a 
Cochrane review, the highest reported average nightly usage in any randomised trial was 5.9 
hours per night for all participants [346]. This is likely to represent best case scenario.  A 
commonly used definition of adherence is that of a minimum of four hours every night. This 
duration was found to be the threshold at which longer use was unlikely to result in further 
improvements in levels of sleepiness [351].  Using this definition, only 46 – 83 % of patients 
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would be considered adherent in a variety of reviewed trials [352]. Given that even one night 
without usage results in the recurrence of OSA [353], studying the effects of CPAP on health 
and social outcomes may be limited by participants adherence to CPAP therapy. 
Partner influence on CPAP adherence can be both beneficial and detrimental.  Patients in one 
study whom had sought treatment for OSA due to their spouse rather than being self-referred 
were less adherent to CPAP therapy [354].  Relationship quality also has an influence, with 
levels of conflict in the relationship, as well as perceived pressure from partners, having an 
inverse relationship with hours of CPAP use [355, 356].  In comparison, another study showed 
that those patients whom were living with a partner tended to have a higher adherence rate to 
treatment, with an odds ratio of 1.5 of being adherent (>4hours/night) with CPAP therapy 
[357].  In a small, 2 week study, the number of nights in which a man with OSA slept in the 
same bed as his wife was positively correlated with CPAP adherence [358].  In a longer term (6 
month) sham controlled study, those who were more adherent to therapy, in both active and 
placebo arms, were more likely to be married [359].  Indeed having a partner at home has been 
identified as being a positive predictor in adherence to therapy [360].   
CPAP treatment has repeatedly been shown to reduce sleepiness, more so for patients whom 
were sleepier pre-treatment [346]. Improvements were seen on ESS scores in a long-term 
randomised controlled study using sham CPAP, particularly in those who had moderate-severe 
OSA and who were more adherent to therapy [359].  In mild OSA (AHI 5-15) a randomised 
control study using an oral placebo, CPAP treatment showed a greater improvement in ESS than 
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that of placebo, however stratification showed those with very mild OSA (AHI 5-10) did not 
show such improvement [361].   
Improvements in other parameters of quality of life have also been noted in CPAP use, 
particularly for those who experience more symptoms pre-treatment [346]. A meta-analysis of 
16 studies using the SF-36 questionnaire found that CPAP does not improve general quality of 
life, however it does improve physical function and vitality [362].  Some studies have found 
these improvements to be more pronounced for those who adhere to CPAP therapy [361, 363].   
In regards to sleep specific quality of life, the Functional Outcomes of Sleep Questionnaire 
(FOSQ) has been used in a several sham CPAP controlled studies, finding improvements in 
vigilance  [364-366], general productivity [364, 366], activity level [365, 366] and social 
outcomes [365]. However, no improvement in any domain in the FOSQ was seen for patients 
with moderate OSA (AHI 10-30) in a conservative treatment (weight loss and sleep hygiene) 
controlled study [367].  In a study assessing dosage, that is, CPAP adherence, with overall FOSQ 
scores, increasing usage of CPAP saw greater improvements in the number of patients with 
normative scores, up to 7 hours usage, after which, no further improvement was seen [351].     
Improvements in depression scores have been noted even with low usage of CPAP (2.8 ± 2.1 
hours) compared to an oral placebo [361].  In contrast, in another oral placebo randomised 
controlled study of those with mild-moderate (AHI 5-30) OSA, no change was seen in any 
parameter of the SF-35 or FOSQ questionnaire by the use of CPAP [368].  Limitations in 
interpreting this result include low usage of CPAP (3.5±2.1 hours/night) and a placebo effect 
was noted in the control arm, which may have contributed to this result [368].  However, a sub-
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analysis of those whom were adherent to CPAP therapy (>4hours) also showed no 
improvement in any domain of the SF36 or FOSQ questionnaires in this mild OSA group [368]. 
Potentially this may be due to lower symptomatology in this group.  
Relationship quality may improve with CPAP use, with one study showing CPAP users, 
compared to those recommended conservative treatment in the same sleep clinic population, 
found to show improvements in marital satisfaction, happiness and communication, all of 
which were correlated with CPAP usage, as well as a reduction in frequency of conflict in the 
relationship to reduce with adequate CPAP use [355, 369].  A potential contributor to an 
improved relationship may be due to an improved quality of life for the patient but also due to 
a better quality sleep for the partner if they share sleeping space. Both patient and partner 
have been shown to be less sleepy after the implementation of CPAP therapy, as measured by 
the ESS [363].  After the commencement of CPAP therapy, bed partners of CPAP users have 
been shown to improve in both objectively measured sleep efficiency and subjective sleep 
quality [370].   
  
 - 49 - 
1.4. SLEEP AND SEXUAL FUNCTION 
Sleep and sex are both essential human experiences.  Several medical conditions exist in which 
sleep and sex intertwine, such as Kleine-Levine Syndrome, in which periods of 
hypersomnolence occur in conjunction with hypersexuality [371].  Links between REM sleep 
deprivation and sexual behavior changes have been noted in animal models.  Sleep deprived 
rats have been shown to have increased erectile function with 24 hours of no REM sleep, but 
this phenomena declines after 96 hours of REM sleep deprivation [372].  Sexsomnia, a distinct  
parasomnia in which sexual acts are performed during sleep, has received increased attention 
through case reports, although research is lacking [373, 374].    No intervention studies on 
humans have investigated the influence of sleep deprivation on sexual function have been 
reported.  Cross-sectional data investigating lifestyle driven sleep restriction in teenagers has 
shown increased risk taking behaviour, including sexual activity related behaviours [375].  
1.4.1. Sleep and Testosterone 
There is increasing recognition of the role sleep plays in metabolic and endocrine processes.  
The circadian pattern in the release of testosterone is so well established that standard 
practices require blood samples be taken at the same time of day – early morning – to ensure 
the sample reflects the peak testosterone level achieved throughout the day [148, 155]. 
During sleep, surges of testosterone are seen when frequent (every 10-20 minutes) blood 
samples are drawn [376, 377]. A testosterone surge is initiated by a rise in luteinising hormone, 
which has been shown to peak around 2 hours prior the peak of testosterone, however, this 
diurnal variation is not seen for those administered exogenous testosterone [378]. 
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Confirmation of a relationship between sleep stages and testosterone has not yet been fully 
documented.  Some studies relate a surge in testosterone with sleep onset, others relating it 
with REM sleep, still others report no relationship with any sleep stage [376, 379, 380]. One 
small study of 6 healthy males found vast interpersonal variability with regards to hormone 
pulsatility, with these pulses maintained for the individual over time  [381].  One limitation with 
the correlations made between sleep stages and testosterone release is the differing sampling 
rate between the two parameters.  Sleep studies are analysed on the basis of each 30-second 
block, each allocated a particular stage of sleep, which are dynamic and can change frequently 
around a basic regular pattern in a healthy adult.  Blood samples were collected every 30 
minutes in some protocols, during which time it is feasible that several sleep stages had 
occurred between samples. The closest blood sampling time interval to that of the 30 second 
sleep staging is that of 2.5 minutely.  This study described testosterone increases as being 
tightly related to sleep stage, in that surges occurred 2.5 minutes prior, and up to 25 minutes 
after, sleep “deepened” but fails to describe which sleep stage, named in the conventional 
manner, this refers to, but may refer to NREM sleep in general [382].   
Testosterone concentrations are at their peak at the beginning of the waking day, and fall as 
the day progresses [383]. To determine whether this is circadian or sleep stage dependent, 
several studies have misaligned sleep and circadian phase. One study allowed 7 minute sleep 
opportunities within every 20 minutes, which allowed for a normal sleep total duration over a 
24 hour period.  This study found that although the levels of testosterone remained the same 
as during continuous sleep, testosterone secretion was delayed, and was only exhibited by 
those who had REM sleep during the short sleep bout [384].  In another study, which 
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misaligned sleep periods so that sleep occurred during the day, testosterone was found to be 
highest after a full sleep period, whether that was during the day or night, and circadian effects 
were only marginal [385].  This concept of testosterone secretion being mediated by sleep is 
confirmed by studies relating reduced sleep efficiency, or reduced time spent asleep with 
reduced testosterone levels.  In extreme cases, such as several days of sleep deprivation in 
military operations, androgen levels have been reported to fall as much as 70-90% [386]. 
Reduced testosterone levels have been associated with decrease in sleep efficiency, sleep 
duration, lower number of REM sleep episodes and altered REM sleep latency [387, 388], 
however, this finding is not consistent, with another study of healthy men with artificially 
reduced testosterone levels showing no change in REM duration or latency [227], suggesting a 
unidirectional relationship of sleep influencing testosterone.  This relationship, however, is not 
consistent, with other authors finding no such association between sleep duration and 
testosterone levels [389].  At the other end of the spectrum, supraphysiological doses of 
exogenous testosterone have been shown to reduce sleep time, in the context of an increased 
severity of OSA [260].   
Suggestion has been made there may also be a seasonal variation in testosterone levels.  For 
example, 915 men living in Northern Norway, exposed to extremes of light and dark across the 
year, were found to have peak testosterone levels in the winter and nadir in the summer, with 
a range of 31% difference between them [390]. The same authors then studied a group of men 
living in California, who are not exposed to such extremes of light and dark, and found no such 
relationship [391]. A large (n=11,000) study in the south-west of United States of America, 
which also lacks light extremes, categorized blood samples in a mens health practice by month 
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and season, and found seasonal variation in oestradiol, follicular stimulating hormone, and sex 
hormone binding globule, but not testosterone [392].  A recent review, however, was unable to 
confirm or deny this relationship, given the vast amount of variables unaccounted for [393].  
1.4.2. OSA and Testosterone 
Potentially, there is a bidirectional relationship between testosterone and OSA – namely sleep 
disordered breathing may reduce levels of testosterone and supraphysiologically high levels of 
testosterone may increase sleep disordered breathing.  Many symptoms of OSA and reduced 
testosterone overlap, including low sexual desire, erectile dysfunction, mood disturbance and 
lack of energy.  A marked preponderance for males to develop obstructive sleep apnoea over 
females is suggestive of a hormonal, namely testosterone, influence in the pathogenesis of this 
condition. 
An independent association between the presence of OSA and a reduced level of total 
testosterone has been previously shown by several authors [384, 389, 394-396]. Compared 
with snorers, those with OSA as measured via exhaled CO2 and pulse oximetry, were found to 
have reduced levels of testosterone [389].  Similarly, reduced levels of testosterone were found 
in a sleep clinic sample of those who had AHI greater than 5 compared with those with an AHI 
less than 5, even after excluding those with diabetes, previous ED treatment, abnormal 
hormonal status and endocrine disturbance, however, the level of testosterone did not differ 
between those diagnosed with mild, moderate or severe OSA based on AHI  [396].  Additionally, 
although age did not differ between the two groups, those with an AHI greater than 5 had a 
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higher BMI (32 vs 28), and since increased weight is known to reduce testosterone [157], this 
result should be interpreted with caution. 
A reduction in testosterone due to OSA may be due to a several factors.  A proposed 
mechanism for this relationship is the interruption to normal sleep related endocrine processes, 
namely the pulsatility of luteinizing hormone and subsequent testosterone release [384].  
Indeed repeated measurement of testosterone during sleep via frequent sampling (every 20 
minutes) found a relationship between the degree of sleep apnoea in terms of AHI and reduced 
bioavailable but not total testosterone, however this association was lost after adjusting for age 
[387]. Sleep efficiency, was however, positively associated with circulating testosterone [387].  
The frequent interruptions to sleep by OSA, may lead to a subsequent reduction in overall sleep 
time obtained, which, as several authors have established, reduces testosterone levels [385, 
397].  
Alternately, the repetitive oxygen desaturation and resaturation which occurs due to repetitive 
apnoeic events may be a contributing factor. This frequent intermittent hypoxia has been 
associated with reduced serum testosterone [389], whereas other physiological measurements 
associated with OSA, such as frequency of respiratory events or their associated arousals have 
not shown any such association [389, 394].  Stratification of OSA severity by minimum 
saturated oxygen levels showed a lower level of testosterone with those who desaturated to a 
lower level, an association which remained after adjusting for age and obesity [398].  
Many men with OSA will unfortunately remain untreated due to difficulties with current 
treatment modalities.  Adherence with the most effective treatment for OSA, CPAP, is poor, 
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with estimated non-adherence rates of between 46-83 percent [352].  These untreated men, as 
well as those yet to be diagnosed, will continue to exhibit symptoms and be at risk of the 
cardiovascular consequences of OSA.  Unfortunately, many symptoms of OSA are also common 
to androgen deficiency – fatigue, low mood, poor concentration and erectile difficulties, which 
may lead to treatment directed toward restoring androgen levels without addressing 
underlying sleep apnoea.  
1.4.3. OSA and Sexual Desire 
The original mention in the scientific literature of sexual problems being present in those with 
OSA is in Guilleminault’s paper describing 25 OSA cases in 1977 [342].   This paper refers to 48% 
of men having “sexual problems” namely “impotence” and proceeds to discuss this in terms of 
a reduction in both erectile function and sexual drive, which can create confusion for the 
modern reader.   
Some studies in the literature state that low sexual desire is a symptom of obstructive sleep 
apnoea, a fact assumed to be so well-known that no reference is given [399, 400].  Many other 
papers refer to Guilleminault’s paper as the proof that men with OSA have low sexual desire 
[57, 401-404], however, there is a paucity of modern research utilising best practice techniques, 
such as using validated measurement techniques and control groups to confirm this 
relationship (see Table 1.1).   
Studies which have looked at the link between OSA and sexual desire have been small and with 
mixed results.  In one survey study, which included only those men with partners, questionnaire 
data was used to classify men into either mild, moderate or heavy snorers, and found no 
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difference between these groups in terms of sexual desire [405]. In a study of men having 
polysomnography for suspected OSA, no difference was found in regards to desire for 
tenderness, intercourse or masturbation between those who did and did not have OSA, 
however those whom had severe OSA (AHI>30) reported less masturbation than those in the 
no, mild and moderate OSA groups [406].  Age was, however, found to be associated with a 
reduction in desire [406]. In a study in which data was stratified by age, only in the age group of 
40-49 years was there a difference in sexual drive between OSA and controls [407].  In a study 
using questionnaire data to determine the presence of OSA, the group was divided into those 
with low and regular sexual desire, and the group of low sexual desire were found to have a 
greater likelihood of OSA than those in the regular sexual desire group [221].  Studies using the 
Golombok Rust Inventory of Sexual Satisfaction questionnaire found that in the domain closest 
to that of sexual desire, ‘nonsensuality’, no difference was found between those with OSA and 
a control group, or between groups of no, mild, moderate and severe OSA [396, 408].  Only one 
study has reported a relationship between the severity of OSA, in terms of lowest recorded 
nocturnal SaO2 with a reduction of sexual desire [409].  In this study, there was a trend toward 
a relationship with AHI (p=0.062) and mean SaO2 (p=0.062) when data was stratified into 
quartiles [409].  One major symptom of OSA, sleepiness, may in theory affect sexual desire. In a 
study of 176 men with OSA, 69% of participants reported reduced sexual desire due to 
sleepiness, as measured in the FOSQ Intimacy and Sexual Relationships domain; however no 
control group exists to compare this result [410]. Survey data in the US in 2008 (National Sleep 
Foundation Poll) investigating this relationship found that 20% of people surveyed have sex less 
often or have lost interest in sex because they are too sleepy [411].   
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Clinical trials of treatment for OSA provide an insight into the effect of OSA upon sexual desire. 
In a small study (n=12), men who had undergone surgery for OSA (uvulopalatopharyngoplasty), 
those who reported low sexual desire pre-surgery via interview, reported improvements to 
normal levels 3 months post-surgery [389]. The results from this study are limited since it was 
uncontrolled, and had no numerical validated measurement of sexual function.  In a larger 
study (n=83) of men prescribed CPAP, those whom adhered to therapy over 3 years (n=56) had 
improved sexual desire, as measured by the IIEF questionnaire, compared to those men whom 
did not use CPAP as recommended [412]. This may have been due to the decline in sexual 
desire in those whom did not use CPAP, but also, those who chose to continue with CPAP may 
have done so because have received a greater treatment effect.  In a separate study comparing 
CPAP with a mandibular advancement splint, no improvement from baseline for either 
treatment was found in any facets of sexuality other than ED after usage for 2-3 months [408].   
The hypoxia experienced by those with OSA may influence levels of sexual desire.  In mice 
models, chronic intermittent hypoxia of reduction of oxygen in the air from 21% to 7% for 6 
minutely intervals, leading to a minimum blood oxygen level of 76%, reduced the number of 
sexual behaviours, although there was notable individual differences between mice [413].  
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Table 1.1 Studies investigating OSA and sexual desire relationship 
Author N  Age (years) Desire 
Measure 
OSA Measure Results Comments 
Guilleminault 
(1977) [342] 
25 44 (25-65) Self-
report  
PSG  48% reported ‘impotence’ Terminology: “sexual problems”, 
“impotence” and “abatement of 
sexual drive” used 
interchangeably.  
Hoekema 
(2007)[408] 
96 OSA: 49±9 (n=48) 
Control: 48±8 
(n=48) 
GRISS  PSG   No difference in non-sensuality 
between OSA and controls 
Treatment with either CPAP or 
MAS did not improve non-
sensuality scores 
Hanak  
(2008) [405] 
827  64 (51-90) BSFI  Questionnaire No difference in sexual desire 
between non-snorers, moderate 
snorers or heavy snorers 
Only men with partners included 
in the study.  Older age group.  
Stannek 
(2009) [406] 
158 OSA: 51±11 
(n=131) Control: 
47±14 (n=27) 
MMAS  PSG No difference in sexual desire 
between OSA and control.  
No difference in sexual desire 
between OSA severity categories.  
Age reduced sexual desire.  
Budweiser 
(2009) [409] 
401 No ED: 50 (42,55)     
ED: 62 (54,70) 
IIEF-15 PSG No difference in sexual desire 
between OSA and controls 
No differences between OSA 
severity categories. 
Petersen 
(2010) [407] 
308 51 ± 10 BSFI  Limited PSG 
(no EEG) 
No difference in sexual desire 
between OSA and controls for 
ages 30-39, 50-69 Only at age 40-
49 years showed OSA less desire 
than controls * 
No correlation with severity of 
OSA 
(Continued over) 
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Table 1.1 Studies investigating OSA and sexual desire relationship (continued) 
Author N  Age (years) Desire 
Measure 
OSA Measure Results Comments 
Reishtein 
(2010) [410] 
123 46 ± 8 FOSQ  PSG 69% reported reduced 
desire  
No differences between OSA severity 
categories. CPAP treatment improved 
number of men with reduced desire 
compared to baseline (69% to 40%) ** 
Martin 
(2012) [221] 
1195 35-80 Sexual 
Desire 
inventory  
Maislin 
Questionnaire 
The probability of having 
OSA increased risk of low 
sexual desire.* 
13.5% of all men had low dyadic desire                                            
68% of all men had low solitary desire. 
Ak (2013) 
[396] 
85 38 ± 8 GRISS PSG No difference in non-
sensuality between OSA 
and controls 
No differences between OSA severity 
categories. 
Note: *p<0.05, **p<0.01, Age data are mean ± SD, mean (range), median (25th, 75th) or range.  Abbreviations:  BSFI = Brief Male Sexual 
Functioning Inventory, ED = Erectile Dysfunction, FOSQ = Functional Outcomes of Sleep Questionnaire, GRISS = Golombok Rust inventory of 
sexual function questionnaire, IIEF = International Index of Erectile Function, MMAS = Massachusetts Male Aging Study questionnaire, 
N=number of study participants, OSA = Obstructive Sleep Apnoea, PSG = Polysomnography. 
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1.4.4. OSA and Erectile Function 
Many authors have interpreted Guilleminault’s original 1977 paper as being 48% of the 25 men 
with OSA (n=12) had erectile dysfunction [342, 414-417].  Guilleminault further stated in a later 
article which reported the success of tracheostomy as a treatment for sleep apnoea, that 44% 
had erectile or ejaculatory difficulties, while 4% had impotence [418].  Some early case reports 
in the early 1980’s of men with OSA also state that these patients had erectile dysfunction [419, 
420].  In more recent times, there has however, been uncertainty regarding this link.  
Prevalence studies have been conducted in patients presenting in general populations (see 
table 1.2), ED clinics (see table 1.3), and sleep clinics (see table 1.4), with differing results.   
One early study on 70 healthy older men (aged 45-74), recruited via media advertisement, 
came to the conclusion there was no link between erectile dysfunction and sleep disordered 
breathing [421]. This study however, used inadequate techniques to establish the presence of 
OSA, such as the use of a single measurement of breathing via a thermister – now known to 
have significant limitations – and no measurement of oxygen saturation levels. Later research 
found this latter measurement relevant, in that oxygen saturation parameters were to be 
strongly correlated with erectile dysfunction [409, 414, 422].  In another study of healthy 
community based men, there was no association found between no, mild, moderate and heavy 
snoring and either erectile function or sexual desire. Although snoring is not indicative of the 
degree of apnoea, the authors however did find that heavy snorers tended to have reduced 
sexual satisfaction compared to the non- and mild snorers [405].  A study of 3,363 defense 
force personnel found an association between sleep quality and sexual function, including 
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when data was adjusted for known risk factors of OSA and ED [423].  This correlation, however, 
was not specific to OSA, rather sleep disorders in general, suggesting that other factors causing 
sleepiness may also be a contributor to sexual dysfunction. Although questionnaire based 
determinants of both erectile function and sleep disorders provide limited evidence, they 
contribute to the overall understanding of the association.   
The risk of developing ED in the context of OSA was determined in a recent large population 
study of 467 men in the city of Sao Paulo, Brazil.  For those men with an AHI of greater than 15, 
the odds ratio of having ED was 2.75 times that of men who had an AHI of less than 15.  
Similarly, for men who exhibited both an AHI of greater than 15 and symptoms of OSA, this risk 
is 2.12 that of men without the OSA syndrome [57].   
Patients presenting with ED to sexual health clinics, urologists, and other related services, have 
been studied in relation to OSA. As recently as 1999, however, a comprehensive review of the 
current literature regarding pathophysiology of ED did not list OSA as a risk factor, or mention it 
in any context [50]. At around this time, ED was sometimes investigated using nocturnal penile 
tumescence measurement during sleep in order to determine if ED was due to a physiological 
or psychological problem [101].  A clinic in Florida performed only 37 such overnight studies 
over 5 years (1990-1995) and found that 60-70% of men had an AHI of greater than 5 [424].  
This may not be representative of prevalence rates since this convenience sample of an erectile 
dysfunction clinic population, which may have advanced age, higher prevalence of diabetes and 
other risk factors common to both conditions. Consecutive patients who presented at a urology 
clinic were administered a Berlin questionnaire regarding symptoms of sleep disorders. Of 
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these 285 men, 27% were considered to have a high risk for OSA.  Initial univariate analysis 
suggested snoring as being correlated with ED, however, once age and pre-existing medical 
conditions were added to the analysis, there was no longer a correlation [416]. 
In men presenting to a sleep clinic, subjective sleepiness, a common symptom of OSA, as 
assessed by the Epworth Sleepiness Score (ESS), was shown to be positively correlated with ED 
severity on the IIEF questionnaire [425]. A study using a limited channel PSG (no EEG), and a 
single questionnaire in 98 men with OSA, found 25% had ED, however, there were no 
correlations between ED and OSA severities [426].  Men undergoing full polysomnographic 
evaluation in sleep clinics have also been assessed regarding sexual function using a variety of 
subjective questionnaires.  Using an abridged form of the IIEF to evaluate erectile function, of 
those 209 men with an RDI greater than 5, the occurrence of ED was higher than those with an 
RDI of less than 5 [427], however, when this group of patients was stratified on the basis of 
severity of OSA, only those with severe OSA (RDI >40) were found to have ED [427].  This study 
was performed using a thermistor to quantify sleep apnoea, now known to underestimate the 
degree of sleep disordered breathing [428].  In a similar study of 85 snoring men being assessed 
at a sleep clinic, no difference was found regards erectile function, as measured by the GRISS 
questionnaire between those with an AHI above and below 5, however, this study excluded all 
participants with previous history of diabetes, endocrine disturbance and hormonal imbalance 
which may have diluted the outcome [396].  This study did not describe the method used to 
assess sleep or breathing, apart from having a sleep test, which limits interpretation.  
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In order to firmly establish the link between OSA and ED, both best practice measurement and 
research techniques needed to be utilized, while accounting for known risk factors. The gold 
standard method of diagnosing obstructive sleep apnoea is a multiple channel nocturnal 
polysomnograph [429], using pressure transduced airflow [282, 428].  The International Index 
of Erectile Function questionnaire has been established as being one of the most robust 
measurements of ED [89, 90, 430].  The most thorough research methodologies would utilize 
both of these measurements.  To date, there have been three such studies.  Budweiser (2009) 
studied patients attending a sleep clinic for suspected OSA.  In men with at least mild 
obstructive sleep apnoea with an AHI of greater than 5, 65% reported at least mild ED as 
measured by the erectile function domain of the IIEF questionnaire, compared to 34% of men 
without OSA. This higher prevalence remained even after the comorbidities of obesity, 
diabetes, hypertension and age were accounted for [409].  Similarly, 44% of patients presenting 
to a sleep clinic were found to have ED, also measured via the IIEF as well as NPT [431].  In the 
largest study done to date (n=1025) in men with erectile complaints, 44% of them were found 
to have at least mild obstructive sleep apnoea (AHI>5) as measured via polysomnography [415].  
In contrast, in a recent study of 62 men, although 64% of men with OSA were found to have ED, 
there was no difference in prevalence of ED between those with and without OSA once BMI 
and age was accounted for [432]. These high quality studies suggest there is a high association 
between OSA and ED, although obesity and age may be contributing factors.  
A potential explanation of the association between OSA and ED is that of disruption of REM 
sleep caused by OSA reducing the quality of sleep related erections, which normally occur 
during each REM sleep period  [30]. These episodes of penile blood engorgement increase 
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corporeal oxygenation and may function to protect the morphological integrity of the penis [30, 
31].  The first study to report impaired NPT with patients with OSA was in 1981 [433]. This study 
found that half of patients with apnoea or hypoventilation (n=7) showed impaired NPT [433].  
Likewise, on review in 1986 of 31 patients being investigated for ED with NPT, 10 of these 
patients had sleep apnoea, resulting in disturbed nocturnal erections. The conclusion of this 
study was that full sleep studies should be performed in conjunction with NPT to ensure that 
there is not an incorrect diagnosis of an abnormal NPT, rather than commenting on a potential 
causal pathway [434]. In the same year, another clinic found that the addition of respiratory 
channels facilitated the diagnosis of sleep apnoea, in that 5 of 30 patients had OSA [435]. As 
recently as 1994, the accuracy of NPT monitoring was said to be reduced, indeed “erroneous”, 
when sleep disturbances such as apnoea are present, rather than a potential cause of erectile 
dysfunction [436].  One of the first studies to report a link between the two was in 1989, when 
a small correlation was found between apnoea index and penile rigidity in a study of 285 
patients [437]. In contrast, a study performed around the same time, which did not monitor 
oxygen levels, found no association between NPT results and AHI [421]. However, this lack of 
oxygen monitoring severely limits both the accuracy of the measurement of OSA.  In a later 
observational study of the effects of CPAP treatment, of 22 patients with ED symptoms and 
OSA, 15 (68%) had abnormal NPT readings [438]. Although this study does not have a control 
group with which to compare frequency of impaired NPT, the presence of 7 men who had both 
OSA and ED who did not have an impaired NPT, suggests there may be other contributing 
factors to this relationship. A more recent study found that morning erection, assessed 
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subjectively, was the characteristic of sleep related erections most affected by the severity of 
OSA, as measured by PSG [427].  
In a review of literature current at the time (2003), data was suggestive of a link between OSA 
& ED, suggestion was made that research into direct correlations between severity of each was 
required, once common risk factors had been removed [439]. Several studies have since 
investigated which parameters of OSA have the most positive correlation with ED. Although a 
higher incidence of ED in men with OSA was reported, three studies have been unable to 
identify any measured OSA parameter to be correlated with ED severity [406-408]. This may be 
due to patient selection including those OSA but without ED, making correlative findings 
difficult.  In contrast, several more studies have found correlates.  Studies using NPT have 
reported that OSA severity was associated with ED aetiology, with the mean AHI significantly 
higher in those with organic compared to psychogenic ED [407, 415, 433].  Margel et al (2004) 
reported that in their OSA sample the respiratory disturbance index (RDI), but not the number 
of oxygen desaturations, predicted ED as measured by the abridged IIEF [427]. Additionally, 
morning tiredness has also been identified as a predictor of ED [427].   The majority of studies 
however, report the highest indicator has been those variables associated with nocturnal 
saturation. The minimum observed SaO2 overnight was found to be correlated with ED 
prevalence in one study, while in another, a minimum SaO2 of less than 77% was found to be 
highly predictive of ED [414, 422].  In a study of 401 men, categories of OSA severity based on 
quartiles of mean (<91%, >91-93%, >93-94%, and >94%) and minimum (≤74%, >74-81%, >81-
85% and >85%) oxygen saturation correlated with the severity of ED, however no such 
correlation was found with AHI [409]. Several studies have found minimum nocturnal SaO2 
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levels to be strongly correlated with ED incidence rates [409, 414, 422]. Furthermore, a recent 
study identified that mean nocturnal SaO2 levels independently predicted ED [409]. The theory 
of intermittent hypoxia causing ED has been tested in mice models, by adjusting oxygen levels 
in the air, leading to 10 hypoxic episodes per hour to a minimum of 76%.  This study found that 
intermittent hypoxia reduced the number of spontaneous erections by 55%, without change in 
testosterone levels, in mice, [413]. One suggested mechanism is that the repeated hypoxia of 
OSA may have an impact on endothelial function, which translates into a reduced ability to 
transport sufficient blood for erections [417]. Alternatively, another author suggests the 
hypoxia of OSA is associated in nerve dysfunction, thereby affecting erectile capacity [404]. 
Another theory is that hypoxia reduced testosterone levels, thereby impacting on erectile 
function [440].  
The relationship between low oxygen levels and gonadal dysfunction was reported more than 
50 years ago after Sir Edmond Hillary’s expedition to the Himalayas, although the exact 
meaning of dysfunction is unclear [441].  A recently case study reported a mountaineer in Nepal 
monitoring his nocturnal erections for 42 consecutive nights via Rigiscan measurement found a 
decline in erection duration and tumescence with ascent to higher altitude with lower 
atmospheric oxygen [442]. Given the preservation of REM sleep at altitude, unlike that of slow 
wave sleep, [443] this is more likely to be due to the reduction in the partial pressure of oxygen 
at altitude and thus overnight oxygen saturation levels.   
There is some evidence that those with respiratory failure have an impaired hypothalamic-
pituitary function which may lead to erectile dysfunction [444, 445]. Nocturnal penile 
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tumescent monitoring of a small group (n=20) of men with chronic obstructive pulmonary 
disease found a relationship between erectile function and pulmonary impairment [446]. The 
influence of testosterone differed in these studies, with one finding no difference in those with 
and without erectile function [446], while another did [447].  Oxygen treatment in these 
patients has been shown to improve erectile function in some cases.  In a group of 12 men with 
chronic obstructive respiratory disease and erectile dysfunction, who received oxygen therapy 
for one month, 5 of these men (42%) regained erectile function, defined as a reappearance of a 
morning erection. Both testosterone and PaO2 was higher in these patients than in those who 
did not respond to therapy.  A single 24 hour period was insufficient to improve erectile 
function in these patients, suggesting longer term therapy is required for effective treatment 
[448].  The effects of oxygen therapy in patients with ED but without respiratory disease have 
not been investigated [444].  
Overall, the literature, though limited by studies being conducted in varying populations, using 
different outcome measurement tools, and often in small study populations, suggests an 
association between ED and OSA, with reduced oxygen levels being one of more likely 
explanatory variables. Potential other variables include a reduction of testosterone, due to 
sleep disruption and hypoxia, depression, and a disruption to sleep related erections, as 
schematically described in figure 1.1. 
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Figure 1.1 Potential mechanisms between OSA, ED and low sexual desire 
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1Table 1.2 Population studies investigating OSA and ED relationship 
Author N  Age (years) ED Measure OSA Measure Results 
Schiavi 
(1991) [421] 
70 Range: 45 -
75 
NPT & 
psychosexual 
interview 
Partial PSG (no 
SaO2 or 
respiratory effort) 
No correlation between sleep disordered breathing parameters 
and NPT/sexual function parameters once age was accounted for. 
Heruti 
(2005) [423] 
3363  36 ± 7    
(mean ± 
SD) 
 
IIEF-5  Sleep Quality 
questionnaire  
Correlation between IIEF-5 and SQ (r=-0.21, p<0.00001) after 
adjusting for age and excluding men with HT, diabetes & obesity.  
Sleep quality questionnaire not specific to sleep apnoea. 
Hanak 
(2008) [405] 
827 64 (51,90)  
median 
(25th, 75th 
percentiles) 
BMSFI  Snoring 
Questionnaire  
Heavy snorers twice as likely to have lower sexual satisfaction 
compared to mild/non-snorers, after adjustment for potential 
confounders.  No association between degree of snoring and 
erectile function. 
Andersen 
(2010) [57] 
467 Range: 20-
80  
MMAS single 
question  
PSG Odds ratio 2.75 of having ED if OSA (AHI>15) compared to no OSA 
(AHI<5) (p=0.0001) 
Odds ratio 2.19 of having ED if OSA (AHI>15) & sleepiness if have 
ED compared to no OSA (AHI<5) (p=0.003) 
AHI = Apnoea Hypopnoea Index, BMSFI=Brief Male Sexual Functioning Inventory, ED = Erectile Dysfunction, HT=hypertension, IIEF-5 = The 5-item 
International Index of Erectile Function, MMAS = Massachusetts Male Aging Study, N=number of study participants,NPT = Nocturnal Penile 
Tumescence, OSA=Obstructive sleep apnoea, PSG = polysomnography, SD=Standard deviation, 
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 Table 1.3 Studies investigating prevalence of OSA in ED populations 
Abbreviations: AI=Apnoea Index, AHI = apnoea hypopnoea index, ED = Erectile Dysfunction, ESS = Epworth Sleepiness Scale, , scale, IIEF= international index 
of erectile function, OSA = obstructive sleep apnoea, N=number of study participants, NPT = nocturnal penile tumescence, NR=Not reported, PSG = 
Polysomnography.  
Author N  Study 
population 
Age (years)  
(mean ± SD) 
ED 
Measure 
OSA 
definition 
OSA Measure Prevalence 
of OSA (%) 
Comments 
Pressman 
(1986) [434] 
31  NPT clinic 58 ± 6.8 NPT AHI ≥ 5 Limited PSG      32 Reviewed 31 men undergoing NPT. 9 
had OSA. Concluded OSA disrupted 
NPT recording, if OSA exists, it may 
give a false reading on NPT. 
Foreman 
(1986) [435] 
30 NPT clinic: 
Both for ED 
and painful 
erections 
NR NPT NR Limited PSG      17 5 of 30 patients had sleep apnoea.  
Case reports of these 5 patients 
presented. AI range: 10-89 
Hirshkowitz 
(1990) [415] 
1025  NPT clinic 54 (NR) NPT AI ≥ 5               
AI ≥ 10            
AI ≥ 15 
Limited PSG      44                         
28                               
20 
AI was 10.5 for men with “organic” 
ED, and 8.3 for men with “non-
organic” ED 
Chediak 
(1996) [424] 
37 NPT clinic 52 ± 14 NPT AHI > 10                 
AHI > 5 
PSG 
 
49                         
57 then 70 
Result consistent across 2 nights                             
1st night then 2nd night 
Seftel (2002) 
[416] 
285 Urology 
clinic 
53 ± 13 Physician 
diagnosed 
NR Cleveland Sleep 
Habits 
questionnaire 
27 (at high 
risk of OSA) 
63% of sample had ED (n=168)             
57% of sample snored 
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y Table 1.4 Studies investigating prevalence of ED in sleep clinic populations 
Author N  OSA definition Age 
(years) 
ED 
Measure 
OSA 
Measure 
Prevalence 
of ED (%) 
Comments 
Guilleminault 
(1977) [342] 
25  NR 44 (25-
65) 
Self-
report  
PSG  48 Terminology: “sexual problems”, “impotence” and 
“abatement of sexual drive” used interchangeably. 
Case report series.  
Guilleminault 
(1981) [418] 
49 NR 47 (12-
66) 
Self-
report 
PSG 44 4% had “impotence”                                                                                      
44% had “erectile or ejaculatory difficulties” 
Fanfulla 
(2000) [404] 
25 AHI>10 
 
48 ± 12 Self-
report 
PSG 72 (any 
ED)  44 
(severe 
ED) 
 
Study assessed bulbocavernosus reflex and somato-
sensory evoked potentials of pudendal nerve in 
assessing possible involvement in cause of ED.  
Concluded nerve dysfunction may be involved in 
association between OSA & ED.  
Margel 
(2004) [427] 
 
209 AHI 5-20 (n=80)             
AHI 20-40 (n=60)    
AHI>40 (n=46)           
AHI<5 ( n=23) 
44 ± 12                    
44 ± 12                   
50 ± 10                   
50 ± 8 
IIEF-5  PSG (no 
oximetry) 
79 (any 
ED) 
All aspects of erectile function declined with 
increased OSA severity*. Severe OSA (AHI>40) had 
increased ED compared to all other groups*. Those 
with severe ED had the greatest AHI.  
Goncalves  
(2005) [414] 
98 AHI>10 
 
47 ± 10 Sexologist 
Interview 
PSG 29 MVA:  MinSaO2* and age* not AHI, BMI or SaO2 
predicted ED. MinSaO2>80%: 15% with ED                                                           
MinSaO2≤80%: 40% with ED. Different between 
groups**. 
Hoekema 
(2007) [408] 
96 AHI>5 (n=48)        
ND (controls, 
n=48) 
49 ± 9                      
48 ± 8 
GRISS  PSG NR More ED* in OSA than controls.                                                   
Correlation between AHI and nonsensuality score of 
the GRISS (r=0.311)* 
(Continued over) 
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Table 1.4: Studies investigating prevalence of ED in sleep clinic populations (continued) 
Author N  OSA definition Age 
(years) 
ED 
Measure 
OSA 
Measur
e 
Prevalenc
e of ED 
(%) 
Comments 
Budweiser 
(2009)[409]  
401  AHI>5 (n=369) AHI<5 
(controls, n=32) 
62 (54, 70) 
(ED)               
50 (42, 55)  
(No ED) 
IIEF-15 PSG 
(23% 
had 
“split 
night”) 
66 (any)    
30 
(severe) 
 
34% of controls had ED. Different to OSA group**. 
Erectile function decreased with worsening 
quartiles of AHI**, Minimum SaO2
** and mean 
SaO2** associated with ED: MeanSaO2** predicted 
erectile function after adjustment for risk factors. 
Zhuravlev 
(2009) [431] 
72  NR 44 (32-56)  IIEF-5 & 
NPT 
PSG 44 25% of those with OSA & ED had normal 
testosterone levels 
Stannek 
(2009) [406]  
158 AHI>5 (n=116)    
AHI<5 
(controls,n=42) 
51 ± 11                        
47 ± 14 
Single
IIEF 
question  
PSG NR More frequent ED in OSA than controls*                                                                 
Severity of OSA not correlated to incidence of 
sexual dysfunction. 
Petersen 
(2010) [407] 
308 
1185 
AHI>5 
ND (controls, 
collected separately) 
51 ± 10 BMSFI & 
LiSat 
PSG NR Erectile function worse in OSA compared to 
controls*.  
AHI not correlated with any outcomes. 
Cruz (2012) 
[426] 
98 AHI>20 55 ± 11 Single 
question  
Limited 
PSG 
25 No correlations or predictive parameters reported. 
Santos 
(2012) [432] 
62 AHI>5 52 (NR) IIEF-5 PSG 64.4 After controlling for BMI & Age, no difference 
between those with and without OSA in terms of 
ED, sexual satisfaction 
Ak (2013) 
[396] 
85 AHI>5 (n=42)  AHI<5 
(controls, n=43) 
38 ± 8 GRISS NR : 
“sleep 
test” 
NR No difference in ED between apnoea and non-
apnoea groups after controlling for age and BMI.  
Note: *p<0.05, **p<0.01, Age data are mean ± SD, mean (range), median (25th, 75th). Abbreviations: AHI = Apnoea Hypopnoea Index, BMSFI = Brief Male 
Sexual Functioning Inventory, ED = Erectile Dysfunction, GRISS = Golombok Rust inventory of sexual function questionnaire, IIEF = International Index of 
Erectile Function, LiSat = Fugl-Meyer Life satisfaction checklist, N=number of study participants, ND=Not Described, NPT = Nocturnal Penile Tumescence, NR 
= Not reported, OSA = Obstructive Sleep Apnoea, PSG = Polysomnography, RDI = Respiratory Disturbance Index, SaO2 = Blood Oxygen Saturation, Split Night 
= ½ of night was diagnostic, other ½ was CPAP titration. 
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1.5. TREATMENT  
Conservative treatments for both OSA and ED include modifications to lifestyle factors which 
may contribute to the severity of the condition, such as weight loss, smoking cessation and a 
reduction of alcohol intake.  If these lifestyle changes are insufficient, several treatment options 
exist.  Obstructive sleep apnoea can be treated using mechanical means such as continuous 
positive airway pressure (CPAP) or a mandibular advancement splint (MAS) or via surgery of the 
upper airway.  Erectile dysfunction is often treated using pharmacotherapy, including PDE-5 
inhibitors and androgen therapy.  There is evidence that in the presence of both conditions, 
CPAP therapy may have positive effects on ED.  Treatment of ED using pharmacotherapy, 
however, may have detrimental effects on the severity of OSA.  Treating the two conditions 
simultaneously may be the optimal treatment choice.  
1.5.1. Testosterone Therapy and OSA 
There has been much discussion in the literature regarding the effects of testosterone 
treatment in untreated OSA due to the risk of increasing the severity of sleep disordered 
breathing.  Worsening of sleep disordered breathing with exogenous testosterone was first 
described in a case report in 1983 [449], and further investigations later that decade finding a 
high degree of individual variability, with some men experiencing worsening, while others did 
not change [450, 451]. A case report on a 13 year old boy in 1994 similarly documented the 
phenomena [452].  At present, current guidelines recommend against using exogenous 
testosterone in men with untreated OSA [155, 453].  Two recent reviews investigated the 
evidence for these recommendations and found little to support such guidelines [454, 455].  
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The only exception noted is in the use of supraphysiological doses [260].  A recent study, using 
clinically appropriate doses, further investigated the relationship and showed an increase in the 
ODI in the short-term, which returned to normal levels in the longer term, with no change in 
AHI at any timepoint [456].  Several mechanisms have been posed as mediating factors 
between the exacerbation of OSA by testosterone supplementation.  Testosterone may 
stimulate breathing directly at the level of the CNS or peripheral chemoreceptors, resulting in 
an increase in ventilator response to hypoxia, thereby reducing carbon dioxide levels below the 
apnoea threshold [457, 458].  Indeed, changes in serum testosterone due to androgen 
administration have been correlated with changes in the hyperoxic ventilatory recruitment 
threshold in men with OSA.  These changes have been shown to have a time course similar to 
that seen during sleep, with a worsening of ventilatory drive correlating with serum 
testosterone levels [459].  In addition to affecting apnoeic thresholds, testosterone has also 
been shown to increase the collapsibility of the upper airway [310].  Both of these effects 
occurring simultaneously can explain a theoretical increase in the likelihood of sleep disordered 
breathing with increased levels of testosterone, however, apart from supraphysiological doses, 
this has not been substantiated.  
1.5.2. PDE-5 Inhibitors and OSA 
PDE-5 inhibitors allow blood flow to increase, enhancing the ability to obtain and maintain an 
erection.  However, for those susceptible to sleep disordered breathing, this increase in blood 
flow creates a theoretical risk of an impaired airway size due to engorgement of upper airway 
tissues, a reduction of nasal patency and an increase in the tendency for relaxation of the soft 
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tissue in the pharyngeal muscles [460-462].  These factors thereby suggest a theoretical 
increased risk of OSA, or worsening thereof. Indeed, a randomised placebo-controlled study of 
13 men with severe OSA showed a 50mg dose of Sildenafil prior to sleep increased the AHI, 
ODI, and amount of time hypoxic while asleep [463, 464].  This small study requires further 
investigation to determine if a lower dose of PDE-5 inhibitors is safe for those with OSA [465]. 
1.5.3. Effect of Treatment for OSA on Sexual Function 
CPAP treatment for OSA has shown mixed results in regard to the effect on testosterone levels, 
however, as with all CPAP studies, adherence to therapy can be as low as less than 50%, which 
limits our understanding of the effect of CPAP on testosterone [352].  An early trial, only 8 years 
after CPAP was first described [466] showed that three months CPAP, total, but not free, 
testosterone increased [398].  This study was performed when the CPAP mask was glued on, 
rather than the current straps which are easily removed, which may have resulted in a high 
adherence rate, however this cannot be verified.  Also showing an increase in testosterone was 
a study in which blood samples were taken every 20 minutes during sleep on men who had 
been treated with CPAP for nine months [467].  This increase was on the basis of mean 
testosterone levels and area under the curve of the frequent overnight sampling, rather than 
the more commonly used one-off morning sample.  Men undergoing UPPP surgery to alleviate 
OSA have been shown to have an improvement in testosterone levels [389].  On the other 
hand, several studies have found treatment of OSA using CPAP did not raise levels of 
testosterone. In a study of men with low (<12 nmol/L) baseline testosterone, no improvement 
with CPAP was seen after three months [431].  However, in that study, the adherence to CPAP 
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therapy was not described, nor exploratory statistics of those men adherent to therapy 
reported. A single night of CPAP therapy was insufficient to improve testosterone levels of 28 
men with OSA [468].  In a sham controlled study of 3 months duration, no change in 
testosterone was seen before and after CPAP use, however, there was a decline in testosterone 
for those allocated to placebo treatment, resulting in a difference between groups [469].  A 
study of patients for whom CPAP therapy was documented as being more than 5 hours usage 
per night for 11-36 months also did not show an increase in testosterone levels [470].  Likewise, 
no change in testosterone levels was found in a study of 16 men after 6-10 months of CPAP 
therapy [471].  Similarly a study comparing the efficacy of CPAP and Mandibular Advancement 
Splints found that neither increased testosterone levels [408].  The majority of these studies do 
not show an increase in total testosterone, with the exception of that seen in frequent 
overnight sampling and those with potentially higher efficacy of therapy, that is, surgery or 
higher adherence with therapy.    
Studies of the effect of CPAP on erectile function have been performed in general OSA 
populations, as well as in men with OSA and ED, the distinction of which should be noted (see 
table 1.5).  A recent review, using theoretical mechanisms together with observational and 
uncontrolled studies concluded that CPAP therapy for OSA improves ED [30].  These studies 
have used objective measures such as nocturnal erection monitoring, or subjective 
measurement, or a combination of the two.  
One of the first studies to report on the effect of CPAP treatment upon erectile function used 
mercury strain gauges to monitor sleep related erections.  Of the 22 OSA patients presenting 
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with ED, 15 had impaired NPT recordings on a night without CPAP, defined as penile rigidity less 
than 500 grams and a tip circumference change of less than 16 millimeters.  Overall, there was 
no change in NPT parameters with one night of CPAP.  There were five individuals who no 
longer had an impaired reading when CPAP was used [438].  However, there was still a 
moderate degree of OSA (RDI 18/hour) despite CPAP treatment.  Potentially, a more effective 
CPAP treatment may have further improved erectile function. Due to the small observational 
nature of this study, interpretation of this result is limited.  Additionally, considerable night-to-
night variability in NPT recordings have been reported [472], which may go some way in 
accounting for the change in NPT, rather than the treatment used. In the only other study 
assessing the impact of CPAP on nocturnal erections, three months of treatment which 
included participants using CPAP or who had undergone surgery, only the change in percentage 
rigidity was reported, which showed an improvement from 13.8% to 40% for rigidity greater 
than 80% [354].  Commonly cited measurements of the Rigiscan device, such as duration, 
rigidity activation units and tumescence activation units were not reported in this study, 
however. 
Several within-individual, before and after studies have also shown improvements in sexual 
function with 2 weeks to 12 months of CPAP therapy [410, 414, 438, 473-475]. Improvements 
in the FOSQ Intimacy and Sexual Relationships domain, as well as its component parts, that is, 
the effect of sleepiness on desire, intimacy, arousal and orgasm, were seen with CPAP use for a 
minimum of 3 months in all OSA patients (n=123) studied.  When stratified by AHI severity, only 
those with AHI greater than 60 had significant improvement [410]. In a study assessing the 
efficacy of a hypnotic medication in relation to CPAP adherence, there was an overall 
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improvement in the domain of intimacy in the FOSQ questionnaire after 2 weeks of CPAP use in 
72 men with OSA, not selected on the basis of ED [476], however, a much larger randomised 
control trial of 113 men and women with mild to moderate OSA (AHI 5-30) did not show any 
improvement in this domain after 8 weeks of CPAP treatment [366].  Another  study of 17 men 
with OSA and ED found that ED resolved after one month of CPAP in 13 subjects; however ED 
assessment was by sexologist interview and not a validated instrument [414].  Using the IIEF 
questionnaire, a study in a group of 15 men with OSA and ED also found improvements in 
erectile function after 3 months of CPAP [473].    In contrast, one study, which included diabetic 
men with and without ED did not find an improvement in erectile function after 3 months of 
CPAP usage, a result which may be influenced by the presence of diabetes, a condition known 
to worsen erectile function [477, 478]. Limitations to these studies, however, include having a 
small number of participants, a lack of placebo control and being of short duration.    
Longer term (6-12 months) uncontrolled studies of men with OSA also show improvement in 
erectile function with continued CPAP treatment, at least in those with severe OSA [479, 480]. 
In a study of 98 OSA patients, 25 had symptoms of ED, assessed clinically.  Of these, one in 
three men had resolution of their ED with 6 months of automatic CPAP (APAP) use however this 
was not statistically significant [426].  In a study of 209 men with OSA, which included those 
with and without ED,  erectile function improved after 12 months of CPAP treatment in 20% of 
subjects, and this improvement was positively correlated with CPAP compliance, baseline AHI 
and minimum oxygen saturation [479].  One year of adherent CPAP treatment (usage > 4 hours) 
in 147 men, again with and without ED, improved scores in erectile function, and sexual drive, 
as measured by the BSFI, however this result comprised 50% no change, 13% scored worse, and 
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37% had improved [474].  One longer term (3 year) study found that in men with OSA, who 
were prescribed CPAP, of which 61% had ED, erectile function declined overall.  This was due to 
a poor adherence rate to CPAP (38% did not use CPAP), and those men who did not use CPAP 
had a decline in erectile function, compared to those who used CPAP having no change overall, 
suggesting that CPAP prevented a decline in erectile function.  In the subset of patients who 
had moderate-severe ED, there was a very slight improvement in erectile function with CPAP. 
Although there was minimal effects on erectile function, this study did show that CPAP users, 
compared to non-users showed a significant increase in overall sexual function as measured by 
the IIEF, as well as individual subdomains ‘orgasmic function’ and ‘overall satisfaction’ [412].  
Prospective studies of CPAP treatment have shown mixed results.  A small (n=27) randomised 
no-treatment controlled study showed a significant improvement in ED after one month of 
CPAP despite a significant residual OSA (AHI = 29) persisting in those randomised to CPAP 
therapy [481]. The lack of an adequate placebo, however, does not allow for the patient to be 
blinded to therapy and limits the interpretation of this result.  Another one month prospective 
randomised study of CPAP therapy, using an unnamed selective serotonin reuptake inhibitor 
antidepressant, as a control, found that CPAP therapy in those with severe sleep apnoea was 
sufficient to increase IIEF scores from 15 to 19, compared with a change from 13 to 14 with the 
antidepressant, however, the significance of this difference was not reported [417].  Given that 
some anti-depressants are known to cause or worsen erectile dysfunction [482], this 
comparison group makes interpretation difficult. No change in erectile function was seen in 
another study of one month duration which compared the effect of CPAP against mandibular 
advancement by oral splint in a crossover design, however, this study did not assess ED by IIEF, 
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and included men with and without ED [408]. In a study using either CPAP, mandibular 
advancement splint, or surgery (uvulopalatopharyngoplasty), as selected by the patient, only 
those who had surgery were found to have improvements in the Korean version of the IIEF, 
however surgery improved but did not resolve OSA (AHI at baseline 29.6±21.6, at follow up 
18.5±15.6, p=0.027) [483]. Similarly, a study using CPAP, and surgery of varying types for those 
not adherent to therapy, in men with OSA and ED, found an overall improvement in both 
subjective (IIEF) and objective (Rigiscan) measurements of ED, however the improvements per 
treatment were not reported [354].    
Two randomised studies of CPAP and Sildenafil, in men with OSA and ED, have been reported 
by the same author [484, 485].  The first randomised 30 men to either Sildenafil on demand or 
CPAP use nightly for 12 weeks.  All domains in the IIEF improved from baseline for both 
treatments.  For those allocated to Sildenafil, the IIEF-ED domain improved by 5 points, 54% of 
intercourse attempts were successful, and 53% of participants satisfied with treatment. For 
those allocated to CPAP, the IIEF-ED domain improved by 2.3 points, 24% of intercourse 
attempts were successful, and 20% were satisfied with treatment.  Differences between 
treatments at week 12 were reported, with all domains of the IIEF, except sexual desire, being 
higher with Sildenafil than with CPAP [484].  The second study of 40 men compared nightly 
CPAP use with Sildenafil, taken on demand, for 12 weeks [485].  This study reported 27% of 
intercourse attempts were successful with CPAP, compared to 51% with Sildenafil, which was 
statistically significant.  Similarly, the IIEF-ED domain improved for both groups compared to 
baseline, with the scores for Sildenafil being higher than that of CPAP after 12 weeks.  The 
degree of OSA in this study was mild, with an AHI of 9, which may limit the effects seen due to 
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CPAP. Neither of these studies reported CPAP adherence rates, which may limit the 
interpretation of these studies.  Additionally, there was no placebo control, nor baseline 
measurement with which to compare successful intercourse attempts.   
A randomised sham-controlled study showing that CPAP improves ED has yet to be performed. 
Sham-control is essential, because the primary outcome of therapy is self-reported [486], but 
none of the available studies are sham-controlled.  Additionally, many of the studies in the 
current literature include men who do not have erectile dysfunction, which may or may not 
dilute the efficacy of CPAP on erectile dysfunction.  
The effect of CPAP on sexual function is not widely acknowledged.  Amidst a questionnaire 
regarding expected outcomes from CPAP usage, 53% of patients about to undergo CPAP 
therapy acknowledged that there may be an increase in sexual desire and performance. About 
two thirds of these same respondents recognized that there would be a positive effect from the 
use of CPAP in regards to feeling better, allowing their partner to sleep better, and have less 
chance of a motor vehicle accident among other factors  [487]. 
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Table 1.5 Trials investigating effects of OSA treatment on Erectile Dysfunction 
Author N Population Treatment  Study Design AHI 
(events/h) 
Duration Erectile 
Function 
measure 
Change in Erectile 
Function  
Guillimenault 
(1981) [418] 
50  OSA Tracheostomy Observation 81 (65-120) 9months
-6years 
Self-
report 
98% “sexual problems” 
disappeared  
Karacan and 
Karatas (1995) 
[438] 
22  OSA & ED CPAP Observation 49.2 ± 28 
 
1 night NPT 33%  of those with 
previously abnormal 
NPT had normal NPT 
with CPAP 
Li (2004) [481] 27                 OSA & ED CPAP (n=15)   
Control (n=12) 
Randomised 
parallel, no 
treatment 
control 
45 ± 11                
42 ± 14 
1 month IIEF-5 ↑* compared to 
controls (non-English 
text) 
Perimenis 
(2004) [484] 
30  Mild OSA & 
ED 
CPAP (n=15) 
Sildenafil 
(n=15) 
Randomised 
parallel 
7.3 ± 1.2            
7.4 ± 1.4 
12 weeks IIEF-5, 
SIA 
Sildenafil was superior 
to CPAP **.  Both 
numerically improved 
from baseline but p-
value was not reported. 
Goncalves 
(2005) [414] 
17 OSA & ED CPAP Observation 71.4 ± 26.8 1 month Sexologis
t 
Intervie
w  
ED resolved in 
76%* (13 out of 17 
patients).    OSA 
parameters did 
not predict  ED 
change 
(Continued over) 
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Table 1.5: Trials investigating effects of OSA treatment on Erectile Dysfunction (continued) 
Author N Population Treatment  Study Design Age AHI (events/h) Duration Erectile 
Function 
measure 
Change in Erectile 
Function  
Margel 
(2005) 
[479] 
60  OSA CPAP Observation 54 ± 10 
(↔) 54 ± 
11 (↑) 59 
± 10 (↓) 
40.6 ± 18 .1 
(↔) 53.7 ± 
15.2 (↑) 38.4 
± 18.9 (↓) 
17 
months 
(range 12-
26) 
IIEF-5 62% no change                                                 
20% ↑(**from baseline)                    
18% ↓(**from baseline),  
UCA: ΔIIEF vs Baseline 
MinSaO2 (r=-0.37**), 
CPAP adherence 
(r=0.69*). ΔIIEF not 
correlated with RDI (NS). 
Karkoulias 
(2007) 
[473] 
15 Mild OSA & 
ED 
CPAP Observation 56 ± 4 7.3 ± 1.2 12 weeks IIEF, SIA ↑ Erectile function 
improved * but sexual 
desire did not.  
Hoekema 
(2007) 
[408]  
48  
 
OSA CPAP (n=27) 
MAS (n=21) 
Randomised 
parallel 
51 ± 9           
48 ± 8 
46.7 (10-64.4) 
20.6 (9.5-31.1) 
2-3 
months,  
GRISS ↔CPAP, ↔MAS. 
Between-group NR 
Perimenis 
(2007) 
[480] 
48  OSA & ED 
& COPD 
CPAP & 
bronchodilat
ors 
Observation 53 ± 10 28.3 ± 23.2 6 months ED 
Intensity 
Score 
 
↑** compared to 
baseline.          Erectile 
function improved in 25% 
AHI greater in patients 
who ↑**.              ΔIIEF 
positively correlated with 
age, AHI. 
(Continued over)  
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Table 1.5: Trials investigating effects of OSA treatment on Erectile Dysfunction (continued) 
Author N Population Treatment  Study 
Design 
AHI 
(events/h) 
Duration Erectile 
Function 
measure 
Change in Erectile Function  
Perimenis 
(2007) 
[488] 
40 OSA & ED CPAP (n=20) 
CPAP + 
Sildenafil (n=20) 
Cross-over 56 ± 5 6 weeks 
each arm 
SIA 
 
SIA greater with Sildenafil than 
CPAP**. 
Perimenis 
(2007) 
[485] 
40 Mild OSA & 
ED 
CPAP (n=20) 
Sildenafil 
(n=20) 
Randomise
d parallel 
8.9 (6–25)          
9.9 (6–24) 
12 weeks IIEF, SIA ↑**CPAP, ↑**Sildenafil but 
Sildenafil was superior                                           
SIA greater with Sildenafil than 
CPAP** 
Taskin 
(2010)[41
7] 
40 Severe OSA 
(AHI>30) 
CPAP (n=20) 
Anti-
Depressant 
(n=20) 
Randomise
d parallel 
35 ± 19.3            
33 ± 21.7 
1 month  IIEF-5 ↑**CPAP, ↔ (NS) 
antidepressant          Stratifying 
by MinSaO2 of 80% did not 
show correlation with ΔIIEF. 
Petersen 
(2012) 
[474]  
14
6 
OSA CPAP (only 
>4hrs use 
included) 
Observation 43.3 ± 
26.3 
12 
months 
LiSat, 
BMSFI 
↑* Sexual life, erectile function, 
sexual desire all improved with 
CPAP overall but half 
unchanged, 37% improved, 13% 
scored lower. 
Cruz 
(2012) 
[426] 
98 OSA Auto-PAP Observation 52.2 ± 
21.4 
6 
months 
Likert 
scale 
↔ in ED with AutoPAP overall  
(25% to 18%, NS)                                             
12%↑ (NS from baseline)                  
5%↓ (NS from baseline) 
(Continued over) 
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Table 1.5: Trials investigating effects of OSA treatment on Erectile Dysfunction (continued) 
Author N Population Treatment  Study 
Design 
AHI 
(events/h) 
Duration Erectile 
Function 
measure 
Change in Erectile Function  
Khafagy 
(2012) 
[354] 
80                 OSA & ED CPAP (n=57) 
Surgery (n=23) 
Observation 
CPAP used 
<4hrs, 
surgery 
performed. 
33.4 ± 1.7        
37.0 ± 7.6 
3 
months  
NPT + 
IIEF-5 
Results combined for both 
treatments. ↑**. ED 
resolved in 22.5% (IIEF-5)              
↑* Percentage rigidity (NPT) 
Commonly reported NPT 
parameters not reported. 
OSA not treated completely 
(AHI 12 & 14 for CPAP and 
surgery respectively) 
Shin 2013 
[483] 
56 
 
OSA UPPP (n=30) 
CPAP (n=16) 
MAS (n=10) 
Observation
Patient 
preference 
determined 
treatment 
29.6 ± 21.6      
51.6 ± 17.1      
29.3 ± 10.6  
7 (4, 15) 
months 
IIEF-5 ↑UPPP (*from baseline)             
↔CPAP (NS)                                  
↔MAS (NS) 
Budweiser 
(2013)  
[412] 
91 
 
OSA CPAP users 
(any use, 
n=56)   
Non-CPAP 
users (n=35) 
Observation  28.1  (18.0, 
40.0)   14.7 
(6.8, 23.7) 
3 years IIEF-15 ↔CPAP users, ↓ non-users. 
Between-group NS.                                               
Sub-Analysis (1): No 
difference in those with 
moderate/severe ED. (2): 
CPAP↑* compared to non-
users in those with both 
moderate-severe ED and 
mean nocturnal SaO2<93%. 
(Continued over) 
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Table 1.5: Trials investigating effects of OSA treatment on Erectile Dysfunction (continued) 
 
Note:  ↑denotes an improvement ↓denotes a worsening ↔ denotes no change. Data are mean ± standard deviation or mean 
(range). *p<0.05, **p<0.01. ∆=change  Abbreviations: ADAM: Androgen Deficiency in the Aging Male questionnaire, AHI = Apnoea 
Hypopnea Index, CPAP = Continuous positive airway pressure, BMSFI = Brief Male Sexual Functioning Questionnaire, COPD = Chronic 
Obstructive Pulmonary Disease, ED = erectile dysfunction, EF=erectile function, IIEF = International index of erectile function, IIEF-5 = 
The 5-item International index of erectile function, GRISS = Golombok Rust inventory of sexual function, IIEF-15 = The 15-item 
International index of erectile function, LiSat11= Life satisfaction 11, MAS = mandibular advancement splint, NPT=Nocturnal Penile 
Tumescence, NR = not reported, NS = not significant, OSA = Obstructive Sleep Apnoea, RDI = Respiratory Disturbance Index, SaO2 
=oxygen saturation levels, SHIM = Sexual Health Inventory for Men questionnaire, SIA = Successful intercourse attempts, UCA=  
Univariate Correlational Analysis, UPPP = uvulopalatopharyngoplasty. 
Author N Population Treatment  Study 
Design 
AHI 
(events/h) 
Duration Erectile 
Function 
measure 
Change in Erectile Function  
Knapp 
(2014) 
[477] 
35 OSA & 
Diabetes 
CPAP  Observation NR. 
Inclusion 
was AHI >15 
3 
months 
SHIM  
ADAM 
↔ in ED with CPAP.  CPAP 
reduced number of androgen 
deficient symptoms (as 
measured by ADAM) but this 
was not sexual function. 
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1.5.4. Simultaneous Treatment for OSA & ED 
The efficacy of using both CPAP and PDE-5 inhibitors as treatment modalities for men with 
OSA and ED have been reported in 2 studies [431, 488]. In 40 men with mild-moderate OSA 
(AHI 15.1±3.9), the effects of CPAP alone was compared to CPAP plus on-demand 100mg 
Sildenafil, in a cross over design [488].  In this study, which included heavy smokers (87% of 
participants), the use of both treatments resulted in a greater number of successful 
intercourse attempts (61%) compared to using CPAP alone (25%).  A run-in phase using 
CPAP alone was conducted for 4 weeks, followed by 6 weeks of the allocated treatment.  
There was no baseline measurement on successful attempts on which to base any change 
data, nor was CPAP usage reported, however there was a slight increase in successful 
intercourse attempts from 19% during the run-in phase to 25% during the treatment period, 
the difference of which was not discussed.  In the only other report of combination therapy 
in OSA and ED, a small observational study reported outcomes for 32 men with OSA and ED, 
using various combinations of CPAP, testosterone and PDE-5 inhibitors, depending on 
patient presentation.  Six out of eight patients with OSA and ED, but with normal 
testosterone levels improved erectile function, and of the five patients who received all 
three treatments, all were reported to have normal erectile function after 3 months [431].  
Although this pilot study shows good efficacy of treatment, the study was not conducted in 
a randomised fashion, and lacks placebo control, as well as being a small study.  Further 
studies of the use of polytherapy in men with OSA and ED using a rigorous protocol design 
are needed.  
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1.5.5 Summary of treatment options 
 
Three treatment options exist for a man with obstructive sleep apnoea and erectile 
dysfunction – testosterone therapy, PDE-5 inhibitor use or CPAP.  The majority of the 
literature shows that testosterone improves erectile function and sexual desire, however 
testosterone may worsen OSA.  PDE-5 inhibitors are an effective treatment, in the majority 
of cases, for ED, but there is some thought that these also have the potential to worsen 
OSA.  CPAP is an established treatment for OSA, and there is some evidence regarding its 
effect on erectile function and sexual desire.  See figure 1.2 below:  
 
Figure 1.2:  Effects of treatment on OSA, Erectile Function & Sexual Desire 
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1.6  CONCLUSION 
Sexual function is an important part of quality of life, which can be affected by a number of 
lifestyle and disease factors.   Evidence suggests that there is a link between OSA and both 
low testosterone and ED.  The causal pathway between these conditions has not yet been 
established, however, there is increasing suggestion that this may be due to hypoxia related 
factors.  There is a strong belief there is a relationship between OSA and low libido; however 
there is a lack of compelling evidence linking the two. The establishment of clinical 
guidelines recommending against testosterone supplementation in men with OSA is 
increasingly shown as having little evidence to warrant such advice.  Together with the 
increasing prescriptions of testosterone in the general population, and potentially, if 
guidelines change due to evidence against them, in men with OSA, there is a need to 
establish the efficacy of testosterone in men with untreated OSA in regard to sexual 
function as this has not yet been investigated in a randomised controlled setting. 
There also remain unanswered questions regarding the efficacy of CPAP treatment on 
testosterone, sexual desire, and erectile function in men with OSA and ED, due to the lack of 
adequately controlled studies, in which participants are blinded to treatment allocation.  
Placebo controlled studies are absolutely required in this field to elucidate the effects of 
therapy upon the subjective matter of sexual function.  
The best clinical treatment plan for men with both OSA and sexual dysfunction has yet to be 
established.  Would testosterone therapy be efficacious? Would testosterone 
supplementation worsen sleep disordered breathing?  Will CPAP treat erectile function and 
improve testosterone levels?  Would a PDE-5 inhibitor be effective in treating ED without 
worsening OSA?  Would a combination of these therapies be optimal?  This thesis aims to 
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contribute to answering this clinical scenario by conducting two randomised controlled trials 
to assess the efficacy of testosterone, CPAP, and a PDE-5 inhibitor in men with OSA.  
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2. Effects of testosterone administration on sexual function, 
quality of life and neurocognitive performance in 
untreated obstructive sleep apnoea. 
2.1 CHAPTER SUMMARY: 
Background:  Sexual dysfunction, testosterone deficiency, obesity and obstructive sleep 
apnoea (OSA) all have high prevalence rates and often coexist. Exogenous testosterone 
prescription frequency is increasing in the general community and may be given to those 
with untreated OSA.  This study comprehensively assessed the impact of testosterone 
administration on sexual function, general and sleep specific quality of life and 
neurocognitive performance in obese men with untreated OSA.  
Methods: Sixty-seven middle aged obese men with moderate to severe OSA received 
intramuscular injections of 1000 mg testosterone undecanoate or placebo at baseline, week 
6 and week 12. General and sleep related quality of life questionnaires, sleepiness levels, 
neurocognitive performance and sexual function were assessed at baseline, 6, 12 and 18 
weeks.   
Results:  Testosterone administration, compared with placebo, significantly suppressed 
gonadotropins and increased blood testosterone concentrations (p<0.001).  Testosterone, 
compared to placebo increased sexual desire by 16% (mean difference between groups, 
95%CI: 5.4-26.8, p=0.004), independently of baseline testosterone levels. There was no 
change in erectile function, frequency of sexual attempts, orgasmic ability, quality of life, 
sleepiness levels or neurocognitive function. Post-hoc analysis in participants with low 
testosterone levels at baseline (<8nmol) found testosterone increase vitality (p = 0.004), and 
reports of both feeling down and nervousness were reduced (p = 0.002 and p = 0.032 
respectively).   
Conclusions: Testosterone therapy does not improve erectile function in men with OSA but 
does increase sexual desire. Exogenous testosterone variably controls different facets of 
quality of life, with benefits seen only for those with lower baseline levels (< 8 nmol/L) in the 
areas of vitality, nervousness and feeling down.  Neurocognition was not changed.   
 - 91 - 
2.2  INTRODUCTION: 
Obstructive sleep apnoea (OSA) and testosterone (or androgen) deficiency are common 
conditions which often co-exist in men [57, 158, 184, 286, 289, 401, 409], and are associated 
with increased age and obesity [290, 296, 489, 490].  Approximately 25% of middle aged-
men have OSA [286] and around 2% have testosterone deficiency [158, 184].  Recent studies 
have found both conditions to be increasing in prevalence in the general community [185, 
287].   
An independent association between the presence of OSA and a reduced level of total 
testosterone has been previously shown by several authors [384, 389, 394-396]. 
Additionally, levels of free and total testosterone have been shown to decline with increases 
in parameters describing OSA severity, particularly the level of hypoxaemia [398]. Potential 
mechanisms of untreated OSA leading to low testosterone levels include the impact of sleep 
restriction, known to reduce testosterone levels [385, 397], interruption of the normal 
pulsatility of luteinizing hormone and subsequent testosterone release in sleep [384] and 
repetitive hypoxia due to sleep apnoea [394].   
The most effective treatment for OSA is continuous positive airway pressure (CPAP), 
however, adherence rates to CPAP treatment are low, with estimations of take up rates 
being between 46-83% [352]. Reasons attributed this low adherence include the intrusive 
nature of the treatment, discomfort, as well as psychological and social reasons [352].  An 
alternative treatment, using a mandibular advancement splint (MAS), has been shown to be 
less efficacious but is more likely to be used than CPAP [491]. The low adherence rates to 
CPAP and the incomplete elimination of OSA with MAS leaves many people with OSA with 
either suboptimal treatment or no treatment at all.  
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Symptoms such as reduced erectile quality, low mood and increased cognitive impairment 
are common to both OSA [57, 404, 409, 492-496] and testosterone deficiency [40, 198, 201, 
242, 246, 497-499].  Given the overlap of symptoms, if OSA and low testosterone co-exist in 
an individual, there is potential for symptoms to be attributed to low testosterone alone, 
and treatment administered without addressing underlying sleep apnoea. 
Symptoms of testosterone deficiency have been shown to become apparent below varying 
thresholds [190]. Serum testosterone levels below 8, 11, 12, and 13 nmol/L have all been 
associated with decline in various aspects of sexual functioning and quality of life [189]. One 
of the earliest symptoms to appear is that of reduced vigour when serum testosterone is 
less than 13 nmol/L [183], whereas below 12 nmol/L, less sexual activity occurs and there is 
a reduction in nocturnal erections [105, 213]. Morning erections decrease at testosterone 
levels below 11 nmol/L [183]. With testosterone concentrations under 8nmol/L, men have 
been found to have reduced sexual desire and subjective erectile function and increased 
rates of depression [183, 202, 500].  These varying thresholds for the appearance of 
androgen deficient symptoms in the general male population need to be considered when 
examining the association between testosterone levels and sexual function and quality of 
life as well as changes after treatment.   
Therapy for testosterone deficiency has been suggested to begin at various level of serum 
testosterone, including below 8, 10, 11 and 13 nmol/L [105, 155, 188, 189]. Treatment for 
low testosterone is via the administration of supplemental testosterone, in various formats 
including transdermal patches, injection and pellets.  The rates of physician prescribed 
testosterone have substantially increased in the general community of Australia at up to a 
nine-fold increase in the last 20 years [192]. Similarly, a 500% increase over the same 
timeframe has been seen in America [188]. This rapid increase in testosterone has not been 
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associated with an increase in the diagnosis of androgen deficiency, and has been 
speculated to be viewed as a non-specific treatment for declining well-being and sexual 
dysfunction [192, 194].  In any case, this increase in usage necessitates greater 
understanding of the effects in populations other than the general healthy population.  
Potentially, there may be a bidirectional relationship between testosterone and OSA. 
Testosterone replacement has been shown to worsen OSA at supraphysiological doses [260] 
and as such, there has been considerable discussion in the literature regarding the effects of 
testosterone treatment in untreated obstructive sleep apnoea, with the current guidelines 
recommending against usage in this population [155, 453].  However, reviews of the 
evidence do not support the idea that conventional doses of exogenous testosterone 
worsen OSA [454, 455]. The results of the current study in regard to testosterones effect on 
sleep disordered breathing have recently been published, which found an initial worsening 
of OSA which was not sustained [456]. Despite studies investigating the effects of 
testosterone administration on OSA severity [260, 450] these studies have not reported the 
impact any purported change in OSA has upon outcomes known to be affected by OSA 
severity, the effect of sleep disruption on activities of daily living, quality of life as well as 
reaction time and neurocognition [32, 339, 492, 501, 502].  Some of these outcomes have 
been investigated in relation to serum testosterone, as well as testosterone 
supplementation, but not in the context of untreated OSA, in which there may be some 
overlap.  
 
Of the few studies which have investigated the relationship between testosterone and 
quality of life measurements such as the SF-36 quality of life assessment tool,  no studies 
have been performed in an OSA population, rather, they have been performed in a general 
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population with OSA status undefined, or not listed as an exclusion criterion.  Some of the 
bigger studies investigating the relationship between endogenous testosterone and SF-36 
domain scores have not reported any association between the two [183, 253].  An analysis 
of individual questions on the SF-36, rather than the conventional domain scores, found a 
testosterone threshold of below 13nmol/L significantly increased the incidence of having 
reduced vigour. Similarly, less than 160pmol/L of free testosterone increased the prevalence 
of feeling down and of having increased fatigue [183]. Pharmaceutical intervention studies 
have reported improvements in differing domains of the SF-36 due to testosterone 
replacement [254, 255, 503], however, other studies have found either no or minimal 
improvement [256-260]. 
The role of testosterone in neurocognition is complex and not completely understood [231].  
Androgen receptors are found in brain regions responsible for learning and memory, which 
may mean that testosterone can influence cognitive processes [231]. Differences in spatial 
abilities due to gender suggest that there is an influence of testosterone on this aspect of 
neurocognition [504]. Indeed, testosterone levels in males have been correlated with 
various aspects of neurocognition, and a link has been made with the decline in 
testosterone with the development of Alzheimer’s disease, however, there does remain 
some differing opinion on the extent to which this occurs [505, 506]. Some studies have 
found a quadratic (U-shaped) relationship between serum testosterone and cognition, 
suggesting an optimal hormone range for particular cognitive tasks [240, 241]. The effect of 
androgen supplementation on neurocognition has received a reasonable amount of 
attention, with differing results. Recent work in older men found no change in executive 
function, memory and spatial cognition with physiological or supraphysiological doses of 
testosterone [242, 243]. Several small studies have reported improvements in memory and 
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spatial cognition after testosterone administration in older men but generally only in those 
who had a lower level of testosterone initially, suggesting a possible baseline threshold for 
improvement [246, 247, 497]. In contrast a recent study found no change in executive 
function, memory and spatial cognition with large doses of testosterone [242]. In men with 
OSA, these cognitive processes , such as executive function, reaction time and memory, may 
be detrimentally affected by repetitive hypoxia from untreated OSA in regards to executive 
function and reaction time [492]. No previous study has investigated the impact of 
testosterone on men with untreated OSA who are already at an increased risk of 
neurocognitive impairment.  
The effectiveness of administration of exogenous testosterone to men with untreated OSA 
upon sexual function, quality of life and neurocognition has not been assessed.  No 
randomised placebo controlled studies have reported the association between exogenous 
testosterone administration and sexual function in men with sleep apnoea while assessing 
the effects on sleep disordered breathing.  Therefore, this study aimed to comprehensively 
assess the impact of testosterone administration in men with untreated OSA in the realms 
of sexual function, neurocognitive performance and quality of life, both general and sleep 
related. The impact of baseline testosterone levels upon these parameters was also 
assessed.  
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2.3 METHODS 
2.3.1 Study Design 
This study was a randomised double-blind, placebo controlled parallel group study.  All 
participants were randomly assigned to receive 3 doses of either Reandron (Testosterone 
undecanoate 1000 mg in 4 ml castor oil vehicle, Bayer Schering) or 4 ml volume-matched oil 
vehicle placebo via intramuscular injection.  A registered nurse administered these 
injections at baseline, week 6 and week 12.  In addition, all participants undertook a 
concurrent weight loss programme, consisting of a dietician prescribed low calorie (< 2500 
kJ) diet and exercise advice (at least 30 minutes brisk walking per day).  Clinical assessments 
were performed at baseline, weeks 6, 12 and 18. 
2.3.2 Participants 
Participants were recruited via sleep clinics at Royal Prince Alfred Hospital and the Woolcock 
Institute of Medical Research, Sydney, Australia and were deemed eligible to take part if 
they were men aged over 18, obese with body mass index (BMI) greater than 30 kg/m2 and 
had polysomnographically determined mild or greater OSA, defined as an 
apnoea/hypopnoea index (AHI) greater than 10 per hour.  Excluded from the study were 
those who had uncontrolled medial or psychiatric illness, severe OSA (SaO2 minimum less 
than 65% or AHI greater than 80 events per hour) or requiring immediate CPAP treatment, 
or who were currently on CPAP treatment, concurrent medication known to alter sleep, 
body weight or androgen action, a desire for paternity in the next 12 months, participation 
in sports that ban supplemental testosterone and require drug monitoring, fasting 
haematocrit greater than 52%, prostate-specific antigen greater than 4 ng/mL   [456]. A 
standard medical history, physical examination and blood sample were obtained upon entry 
to the study. All subjects provided written informed consent and the study was approved by 
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the Sydney South West Area Health Service Human Research and Ethics Committee (Royal 
Prince Alfred Hospital Zone). All procedures complied with Good Clinical Practice guidelines, 
applicable regulatory requirements and the Declaration of Helsinki. The study is registered 
with the Australia New Zealand Clinical Trials Network, number ACTRN12606000404527.  
2.3.3 Hormone Analysis 
Venous blood samples were collected in the early morning at baseline, weeks 6, 7, 12, and 
18. Blood samples were stored at -80 and batched for assaying. All samples of each 
individual participant were run in the same assay. Luteinizing hormone, follicle-stimulating 
hormone were analysed by commercially available Delfia assays (Perkin-Elmer Life Sciences, 
Rowville, Australia).  Total testosterone was measured by mass spectrometry (API-5000 
triple-quadruple; Applied Biosystems/MDS SCIEX, Ontario, Canada). Free testosterone was 
calculated using Vermeulen mass equations [507].   
2.3.4 Sexual function and quality of life  
A series of computerised questionnaires regarding quality of life, levels of sleepiness and 
sexual function were administered in an isolated room to maintain privacy at baseline, 
weeks 6, 12 and 18.   General and sleep-related quality of life was assessed using the Short 
Form 36 (SF-36) [333] and Functional Outcome of Sleep (FOSQ) [339] questionnaires 
respectively.  Analysis was performed using established scoring methodologies for various 
domains, as well as assessment of individual questions previously found to have an 
association with testosterone levels [183, 339]. Self-rated levels of sleepiness over the last 
two week was assessed by the Epworth Sleepiness Scale [324] and momentary sleepiness 
was assessed by the Karolinska and Stanford Sleepiness Scales [326, 328].  
 Various facets of sexual function were assessed using a Sexual Activity Questionnaire, using 
a visual analogue scale, as previously utilised in a testosterone treatment study [187]. 
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Participants were asked 8 questions regarding their degree of sexual thought, desire, 
erectile and ejaculatory function, as well as sexual frequency and satisfaction (Figure 2.1). 
Responses were quantified and expressed as a percentage.  
Please mark on the line how you have been feeling in the last month: 
Have had no sexual thoughts ------------------------- Have had many sexual thoughts 
Have had no sexual desire ------------------------- Have had strong sexual desire 
Have had no erections on wakening ------------------------- have had erections on wakening 
Have not engaged in sexual activity by myself ------------------------- Have engaged in sexual activity by myself 
Have not had sexual activity with a partner ------------------------- Have had sexual activity with a partner 
Have not had sexual satisfaction ------------------------- have had strong sexual satisfaction 
Have not ejaculated ------------------------- Have ejaculated 
yFigure 2.1 Sexual Activity Questionnaire 
 
2.3.5 Neurocognitive Function  
Computerised neurocognitive function testing was conducted at the same time of day for 
each participant. Spatial cognition was assessed using the ‘Tower of London’ [508], a task-
based test in which balls must be moved into a pre-specified position in the least amount of 
moves.  Executive memory was measured by the ‘Stroop’ test in which a series of words 
describing colours were presented in differing coloured fonts. These words were to be 
identified by the participant in terms of the colour of the word rather than the word itself – 
for example the word ‘RED’ may be presented in green font so the correct answer is green  
[509].  Reaction time, which is reduced in untreated OSA [32, 353, 492], was assessed using 
the psychomotor vigilance task (PVT) in which the subject pressed a button in response to a 
stimuli which recorded as well as displayed to the subject each reaction time in milliseconds 
[510].  These neurocognitive tests were performed at weeks 6, 12 and 18 weeks.  
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2.3.6 Statistical Analysis 
Statistical analysis was performed using SAS statistical package version 9.2 (SAS Institute, 
Cary, North Carolina, USA).  Significant difference was defined as p<0.05. As this was part of 
a larger study, an estimation of 60 patients completed would have 90% power to detect a 
clinically relevant change in the primary outcome of the larger study, this being weight loss 
of 10% compared to placebo, with α set at 0.05, based on preliminary data obtained at the 
study location. The current analyses presented as part of this thesis were secondary endpoints and 
accordingly, unpowered. The randomisation code was broken only after all data were 
collected and the database cleaned and locked. Outcome variables were differences from 
baseline at 6, 12 and 18 weeks with all analyses performed using an intention-to-treat 
analysis. Overall and individual time point differences between groups were assessed from 
mixed model analyses of treatment, time and the interaction between these. Normality of 
residuals was confirmed.  
The influence of baseline testosterone (total and free) on the effectiveness of testosterone 
treatment was also explored. Baseline total and free testosterone were included in separate 
mixed models as dichotomised factors using predefined cut points of baseline total 
testosterone (8, 11 and 13nmol/L) and free testosterone (160, 220 and 280pmol/L)[183].  
The statistical significance of the interaction terms of treatment and each variable were 
examined. Results of those with a significant interaction term are shown as stratified by the 
variable. Additionally baseline total and free testosterone were included as linear covariate 
variables, as was age. 
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2.4 RESULTS 
The flow of participants through the study is shown in figure 2.2.  Sixty-seven men were 
recruited into the study.  Of these participants, 33 were randomised to receive testosterone, 
34 to receive placebo. The baseline characteristics of these men are shown in Table 2.1. 
There were no significant differences between the groups at baseline.  There were 13 
withdrawals: 7 from the testosterone group, 6 from the placebo group.  Withdrawal was 
due to pain from injection (n=2), time commitments (n=5), personal reasons (n=3) and 
unspecified (n=1).  There was no difference in any demographic, sleep or hormone level 
between those who withdrew and those who completed the study (data not shown). One 
adverse event also resulted in withdrawal. This was due to the development of basal cell 
carcinoma, which was considered to have an unlikely relationship to study drug. A total of 
54 men completed all protocol procedures.  Weight decreased during the study due to the 
weight loss programme (1.8kg) but there was no significant difference between the groups 
at any timepoint or overall.  
 
yFigure 2.2 Study Flow.  
NOTE: =injection given of either testosterone undecanoate or placebo as appropriate.  
SM = Subjective measurements, NF=Neurocognitive Function, HA=Hormone Analysis 
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yTable 2.1 Baseline Characteristics 
 Testosterone 
(n = 33) 
Placebo 
(n = 34) 
p-value 
Age (years) 48.2 ± 2.5 49.2 ± 2.6 0.50 
BMI (kg/m2) 34.9 ± 4.3 36.6 ± 4.9 0.15 
Weight (kg) 108.0 ± 15.3 114.7 ± 17.8 0.10 
Total AHI (events/hour) 30.3 ± 15.8 33.2 ± 22.5 0.55 
REM AHI (events/hour) 32.2 ± 22.7 42.8 ± 24.1 0.07 
NREM AHI (events/hour) 29.7 ± 17.2 29.8 ± 23.3 0.95 
ODI (events/hour) 21.6 ± 16.1 29.6 ± 24.3 0.12 
Minimum SpO2 (%) 82.3 ± 9.0 78.6 ± 8.3 0.08 
LH (IU/L) 3.3 ± 2.2 3.4 ± 1.4 0.82 
FSH (IU/L) 4.3 ± 3.7 4.5 ± 2.5 0.76 
Testosterone (nmol/L) 13.2 ± 5.3 13.4 ± 5.1 0.77 
Free Testosterone (nmol/L) 0.29 ± 0.02 0.28 ± 0.07 0.81 
Sex Hormone Binding Globule (nM) 22.2 ± 8.0 21.9 ± 8.6 0.90 
Note: Values are mean ± SD. p-values were calculated by Student’s t-test.  Abbreviations: BMI=body mass 
index; AHI=apnoea hypopnoea index; REM = Rapid Eye Movement sleep, NREM = Non-Rapid Eye Movement 
Sleep, ODI=oxygen desaturation index; Sp02= arterial oxygen saturation; LH=luteinizing hormone; FSH=follicle-
stimulating hormone, IU/L =international units per litre, nmol/L=nanomoles per litre, nM=nanomoles. 
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2.4.1 Hormone profile 
Baseline testosterone level was 13.3 ± 5.2 nmol/L.  In this population of obese men with 
OSA, 62% were incidentally found to have testosterone less than 13nmol/L.  Alternate 
thresholds of 11nmol/L and 8nmol/L yielded prevalence rates of 47% and 23% respectively.  
As expected, men who were randomised to active treatment showed an increase in serum 
testosterone and a decrease in both follicular stimulating hormone and luteinizing hormone 
from baseline compared to those in the placebo group (p≤0.001).   
2.4.2 Sexual Function 
Testosterone treatment increased sexual desire by 16% compared to placebo (p = 0.004) 
(Figure 2.3).  There were no between-group differences in any other sexual function 
outcome including the number of sexual encounters, erectile or ejaculatory function. The 
increase in sexual desire occurred from the first assessment period (week 6) and remained 
elevated for the duration of the study and was independent of baseline testosterone levels 
(figure 2.4). To determine if the degree of baseline testosterone influenced response to 
androgen therapy, the data was then stratified using predetermined cut points of 8, 11 & 13 
nmol/L.  No difference was found in treatment response between those above or below any 
cut point in any sexual function parameter.  
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Figure 2.3 Sexual Function change from baseline with Testosterone. 
Note:  This figure shows the mean and 95% confidence interval for testosterone minus 
placebo changes from baseline scores for each parameter.  The bar marked ** shows a 
significant difference between testosterone and placebo (p=0.004). 
 
 
y Figure 2.4 Changes in sexual desire over time with testosterone versus placebo 
Note:  This figure shows mean change from baseline plus standard deviation for each time 
point for both testosterone and placebo.  This had an overall difference between groups 
(p=0.0039). 
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2.4.3 Quality of Life 
Testosterone therapy did not change subjective sleepiness or any of the overall domains in 
the SF-36 and FOSQ questionnaires compared to placebo. Furthermore there were no 
between-group differences in the change for the single items of interest from the SF-36 and 
FOSQ questionnaires (Table 2.2). When the results for quality of life, as measured by the 
SF36 were stratified, the interaction term of treatment and the dichotomised factor for 
baseline testosterone at a level of 8 nmol/L was significant for vitality (p=0.01), degree of 
feeling down (p=0.004), and nervousness (p=0.04) (Figure 2.5).  Further analysis showed the 
improvement after active treatment was only in those with baseline testosterone of less 
than 8nmol/L. Of these men, nine were in the treatment group and six were from the 
control group.  
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Table 2.2 Effect of testosterone on quality of life  
 Testosterone  (n = 33) Placebo  (n = 34) Mean  differences   
 Baseline 
Mean ±  SD 
Mean 
change 
from 
baseline 
Baseline 
Mean  ± SD 
Mean 
change 
from 
baseline 
(95% CI) Effect 
size (d) 
p-value 
SF-36 Domains        
 
Physical health 
 
66.1 ± 15.0 
 
6.3 
 
66.1 ± 16.6 
 
5.3 
 
1.0 (-4.4 to 6.4) 0.06 
 
0.71 
Mental health 70.8 ± 14.1 10.3 79.3 ± 11.8 4.5 5.7(-2.4 to 13.9) 0.48 0.16 
Physical function 76.7 ± 19.4 7.3 75.2 ± 16.3 6.2 1.1(-5.0 to 7.3) 0.07 0.71 
Role – Physical 71.2 ± 29.4 6.7 73.5 ± 33.1 7.8 -1.1(-14.9 to 12.6) -0.03 0.87 
Body Pain 82.7 ± 21.4 -1.8 72.1 ± 26.8 2.5 -4.3(-12.0 to 3.1) -0.16 0.27 
Vitality 44.8 ±  23.6 9.4 48.7 ± 17.2  4.0 5.4(-1.9 to 12.7) 0.31 0.14 
General Health 55.9 ± 19.5 10.2 62.0 ± 17.8 5.8 4.4(-2.6 to 11.3) 0.25 0.21 
Social Functioning 72.9 ± 22.0 7.9 78.8 ± 21.0 6.9 1.0(-8.7 to 10.7) 0.05 0.83 
Role – Emotional 63.6 ± 38.6 17.8 78.4 ± 33.8 6.8 11.0(-3.7 to 25.7) 0.33 0.14 
SF-36 Single questions of interest* 
“During a typical day, did your health limit you : 
-doing vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports?” 
 
 
 
1.9 ± 0.8 
 
 
 
0.2 
 
 
 
1.6 ± 0.6 
 
 
 
0.2 
 
 
 
-0.2(-0.4 to 0.3) -0.33 
 
 
 
0.68 
-walking more than one kilometer?” 2.5 ± 0.7 0.3 2.6 ± 0.6 0.2 0.0(-0.3 to 0.4) 0.00 0.80 
-bending, kneeling or stooping” 2.5 ± 0.7 0.2 2.4 ± 0.7 0.2 0.0(-0.3 to 0.3) 0.00 0.91 
“Have you felt down during the past month?” 4.6 ± 1.0 0.4 5.1 ± 0.8 0.1 0.3(-0.2 to 0.8) 0.38 0.24 
        
Note: Values are mean ± standard deviation * Single questions of interest - as reported by Wu, 2010 as being indicative of symptoms associated with low 
testosterone levels.  The p values of the change from baseline were calculated by mixed model analysis, Effect size (Cohen’s d) calculated by dividing difference 
between testosterone and placebo by the standard deviation of placebo standard deviation at baseline. 
(Continued over)  
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Table 2.2 Change in quality of life between testosterone and placebo (continued).     
 Testosterone (n = 33) Placebo  (n = 34)   
 Baseline 
Mean ± SD 
Mean change 
from Baseline 
Baseline 
Mean ± SD 
Mean change 
from Baseline 
Mean differences 
(95% CI) 
Effect 
size (d) 
p-value 
Epworth Sleepiness Scale 10.8 ± 5.0 -1.6 12.0 ± 4.3 -1.6 0.0 (-1.4 to 1.4) 0.00 0.99 
Karolinska Sleepiness Scale 4.9 ± 2.2 -0.4 4.9 ± 1.9 0.0 -0.4(-1.4 to 0.7) -0.21 0.48 
Stanford Sleepiness Scale 2.8 ± 1.1 -0.1 2.6 ± 1.1 0.2 -0.4(-0.9  to 0.1) -0.36 0.15 
FOSQ  Domains 
General Productivity 
 
3.2 ± 0.6 
 
0.2 
 
3.2 ± 0.5 
 
0.2 
 
0.0(-0.2 to 0.2) 
 
0.00 
 
0.93 
Social Outcome 3.4 ± 0.8 0.2 3.2 ± 0.7 0.3 -0.1(-0.4 to 0.2) -0.14 0.34 
Activity Level 2.8 ± 0.8 0.2 2.8 ± 0.6 0.3 0.1(-0.3 to 0.2) 0.17 0.59 
Vigilance 2.8 ± 0.7 0.2 2.8 ± 0.6 0.2 0.0(-0.2 to 0.2) 0.00 0.71 
Intimate Relationships and Sexual Activity 3.0 ± 0.9 0.3 3.2 ± 0.7 0.2 0.1(-0.2 to 0.5) 0.14 0.50 
FOSQ single questions of interest  
“Has sleepiness or tiredness affected your…” 
Intimate or sexual relationship 
 
 
2.7 ± 1.2 
 
 
0.4 
 
 
2.9 ± 0.8 
 
 
0.4 
 
 
0.0 (-0.8  to 0.8) 
 
 
0.00 
 
 
0.94 
Desire for intimacy or sex 2.8 ± 1.2 0.3 3.1 ± 0.9 0.1 0.3(-0.5 to 1.1) 0.33 0.49 
Ability to become sexually aroused 2.9 ± 1.2 0.5 3.2 ± 1.0 0.3 0.2 (-0.7  to 1.1) 0.20 0.67 
Ability to orgasm 3.2 ± 1.1 0.3 3.6 ± 0.8 -0.5 0.8 (-0.4 to 2.1) 1.00 0.19 
Note: Values are mean ± standard deviation. * Single questions of interest - as reported by Wu, 2010 as being indicative of symptoms associated with low 
testosterone levels. The p values of the change from baseline were calculated mixed model analysis. Effect size (Cohen’s d) calculated by dividing difference 
between testosterone and placebo by the standard deviation of placebo standard deviation at baseline.  
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yFigure 2.5 Quality of life changes with testosterone stratified by baseline testosterone  
Note:  Low T defined as <8nmol/L, high T defined as >8 nmol/L.  These graphs show changes 
from baseline for testosterone and placebo for low and high initial testosterone levels for 
SF-36 questions for vitality, nervousness and feeling down.  The overall interaction term is 
shown at the bottom of the graph, and those at the side show between group differences. 
The solid bar indicates significant differences between testosterone and placebo in those 
with low testosterone.  The dotted lines indicate no significant difference between 
testosterone and placebo in the higher baseline testosterone group.  
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2.4.4 Neurocognitive Function 
Testosterone treatment did not change any parameter of neurocognitive function as 
measured by the Stroop, Tower of London and PVT compared to placebo (Table 2.3).  
Adding baseline blood testosterone concentrations as a continuous covariant, or via 
stratification, did not alter the significance of any of the between-group associations in 
mixed model analyses. 
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Table 2.3 Effect of testosterone on neurocognitive tasks  
      Testosterone (n = 33)     Placebo (n = 34)     
 Baseline Mean change 
from baseline 
Baseline Mean change 
from baseline 
Mean  differences 
(95% CI) 
Effect size 
(d) 
p-value 
Tower of London 
Number of errors 
 
    0.2 ± 0.1 
 
-0.1 
 
0.3 ± 0.2 
 
-0.1 
 
0.0(-0.1 to 0.1) 
 
0.00 
 
0.98 
Number of missed 
goals 
       4.0 ± 3.0 -1.3 4.8 ± 4.0 -1.4 0.1(-1.6 to 1.7) 0.03 0.92 
Execution time 
(µsec) 
  22592.0 ± 7881.9 -1573.1 23543.2 ± 8399.2 -3761.3 2188.1 
(-1369.6 to 5745.8) 
0.26 0.22 
Planning Time 
(µsec)  
  12678.6 ± 5113.1 159.5 14547.9 ± 6910.6 -2024.2 2183.6 
(-700.7 to 5068.0) 
0.32 0.13 
Psychomotor Vigilance Task        
Reaction Time 
(msec)    
  276.9 ± 7.7 -12.7 271.2 ± 9.2 -9.0 -3.7(-23.2 to 15.8) -0.40 0.70 
Reciprocal reaction time 
(msec)  
     3.9 ± 0.5 0.1 3.9 ± 0.1 0.1 0.1(-0.1 to 0.3 ) 1.00 0.35 
Number of Lapses     2.0 ± 0.5 -0.9 2.3 ± 1.3 -0.3 -0.7(-1.9 to 0.6 ) -0.54 0.29 
Fastest Reaction 
Time (msec) 
  206.6 ± 4.7 -6.5 204.7 ± 4.6 -2.9 -3.6(-14.6 to 7.4) -0.78 0.51 
Slowest Reaction Time 
(msec) 
     43.4 ± 26.2 -34.0 41.50 ± 18.2 -13.5 -20.6(-83.24 to 42.15 ) -1.13 0.51 
Stroop Test 
Number of Text correct 
 
97.2 ± 10.3 
 
0.1 
 
94.2 ± 19.4 
 
5.6 
 
-5.5(-14.8 to 3.8) 
 
-0.28 
 
0.24 
Number of Colour correct 95.2 ± 16.8 -4.1 98.3 ± 3.5 -11.5 7.4(-5.7 to 20.6) 2.11 0.26 
Text Reaction Time 1.0 ± 0.2 0.0 1.1 ± 0.3 -0.1 0.1(-0.1 to 0.2) 0.33 0.53 
Colour Reaction Time 1.0 ± 0.3 0.1 1.2 ± 0.4 0.0 0.1(-0.1 to 0.2) 0.25    0.34 
Note: p-values of the change from baseline were calculated by mixed model analysis. Effect size (Cohen’s d) calculated by dividing difference between 
testosterone and placebo by the standard deviation of placebo standard deviation at baseline. 
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2.5 DISCUSSION 
This is the first randomised controlled trial to examine the effect of testosterone on sexual 
function, quality of life and neurocognitive performance in untreated OSA. These findings 
show that in this population, testosterone administration, compared to placebo, increased 
sexual desire independent of baseline testosterone levels but had no effect on erectile 
function, neurocognitive function or overall quality of life.  Furthermore vitality, 
downheartedness, and nervousness were improved in OSA patients with testosterone in the 
hypogondal ranges. 
2.5.1 Hormone Profile 
Although the definition of low testosterone is unclear, there is general agreement that 
levels above 12 nmol/L are normative, and below 8 nmol/L are low [189]. Inclusion into the 
study was not on the basis of testosterone levels, rather the degree of obesity and 
obstructive sleep apnoea, both known to reduce testosterone levels. The mean 
testosterone level classifies this group as eugonadal, however, there were men found to be 
in the hypogonadal range. This supports previous work which also found normative 
testosterone levels in a sleep clinic population [396].  One small study found that 60% of 
men with OSA were eugonadal, compared to 100 % of the age-matched non-OSA controls.  
Furthermore, an additional study found eugonadal testosterone concentration even in 
patients with more severe OSA (minimum oxygen saturation less than 70%) [398].  This is 
despite several authors finding an independent association between the presence of OSA 
and a reduced level of total testosterone, after  other potential factors such as age and 
obesity  have been accounted for [287, 384, 389, 394, 395, 469].  
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2.5.2 Sexual Function 
Testosterone administration increased sexual desire in this eugonadal group of men.  This 
improvement occurred after only one dose of testosterone undeconate, and remained for 
the duration of the study. The effect remained when only those with levels above previously 
defined cut points were analysed proving unequivocally that this effect was independent of 
baseline testosterone levels. Similarly, in a previous study on eugonadal (>20 nmol/L) men 
with chronic obstructive pulmonary disease, testosterone administration increased overall 
quality of sexual life with 6 months of treatment, however the effects on sexual desire was 
not reported [230].  Previous randomised placebo-controlled studies which have specifically 
recruited eugonandal men, using varying definitions to determine eugonadism, have 
generally not reported any change in sexual function after the addition of exogenous 
testosterone levels [205, 214]. Only one study of eugonandal men has found a similar result, 
when supraphysiological doses were investigated as a contraception, in which there was an 
increase in sexual desire without a corresponding change in sexual encounters, however this 
increase was attributed to one individual, without whom the result was no longer significant 
[214]. A meta-analysis of randomised controlled studies with androgen therapy showed no 
difference between testosterone and placebo on erectile function, sexual desire or any 
other sexual function in men with normal testosterone levels [213]. A later meta-analysis 
found a non-significant increase in libido due to testosterone administration which was not 
different across categories of testosterone level [196]. A similar result was found in a group 
of men with diabetes, with baseline testosterone level of between 8 to 12nmol/L, in which 
all sexual function parameters improved with testosterone administration, which was no 
different than the response of those with testosterone of less than 8nmol/L, suggesting 
baseline levels had little influence on response [503]. A potential reason the current study 
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shows an increase in sexual desire, but not in other studies on eugonadal men may be that 
the baseline testosterone level was in the lower end of eugonadal range (13nmol/L), 
whereas other studies of eugonadal men have been in the range of 17-19nmol/L [212, 214]. 
In the meta-analyses mentioned, all studies were on men with higher baseline testosterone 
than the present study [212, 214, 215, 472]. Indeed one early study reported that sexual 
function parameters may be influenced at the lower range of normal [511].  Other authors 
have previously reported similar positive treatment response in regard to erectile function 
and libido, but only for those with low baseline testosterone levels, rather than overall [206, 
213]. The current study was unable to replicate this finding, with the change in sexual desire 
seen in the overall population, but not when data was stratified using predefined thresholds 
of 8, 11 and 13 nmol/L [183].  Potentially, this may be explained by the increasingly 
documented phenomena of different symptom appearance and reduction at differing levels 
of serum testosterone in different populations [183]. On the other hand, the difference in 
this study may be due to the population in this current study had severe OSA, and there may 
be an alternate mechanism or testosterone threshold at which testosterone administration 
increases sexual desire, which differs from those with normal breathing during sleep.  
Despite an increase in sexual desire, no increase in sexual activity was seen in this 
population. There was no requirement for participants to have a regular partner during the 
study which may have an influence on the number of sexual attempts; however, there was 
also no change in masturbation frequency. Habit, as well no change in social and 
relationship factors concordant with the increase in libido may contribute to this finding. In 
this study, the rating of sexual satisfaction did not change with testosterone administration. 
This supports the findings of a previous meta-analysis of clinical trials in men with either low 
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or normative levels of serum testosterone having no increase in sexual satisfaction, and 
extends the finding to men with severe OSA [196].  
2.5.3 Quality of Life 
Testosterone not only mediates sexual function in males, it also contributes to aspects 
regarding quality of life such as vitality and strength. Our results do not show, overall, any 
increase in quality of life parameters of the SF-36 questionnaire with testosterone 
compared to placebo. Similarly, there were no improvements in any SF-36 parameter with 
testosterone compared to placebo in a study of men of older men (age 60-80 years) with 
low (11 nmol/L) serum testosterone [512]. In contrast, in a non-placebo controlled study 
comparing efficacy of injectable versus implantable testosterone in men with similar levels 
of testosterone (13.8 nmol/L), improvements in quality of life as measured by the SF-36 
questionnaire were seen in the domains of vitality, physical function and social function 
with both treatment modalities [187]. Lack of placebo control, however, limits the 
interpretation of these improvements seen.  
Previous investigations have found improvements in individual questions of the SF-36 
(fatigue, vigor, ability to walk more than more than 1 kilometre, bending, kneeling or 
stooping and of feeling down) with testosterone supplementation, but only for those with a 
the lowest baseline threshold tested, that of 8nmol/L [183].   This study also analysed these 
individual questions of interest, and similarly, found a threshold of 8nmol/L to be below 
which, testosterone therapy is able to improve the parameter of feeling down, however, 
was unable to replicate the other findings.  However, other domains on the SF-36 were 
found to have a threshold influence, that of vitality and of nervousness.  Vitality has been 
shown to increase with testosterone supplementation, when performed in men with very 
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similar basal testosterone levels to the current study (13.8nmol/L) [187].  This difference 
may be due to a differing population, that of men with OSA, who may have a differing 
threshold at which treatment is effective.      
There was no change with the level of sleepiness, nor functional outcomes of sleep 
questionnaire with testosterone compared to placebo, a finding which supports that of the 
only other study reporting this outcome, which used higher doses of testosterone than the 
present study [260].   
2.5.4 Neurocognitive Function  
Men with OSA are more likely to have mild detriments in some aspects of memory than the 
general population, which may be due to a reduction in alertness [494, 496], while the 
reduction in executive and psychomotor tasks, such as reaction time also seen in men with 
OSA, may be due to repetitive hypoxia [492].  Thus, this group of men with OSA may have 
some neurocognitive impairment prior to study entry. Given the inconsistency of results 
regarding the impact of supplemental testosterone in neurocognitive function, this study 
provides an opportunity to examine, in a population more likely to have impairment, the 
effects of testosterone. Our results show that in this population of men with OSA, 
neurocognitive function, including memory, executive function, and reaction time, does not 
change with testosterone administration. Recent work in older men, with OSA status 
unspecified, also found no change in executive function, memory and spatial cognition using 
large doses of testosterone [242]. Several small studies have reported improvements in 
memory and spatial cognition for older men but generally only those who had an initial 
lower level of testosterone [246, 247, 497].  Stratification of the current data by baseline 
testosterone levels of 8, 11 & 13nmol was unable to show any changes in neurocognitive 
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outcomes at any threshold. In the non-OSA population there is no clear conclusion that 
testosterone therapy enhances, impairs or has little effect on neurocognition [205, 231, 242, 
245, 246].  The current results suggest that in an OSA population, testosterone therapy has 
no effect on memory, executive function, or reaction time.  
2.5.5 Strengths and Limitations 
This study provides a randomised placebo controlled study of the subjective effects of 
testosterone in regards to sexual function.  Being a purely subjective measurement, placebo 
control is imperative to assess the impact of therapy.  Defining sexual desire and describing 
its manifestation is difficult [8].   Various aspects of sexual function such as arousal, desire, 
and behaviour, intertwine and influence each other.  These different facets are driven by a 
complex mix of neurochemical, neuroanatomical, psychological and social factors, and 
sexual desire can be difficult to report in a quantitative research [5]. Subjective 
measurement via questionnaire is an easy to administer method in clinical research; 
however, the limitations in this technique must be recognised.  A visual analogue scale 
(VAS), previously been used to assess sexual function in testosterone therapy has been used 
in this study [187].  An alternative subjective questionnaire, the International index of 
Erectile Function, has been validated and is more widely used than the VAS used in this 
study, and may have been a useful measurement tool to allow comparisons between this 
and other studies [89, 90].    There is no objective measurement of sexual desire, resulting in 
a reliance on subjective assessment.  Erectile function can be quantified using penile 
tumescence monitoring under nocturnal or provocative conditions [513, 514]. Other studies 
have shown an increase in erection quality with testosterone using this technique [515].  
Analysis of erectile function in this manner may have given a greater insight into 
testosterone effects on physiologically measured erections. Nevertheless, this study, being 
 - 116 - 
placebo controlled overcomes some of the limitations of subjective measurements, and 
thus provides valid outcomes for this population.  
Consideration should be given to the concept that the sexual function effects of 
testosterone administration in OSA may only be relevant in patients with symptoms.  There 
is no reference value available for a normal level of sexual desire.  As a result it is unclear if 
this group of men had reduced or normal libido at baseline.  This study did not specifically 
target those with such symptoms, nor was a reduced level of testosterone a study entry 
requirement.  The population in this study, having severe obstructive sleep apnoea, differs 
from that in the majority of previous research in androgen administration.  Sleep apnoea 
has not been listed as an exclusion criterion in previous studies, and has not been routinely 
excluded in the majority of these studies, despite the recommendations not to give 
testosterone to men with OSA.  Given the prevalence rates of undiagnosed or untreated 
sleep apnoea, there may well be some men in these studies which do have sleep apnoea; 
however, this is not able to be determined.     
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2.6 CONCLUSION 
Testosterone therapy improved sexual desire in obese men with OSA regardless of baseline 
serum testosterone in this 18 week study. Neither erectile function, nor any other 
parameter of sexual health improved with testosterone.  There were no overall changes in 
neurocognition or quality of life; however, those with lower levels of baseline serum 
testosterone were shown to improve in the genres of vitality, feeling down and nervousness 
only, as measured by the SF-36.   These positive effects on quality of life measurements for 
men with OSA and a baseline testosterone of less than 8 nmol/L, are similar to those seen in 
the non-OSA population.    Although testosterone therapy can be safely prescribed to men 
with OSA, its efficacy is limited to an increase in libido for all men and some quality of life 
parameters for those with low baseline levels. 
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3 Methodology:  2x2 Factorial designed study - the effect of 
CPAP and Vardenafil on Sexual Function in men with 
Obstructive Sleep Apnoea and Erectile Dysfunction.   
3.1 CHAPTER SUMMARY 
This National Health and Medical Research Council (NHMRC) funded study was a 2 x 2 
factorial design randomised ‘sham’ & placebo controlled protocol investigating the effect of 
both CPAP and Vardenafil, in men with OSA and ED.  Sixty-one men were recruited into the 
study at one of two sites – Sydney and Melbourne.  Participants were randomised to receive 
12 weeks of either CPAP or sham CPAP, as well as 12 weeks of 10mg daily Vardenafil, a PDE-
5 inhibitor or placebo.  
This chapter describes methods used to both acquire and analyse the data, including study 
design, inclusion criteria, polysomnographic methods, subjective and objective assessments 
of sexual function, as well as subjective measures of quality of life, and the statistical 
analysis of the factorial design.  
Factorial studies provide a cost and resource effective tool to evaluate two separate 
interventions, in which the efficacy of one treatment does not affect the efficacy of the 
other.  This assumption was tested, with analysis of the interaction between treatments 
provided here.  No interactions were found; therefore the factorial study can be treated as 
two separate trials which are reported in Chapters 4 and 5. 
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3.2 METHODS 
3.2.1 Study Design 
This 2x2 factorial designed study, assessing the efficacy of both CPAP and Vardenafil in men 
with obstructive sleep apnoea (OSA) and erectile dysfunction (ED) was performed in Sydney 
at the Woolcock Institute of Medical Research, Glebe, New South Wales and in Melbourne 
at the Department at Respiratory and Sleep Medicine, Monash Medical Centre, Clayton, 
Victoria.  After screening to ensure all inclusion and exclusion criteria were met, a baseline 
visit was conducted to determine initial levels of sleep disordered breathing, objective 
erectile function, hormonal analysis, subjective measurements of sexual functioning and 
quality of life.  After baseline data collection, eligible participants at each site (Sydney and 
Melbourne) were randomised using two separate computer generated randomization list in 
blocks of four to one of four groups, as follows –  
1. CPAP & Vardenafil; 
2. CPAP & Placebo; 
3. Sham CPAP & Vardenafil; 
4. Sham CPAP & Placebo.   
Short visits at week 4 and week 8 were undertaken, during which subjective measurements 
were conducted, as well as CPAP / sham CPAP machine download to assess adherence to 
treatment, and a manual count of returned medication in order to assess medication 
adherence.  At these visits, routine clinical observations were also taken (blood pressure, 
pulse rate), and participants were asked about any adverse events which may have 
occurred.  At 12 weeks, all measurements which were taken at baseline were again 
performed while using the allocated treatments (see figure 3.1).  
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3.2.2 Participants 
Sixty-one men aged between 18-65 years who had both obstructive sleep apnoea, and 
reported erectile dysfunction were recruited into the study from sleep clinics at Royal Prince 
Alfred Hospital, Sydney,  the Woolcock Institute of Medical Research, Sydney, and Monash 
Medical Centre, Melbourne, or via community advertising in print and radio.   
This study protocol was approved by Human Research Ethics Committee, Concord 
Repatriation General Hospital for the Sydney site, and Southern Health Human Research 
Ethics Committee for Melbourne.  Site specific ethics approval was obtained through Human 
Research Ethics Committee, Royal Prince Alfred Hospital, and the Research Governor, 
Woolcock Institute of Medical Research.  All participants provided written consent.  Protocol 
development, electronic source note provision and records, analysis and overall supervision 
of the study was conducted at the Woolcock Institute of Medical Research. 
yFigure 3.1 Study Design 
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Participants were required to have at least moderate OSA, defined as an AHI of greater than 
20 events per hour, with an oxygen desaturation index of 3% or greater (ODI3) of at least 15 
events per hour, as well as erectile dysfunction, defined as a score of less than 26 in the 
erectile function domain of the International Index of Erectile Function (IIEF) questionnaire 
since a score of 26 or more indicates no erectile dysfunction.   To be included in the study, 
participants must have been in a stable relationship for at least six months.  Excluded from 
the study were those who had irreversible erectile dysfunction, concurrent treatment with 
nitrates or nitric oxide donors, treatment of ED within the last month, severe renal or 
hepatic impairment, uncontrolled diabetes or hypertension, were current smokers, night 
shift workers, were unable to read the information sheet due to language barrier, or had 
any chronic medical condition that may limit participation.   Those men who were unwilling 
to use CPAP or whose condition required immediate treatment due to severity or 
occupation were also excluded. Current medications taken by participants were 
documented, and the possibility of drug interaction was avoided by careful screening.  No 
medications, apart from the investigational drug, Vardenafil, were changed or initiated by 
the investigators during the study.     
3.2.3 Interventions 
Continuous Positive Airway Pressure (CPAP), the first line therapy for obstructive sleep 
apnoea, was used to maintain upper airway patency during sleep.  An established method of 
a placebo control, an inactive CPAP, “sham CPAP” [516], was used to ensure blinding of 
participant and study co-ordinator (further explained in section 4.3.3). 
A PDE-5 inhibitor, the first line therapy for erectile function was also used.  A low (10 
milligrams) daily dose of Vardenafil hydrochloride trihydrate (product name Levitra) or 
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placebo (Bayer Schering, Berlin, Germany) was administered.  Participants were instructed 
to take one tablet daily 60 minutes before attempting to fall asleep, regardless of their 
intention to attempt sexual activity (further explained in section 5.3.2)    
3.2.4 Statistical Analysis 
Statistical analysis was performed using SAS statistical package version 9.2 (SAS Institute, 
Cary, North Carolina, USA). The sample size was determined on the basis of previously 
published data of a non-placebo controlled study, in which 3 months of CPAP increased the 
IIEF-ED domain from 7.0 ± 2.1 to 9.3 ± 3.3 [484].  Assuming conservatively that vardenafil 
exerts an effect at least as great as CPAP, a sample size of 100 (n=20 withdrawal 
allowance. Total subjects = 120) will have 80% power to detect both a CPAP vs sham and a 
vardenafil vs placebo effect. The randomisation code was broken only after all data were 
collected, data was cleaned and locked, and data was analysed using intention-to-treat 
principles. This study was analysed as per established guidelines on factorial randomised 
controlled trials [517, 518]. By performing a 2x2 factorial study, two interventions, which do 
not have an effect on each other, can be evaluated in the same patients in parallel, allowing 
a cost-effective method of research [517].  This assumption was tested prior to the two 
treatments being considered individually. Firstly, a mixed model analysis was used to test 
the 3 way interaction between the two treatments as well as time.  Following this, if no 
significance was found, the interaction between the two treatments was tested, removing 
time from the analysis, in order to ensure no interaction between the two treatments.   
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3.2.5 Subjective Assessments 
Subjective measurements of sexual function, relationship quality and quality of life were 
assessed at baseline and after 4, 8 and 12 weeks of treatment using self-administered 
computerized or paper based questionnaires, the administration method of which was 
consistent for individual patients.   The session required approximately 1 hour of patient 
time.  Sexual function was assessed primarily using the International Index of Erectile 
Function, which comprises 16 items related to various facets of erectile and sexual function 
[89].  This questionnaire is now the gold standard patient reported outcome which is 
accepted by the US Food and Drug Administration and other regulatory authorities for 
registration of new therapies for erectile dysfunction [89].  From this questionnaire, an 
overall score is obtained, as well as scores for the domains of erectile function, intercourse 
satisfaction, orgasmic function, overall satisfaction and sexual desire.  Additional measures 
of sexual function were obtained from the European Male Aging Study (EMAS) 
questionnaire, which is of particular relevance for the aging male, with questions relating to 
changes in and distress caused by sexual dysfunction, as well as overall sexual functioning 
[84, 85].  An insight into confidence, self-esteem and relationship functioning was gained 
through the use of the Self-Esteem And Relationship (SERS) questionnaire [519].  Quality of 
life was assessed using questionnaires designed for general and sleep specific applications.  
To assess overall health, the generic Short-Form Medical Outcomes Survey (SF-36) was 
used. This 36 item questionnaire consists of eight domains – physical functioning, role 
limitations because of health or emotional problems, body pain, general health, vitality, 
social function and mental health, as well as 2 summary measures of physical and mental 
health [333, 334, 520].  To assess mood, the 21 item Depression Anxiety Stress Scale was 
used [521-523].  The Functional Outcomes of Sleep Questionnaire has been developed for 
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use in patients with sleep disorders to assess the impact of sleepiness on quality of life and 
was used to provide an overall score, as well as scores for the domains of activity, vigilance, 
intimacy, productivity and social factors [339].  Levels of sleepiness were assessed using the 
Epworth Sleepiness Score (ESS), a questionnaire in which 8 scenarios are presented for 
participants to rate their likelihood of falling asleep or dozing [324, 524].   
Satisfaction of the treatment used in regards to its effect on erectile function was assessed 
at Week 4, Week 8 and Week 12 using the Erectile Dysfunction Inventory of Treatment 
Satisfaction (EDITS) questionnaire [93]. All items on the EDITS were scored from zero (no 
satisfaction or dissatisfaction) to four (high satisfaction). The mean satisfaction score for 
each patient was calculated.  Each mean score was multiplied by 25 giving a range between 
0 (extremely low treatment satisfaction) to 100 (extremely high treatment satisfaction). A 
score over 50 deemed the participant to be satisfied with treatment [525].  Treatment 
satisfaction, as determined via this questionnaire, has been found to be pivotal in regards to 
successful long term therapy for ED [526]. 
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3.2.6 Measurement of Sleep Related Erections 
Sleep Related Erections (SRE’s) were measured via Nocturnal Penile Tumescence (NPT) 
monitoring prior to treatment and at study completion using a Rigiscan Plus monitor (Timm 
Medical Technologies, Minnesota, USA). This device records the frequency and duration of 
tumescence (circumference) and rigidity (hardness) of the base and tip of the penis during 
sleep.  The recording device is strapped to the participant’s thigh using a commercially 
available strap with a customised pocket to hold the device for the duration of the sleep 
period.  Two small tension cables extend from the device to the penis, which move freely 
through a conduit and disposable loop covers. These loops are placed around the base and 
tip of the penis which gently tighten and release every 15 seconds at a force of 114 grams. 
After the dilatation of the loop, the penile tissue rebounds to the pre-intervention state.  
During this rebound, a measurement of the erectile tissue engorgement is taken. If an 
increase in tumescence is detected, compared to previous results, and has shown at least a 
6mm increase, a second measurement is taken every 30 seconds.  This second 
measurement records rigidity by tightening the loops to a linear force of 283.5grams and 
determines the cross sectional response to radial compression [102].  
Parameters recorded for each session included number of erections (defined as a 20% 
increase in tumescence from baseline lasting at least 3 minutes), erection duration in both 
time and percent of recording, percentage rigidity (compared to 100% being a hard-rubber 
cylinder), rigidity activation units (a product of minutes spent at a given rigidity level in 
decimal form, summated for the duration of the erectile event)  of both the base and the 
tip, as well as tumescence activation units (the duration of an erectile event multiplied by 
the percentage increase in circumference, as a decimal, over the baseline tumescence) of 
both base and tip [103].  
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Criteria used to distinguish between the traditional categorisations of organic and 
psychological origin of ED was as described in commercial documentation of the Rigiscan 
[527]. To fulfil the criteria of ED due to organic causes, three of the following were required 
during one night of recording: 
1. Less than 3 erections recorded.  
2. Less than 10 minutes of erection recorded  
3. Less than 10 minutes of erection at greater than 60% rigidity at the base or tip 
4. Less than 3cm increase in tumescence at the base of the penis 
5. Less than 2cm increase in tumescence at the tip of the penis 
As penile tumescence monitoring may be viewed as unacceptable by some participants, a 
choice was given to opt out of having this test performed.   If participants did agree to be 
monitored, a short fifteen minute characterisation session was performed in the laboratory. 
This was used for both patient orientation to the device and for measurement of a baseline 
recording of tumescence. After watching an instructional DVD (Timm Medical Technologies, 
Minnesota, USA), the participant self-applied the Rigiscan and a baseline recording of at 
least 5 minutes duration was performed while the penis was in the flaccid state.  After 
ensuring the participant was able to correctly use the Rigiscan, two consecutive nights of 
data were collected while the participant slept at home, as acclimatization nights.  A third 
recording was performed concurrently with polysomnography in the sleep laboratory.    
A unique calibration tool was developed in-house to ensure intra- and inter-reliability of the 
recordings. Cylindrical cross sectional areas of differing diameters representative of varying 
penile size were lathed into a solid pipe, providing a known circumference to measure 
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against. Regular testing of the Rigiscan using this device was undertaken, particularly at 
times of instability and after annual servicing.   
3.2.7 Polysomnography 
Overnight polysomnography was performed prior to commencement of study treatment, as 
well as after 3 months of treatment, in an attended laboratory setting and analysed using a 
Sandman Elite system and software (Sandman Elite v9.2, Tyco Healthcare, Denver, 
Colorado) at the Woolcock Institute of Medical Research, Glebe, New South Wales (Sydney 
site),  or Compumedics Profusion 2 (Melbourne, Australia) at the Department of Respiratory 
and Sleep Medicine, Monash Medical Centre, Clayton, Victoria (Melbourne site).  
Standard sensors and measurement techniques were used as per contemporary guidelines 
for clinical polysomnography [528].   Sleep stage was recorded via electroencephalography 
(EEG) using the conventional 10-20 system [529] at four sites – C3, C4, O1, & O2 which were 
each referenced to their opposing mastoid - M1 & M2. Eye movements were recorded using 
electrooculography for left and right eyes, referenced to M2 and M1 respectively.  Sub-
mental chin electromyography via differential surface electrodes provided an indication of 
muscle tone.  At the baseline visit, respiratory flow was measured using pressure 
transduced airflow obtained via nasal cannula, as well as via thermistor to obtain oral 
respiration.  The degree of thoracic and abdominal movement was monitored via 
respiratory inductive plethysmography using specialised belts around the chest and 
abdomen. Peripheral oxygen saturation (SaO2) was obtained as a continuous measurement 
using either inbuilt (Sydney site) or external finger pulse oximetry entrained into the 
polysomnograph (Melbourne site).  Other routine polysomnographic variables were also 
recorded as per standard practice [528]. These comprised a single channel 
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electrocardiograph, anterior tibialis electromyography (leg EMG), body position and digital 
video. 
Manual sleep staging and scoring of these recordings was performed by the same blinded 
sleep technologist at each site using American Academy of Sleep Medicine guidelines for 
sleep staging and respiratory scoring [528].  Each 30 second epoch was designated as being 
either wake, Stage N1, Stage N2, Stage N3 or REM sleep. Stages 1 through 3 were summated 
and reported as NREM.  From this analysis, calculation of sleep parameters was performed, 
including time spent in each sleep stage, total sleep time, sleep latency (time to fall asleep), 
and sleep efficiency (percentage of time in bed spent asleep).   
Arousals from sleep were identified as being a significant shift to a faster frequency for at 
least 3 seconds after at least 10 seconds of sleep had occurred.  Those arousals which 
occurred in REM sleep also required an increase in muscle tone [528].  The number of 
arousals per hour of sleep recorded was reported as the arousal index.  
Respiratory events were identified and scored manually on the basis of airflow, oxygen 
saturation and EEG.  Apnoeas were defined as being a cessation of airflow for a minimum of 
10 seconds and classified as being obstructive if respiratory effort was seen on the 
abdominal or thoracic trace, central if there was an absence of such effort, or mixed if there 
was a combination of the two.  Hypopnoeas were defined as a reduction of airflow for more 
than 10 seconds, followed by an arousal or at least 3 per cent oxygen desaturation.  All of 
these events were reported in terms of events per hour of sleep as the apnoea hypopnoea 
index (AHI). Oxygen desaturation index was automatically determined via the acquisition / 
analysis software, through identification of decrease in oxygen saturation by at least 3 per 
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cent during periods of sleep, expressed as the number of these events per hour of sleep 
(ODI3). 
At the week 12 visit, CPAP or sham CPAP was used for the duration of the sleep period. 
Polysomnography was repeated using the same methodology as baseline, however, oxygen 
tubing was attached to the CPAP mask to obtain respiration measurements through a 
pressure transducer, rather than via nasal cannula and a thermistor was not used.  All other 
methodologies remained the same between visits.  The CPAP or sham CPAP device was set 
to the pressure settings used during the study period. 
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3.3 RESULTS 
The flow of participants through the study is shown in figure 3.2. Sixty-one men were 
randomized into the study, of these, 49 were from the Sydney site and 12 were from 
Melbourne.  There were no significant differences in any of the primary outcome variables, 
between the participants from Sydney & Melbourne however, participants from Sydney 
reported a higher masturbation frequency (data not shown).  Six participants withdrew from 
the study after randomisation.  Four participants were from the Sydney site, while two were 
from Melbourne.  Of these, two withdrew from the study due to being unhappy with the 
CPAP/sham CPAP and four withdrew due to personal reasons.  Four of the six withdrawals 
were randomised to receive placebo medication, and four of the six withdrawals were 
randomised to receive sham CPAP. There was no difference in any demographic, sleep or 
erectile function parameter between those who withdrew and those who completed the 
study (data not shown). Fifty five men completed the study. 
Twenty participants were adherent to CPAP/sham CPAP, as defined by at least 4 hours per 
night usage.  Of these, 12 were allocated to CPAP, 8 to sham CPAP, further explained in 
section 4.4.6. 
 - 131 - 
Figure 3.2: Study Flow 
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3.3.1 Interactions between Treatments 
No interactions were found between the two treatments in either a three way or two way 
analysis.  Subjective outcomes, that of questionnaire data, are presented in table 3.1, for 
both 3 way (CPAP/sham*Vardenafil/Placebo*time) and, since none were significant, a 2 way 
(CPAP/sham*Vardenafil/Placebo) analysis, also shown in table 3.1. One objective outcome, 
the measurement of sleep related erections, is presented in a 2 way interaction only 
(CPAP/sham CPAP*Vardenafil/Placebo), since this was performed only at the baseline & 
final visits (table 3.2). There were no interactions between the two treatments in either a 3-
way or 2-way analysis for any objective or subjective parameter measured.  The factorial 
design assumption, that CPAP does not affect the efficacy of Vardenafil, and vice versa, was 
confirmed to be upheld.  
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Table 3.1:  Interaction terms for subjective parameters 
 
3-way  
p-value  
2-way  
p-value 
International Index of Erectile Function (IIEF)   
IIEF - Overall Score 0.7647 0.5641 
IIEF - Erectile Function 0.6274 0.6287 
IIEF - Intercourse Satisfaction 0.7840 0.5118 
IIEF - Orgasmic Function 0.8124 0.4229 
IIEF - Overall Satisfaction 0.4974 0.8174 
IIEF - Sexual Desire 0.2194 0.8201 
European Male Aging Study questionnnaire (EMAS)   
EMAS - Overall Score 0.7413 0.7081 
EMAS - Sexual Function Distress 0.7609 0.8238 
EMAS - Change in Sexual Function 0.9543 0.9340 
EMAS - Overall Sexual Function 0.5679 0.9187 
EMAS - Masturbation 0.4843 0.9496 
Self-Esteem and Relationship Satisfaction (SERS)   
SERS - Overall Score 0.9381 0.6539 
SERS - Sexual Relationship Satisfaction 0.8324 0.5662 
SERS - Confidence 0.9764 0.9573 
SERS - Self Esteem 0.4464 0.8250 
SERS - Overall Relationship Satisfaction 0.2087 0.4835 
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) 0.7692 0.0552 
Functional Outcomes of Sleep (FOSQ)   
FOSQ - Activity 0.1802 0.5258 
FOSQ - Vigilance 0.1541 0.8248 
FOSQ - Intimacy 0.5258 0.1757 
FOSQ - Productivity 0.3789 0.7839 
FOSQ - Social Outcomes 0.683 0.5422 
Short-form 36 (SF-36)   
SF-36 Physical Function 0.8658 0.4801 
SF-36 Role Physical 0.3894 0.3732 
SF -36 Body Pain 0.1139 0.2254 
SF-36 General Health 0.9690 0.1648 
SF-36 Vitality 0.4036 0.7082 
SF-36 Social Function  0.4396 0.4267 
SF-36 Role Emotional 0.2568 0.4513 
SF-36 Mental Health Scale 0.0717 0.6157 
SF-36 Physical Health 0.3559 0.1364 
SF36 Mental Health Dimension 0.1128 0.4213 
Depression Anxiety Stress Scale (DASS)   
DASS Depression 0.9421 0.2350 
DASS Anxiety 0.538 0.4421 
DASS Stress 0.8581 0.5940 
Epworth Sleepiness Score (ESS) 0.1697 0.7379 
Note:  p-value determined via mixed model analysis.
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Table 3.2:  Interaction terms for sleep related erections 
Sleep Related Erections 2-way  
 p-value 
Total Number of Erections 0.7216 
Tip Rigidity Activation Units  0.1550 
Tip Tumescence Activation Units  0.3073 
Base Rigidity Activation Units  0.4923 
Base Tumescence Activation Units 0.2739 
Note: p-value determined via mixed model analysis. 
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3.4 DISCUSSION & CONCLUSION 
The efficacy of CPAP treatment was not affected by Vardenafil and vice versa for any of the 
outcomes of this study. In a systematic review regarding the reporting of factorial studies, 
recommendations were made that interactions from a 2x2 factorial study should be 
reported, which has been presented here, and that factorial trials are an efficient means of 
testing two treatments [518].  According to this review, performed in 2003, 82% of the 44 
factorial studies found were performed in order to be an efficient manner of testing two 
treatments in the same population, with the remaining studies testing cumulative effects of 
two treatments.  All trials, except one, reported outcomes for each treatment individually 
(that is, treatment A versus treatment B, and Treatment C versus Treatment D), 59% 
reported interactions between the two treatments, and only 6% found any such interaction 
[518].    The current trial fulfils the requirements of reporting results of interaction analysis, 
with no such interactions present.  The two trials are able to be analysed separately with 
confidence that the other treatment did not influence efficacy.  These two trials are 
presented in Chapters 4 and 5 respectively. 
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4 Effect of CPAP treatment on sexual function, relationship 
quality, mood and quality of life in men with obstructive 
sleep apnoea and erectile dysfunction 
4.1 CHAPTER SUMMARY 
 
Background:   Erectile dysfunction and obstructive sleep apnoea often coexist.  Treatment 
of OSA using CPAP has been reported to improve erectile function; however previous 
studies have not been performed using the best available placebo (sham) control.  The 
effects of CPAP on other parameters of sexual function have been conflicting. This study 
aims to assess the effect of CPAP, using a sham CPAP control, on sexual function and quality 
of life.  
Methods:  Sixty-one men with severe OSA (AHI 46.1 ± 25.8), who were naïve to CPAP were 
randomised to either CPAP or sham CPAP as part of a 2x2 factorial study also investigating 
the efficacy of a PDE-5 inhibitor, Vardenafil, for a period of 12 weeks.  Subjective measures 
of sexual function, mood, relationship factors and quality of life were assessed prior to, and 
after 4, 8 and 12 weeks of allocated treatment.  Objective measurement of erectile function 
was assessed at baseline and at study completion with nocturnal penile tumescence 
monitoring.   
Results: CPAP, overall, improved overall sexual satisfaction but did not improve subjective 
erectile function. By week 12, both subjective erectile function and sexual desire improved 
but only in those men who used CPAP more than 4 hours per night during the treatment 
period. The number of erections during sleep increased with CPAP compared to sham CPAP 
(from 2.7±1.9 to 4.1±2.0, p=0.0006), but these did not change in quality.   CPAP, compared 
to sham CPAP, when used more than 4 hours, reduced distress due to sexual dysfunction, 
and improved mental health, depression, stress, anxiety, sexual relationship satisfaction and 
participants were satisfied with treatment efficacy.  
Conclusion: CPAP, when used as prescribed, is effective in improving sexual health and 
function in men with erectile difficulties, as well as improving mental health and quality of 
life.  However, effective treatment was tolerated by less than half of study participants.  
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4.2 INTRODUCTION 
Erectile dysfunction (ED) is associated with untreated obstructive sleep apnoea (OSA) [30, 
396, 409, 415, 422, 425]. An apnoea hypopnoea index (AHI) of greater than 15 has been 
found in a large population study to have an odds ratio of having ED as 2.75 [57], with 
prevalence rates of ED reported in men with OSA ranging from 29-69% [409, 414, 422]. The 
association between the two conditions is often not addressed in clinical practice and is 
unknown to many patients undergoing Continuous Positive Airway Pressure (CPAP) 
treatment for OSA [414, 487].     
Quality of life for both men with OSA and men with ED is known to be reduced [338, 530-
532] However, for those men who have both conditions, there can be further decrements in 
quality of life and mood than with OSA alone [414].  Erectile dysfunction impacts on the 
ability to maintain a healthy sexual relationship, and the social impacts of loud snoring and 
disrupted sleep for the bed partner can result in a reduction of relationship quality and 
increase marital conflict [369, 533, 534].  
Treatment of OSA using CPAP has long been established as an effective treatment to reduce 
airway obstruction during sleep [466].  In addition to improvements in hypertension [365], 
cardiovascular disease [535], sleepiness [536], and quality of life [330],  CPAP has also been 
shown, to a lesser extent, to improve some aspects of sexual function and relationship 
quality [412, 474]. Erectile function, measured using the International Index of Erectile 
Function (IIEF) questionnaire, the gold standard of measurement of ED, has shown to 
increase with CPAP use in uncontrolled trials [484].  Objective measurements of erectile 
function through the use of nocturnal penile tumescence monitoring have also shown 
improvements due to CPAP [433, 438, 537].  To date, however, studies investigating the 
effects of CPAP on sexual function have been limited to observational or non-CPAP placebo 
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or alternate treatment trials.  Randomised sham-controlled CPAP studies have not been 
performed.  
This study aims to investigate the efficacy of CPAP as a treatment for ED using a sham 
control, while assessing sexual function, mood, and quality of life parameters. Since sexual 
function is a self-reported subjective outcome, sham control is paramount to ensure 
adequate blinding.  
4.3 METHODS 
This was a multisite study, performed in Sydney at the Woolcock Institute of Medical 
Research, Glebe, New South Wales and in Melbourne at the Department at Respiratory and 
Sleep Medicine, Monash Medical Centre, Clayton, Victoria, as described in section 3.2. 
4.3.1 Study Design 
This study was performed as part of a 2x2 factoral study, investigating the effects of CPAP 
and Vardenafil in men with OSA and ED.  Sample size was determined as described in 
section 3.2.4.  After baseline data collection, eligible participants at each site (Sydney and 
Melbourne) were randomised, using two separate computer generated randomization list in 
blocks of four, to either CPAP or sham CPAP, to be used for 12 weeks at home.  Clinical 
assessments and subjective measurements were assessed before, as well as after 4, 8 and 
12 weeks of treatment.  Objective measurements were performed at baseline, and at Week 
12 whilst using their allocated treatment (see section 3.2.1). 
4.3.2  Participants 
Sixty-one men aged between 18-65 years who had both OSA, and reported ED were 
recruited into the study as described in section 3.2.2.  Briefly, participants were required to 
have at least moderate OSA, defined as an apnoea-hypopnoea index (AHI) measured by 
polysomnogram, of greater than 20 events per hour, with an oxygen desaturation of 3 % or 
greater (ODI3) of at least 15 events per hour, as well as ED, defined as a score of less than 26 
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in the erectile function domain of the International Index of Erectile Function (IIEF) 
questionnaire. 
4.3.3  CPAP Treatment and Sham CPAP Control 
CPAP is the first line therapy for obstructive sleep apnoea.  Participants were randomly 
allocated to receive either active CPAP or inactive CPAP therapy – “sham CPAP”- for the 
duration of the study.  Sham CPAP comprised an adapted machine and mask which ensured 
that the patient received sub-therapeutic (less than 1 cmH2O) therapy, but experienced all 
other facets of CPAP use.  The CPAP motor was set to deliver 10 cmH2O, which was 
displayed on the patient interface screen.  A setting of 10cmH2O is a valid setting for real 
CPAP, and would not unblind the staff member to the treatment allocation. A restrictor 
within the device limited the flow output, considerably reducing the pressure delivered.  In 
addition, the usual mask elbow was replaced with a sham mask variant, which had a larger 
than normal expiratory port [538] .  This method of sham control has been successfully used 
in several other studies [364, 539-542], and analysis of patient perception shows that when 
used in CPAP naïve patients, adequate blinding is maintained [516].  
Prior to commencing on therapy, all participants received an individual education session on 
obstructive sleep apnoea and CPAP, lasting 1-1.5 hours, delivered by the same staff member 
in each location, using methods shown to increase adherence to CPAP therapy [543]. 
Following the education session, each participant chose the most appropriate mask out of 
those provided to him, which was then tested for suitability regarding correct seal and 
comfort.  The mask was applied with low pressure for about 15 minutes for the participant 
to become familiar with the sensation, and any questions or concerns allayed.  Correct 
application of the mask and usage of the CPAP machine was reinforced. 
Individual pressure requirements for each participant allocated to receive real CPAP were 
determined via a minimum three night home auto-titration using a Respironics Remstar Pro 
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CPAP machine (Pittsburgh, USA).  A minimum of 4 hours use on any one night was required 
for the titration to be acceptable.  The internal algorithm was used to determine a pressure 
sufficient to maintain airway patency in each subject.  The pressure listed as the 95th 
percentile was then used to set the machine in a fixed mode for the remainder of the 12 
week treatment period.  Those participants allocated to receive sham CPAP completed the 
same procedure, using a sham version of the Respironics Remstar Pro (Pittsburgh, USA).  
Double blinding of CPAP settings was strictly maintained via complete separation of 
machine and mask preparatory procedures from those who had interaction with the 
participant. All patients, regardless of randomization, completed the home titration 
procedures.  Due to the possibility of unblinding by observation of the CPAP mask, all 
participants were instructed to speak with an alternate staff member, other than the study 
co-ordinator, concerning any difficulties they may have with CPAP.  This staff member was 
not involved in any data analysis.  CPAP mask choice was limited to those which had a sham 
version available.  This limited the range of masks which could be used to contemporary 
Respironics nasal masks, namely, Comfort Fusion, Comfort Select, Comfort Gel, Comfort 
Classic and Profile Lite.   Neither full face masks nor nasal pillows were used.  
Adherence to CPAP therapy was monitored via product specific memory cards, which were 
downloaded every 4 weeks of the study.  To aid adherence, after 4 weeks of usage all 
participants watched an 8 minute short film of 4 individuals whom had overcome initial 
difficulties using CPAP but had persevered to become successful CPAP users.  During the 
study, all efforts were made to encourage participants to use the device whenever they 
slept.  CPAP therapy was commenced without humidification, however, if the participant 
expressed any concerns regarding nasal stuffiness or dryness, a humidifier was supplied.  
Appropriate education regarding correct and safe usage of the humidifier was provided 
prior to initiation.  
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4.3.4  Subjective Assessments 
Subjective measurements of sexual function, relationship quality and quality of life were 
assessed at baseline and after 4, 8 and 12 weeks of treatment using self-administered 
computerized or paper based questionnaires as described in section 3.2.5.  
4.3.5  Measurement of Sleep Related Erections 
Sleep Related Erections (SRE’s) were measured via Nocturnal Penile Tumescence (NPT) 
monitoring prior to treatment and at study completion, during polysomnography, using a 
Rigiscan Plus monitor (Timm Medical Technologies, Minnesota, USA) as per section 3.2.6.  
4.3.6  Blood Parameters 
Fasting blood samples were collected in the morning after the overnight sleep study at 
baseline and at Week 12. Parameters assessed included reproductive hormones and routine 
full blood examination.   
4.3.7  Polysomnography    
Overnight polysomnography was performed prior to commencement of study treatment, as 
well as after 12 weeks of treatment, in an attended laboratory setting and analysed using a 
Sandman Elite system and software (Sandman Elite v9.2, Tyco Healthcare, Denver, 
Colorado) as per section 3.2.7.  
At the week 12 visit, CPAP or sham CPAP was used for the duration of the sleep period. 
Polysomnography was repeated using the same methodology as baseline, however, no 
thermistor was used and oxygen tubing was attached to the CPAP mask to obtain 
respiration measurements through a pressure transducer, rather than via nasal cannula. All 
other methodologies remained the same between visits.  The CPAP or sham CPAP device 
was set to the pressure settings used during the study period.  
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4.3.8 Statistical analysis 
Statistical analysis was performed using SAS statistical package version 9.2 (SAS Institute, 
Cary, North Carolina, USA), as described in section 3.2.5. Student t-tests and Fishers exact 
test were first used, as appropriate, to establish differences in groups at baseline.  Mixed 
model analysis was first used to ensure there was no interaction between the two 
concurrent study protocols, as described in section 3.2.4.  Since this hypothesis was upheld, 
(see section 3.3.1), the effect of each treatment was assessed in separate models. Data was 
analysed using intention-to-treat principles and the outcome variables were the mean 
values at weeks 4, 8 and 12 weeks as appropriate. A mixed model analysis compared CPAP 
with sham CPAP, taking baseline data into consideration.   The raw mean, standard 
deviation, and between-group difference at each time point was reported, with the Week 
12 time point being the outcome of interest.  Normality of residuals of the final model was 
confirmed.   Per-protocol analysis was then undertaken using the same mixed model 
analyses in order to examine the influence of CPAP adherence on the effect of treatment.  
The between CPAP and sham group difference were reportedly separately in the adherent 
participants.    
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4.4 RESULTS 
The flow of participants through the study is shown in figure 4.1.  Sixty-one men were 
randomized into the study.  Of these participants, 31 were allocated to receive real CPAP, 
and 30 to sham CPAP. Six participants withdrew from the study after commencing 
treatment.  Of these, two withdrew from the study due to being unhappy with treatment 
(both from the sham CPAP group), and four (2 on sham, 2 on real) withdrew due to personal 
reasons.  There was no difference in any demographic, sleep or erectile function parameter 
between those who withdrew and those who completed the study (data not shown). Fifty 
five men completed the study. Baseline characteristics of demographic, medical history, 
sleep and breathing, and sexual function parameters between those who were randomised 
to CPAP or sham CPAP as shown in table 4.1. Despite randomisation, a significant difference 
was noted in the primary outcome, namely the IIEF questionnaire overall.  Additionally, the 
IIEF domains of intercourse satisfaction, orgasmic function, and overall satisfaction, as well 
as the FOSQ domain of intimacy were also found to be different at baseline.  
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 Figure 4.1 Study Flow 
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yTable 4.1 Baseline Characteristics 
 
CPAP           
(n=31) 
Sham CPAP   
(n=30) p-value 
Age (years) 55.7 ± 7.7 52.6 ± 10.4 0.178 
Medical History               
Hypertension n (%)^ 18 
15 
8 
6 
7 
 7  
(58) 14  (47) 0.401 
Using antihypertensives n (%) 15 (48) 10 (33) 0.192 
Hypercholesterolemia n (%)^ 8 (26) 8  (26) 0.999 
Using statins n (%) 6 (19) 5  (17) 0.802 
Diabetes n (%)^ 7 (23) 4  (13) 0.187 
Using diabetic medications (%) 7 (23) 4  (13) 0.188 
Lifestyle Factors               
Number of drinks per week 9.1 ± 9.8 10.6 ± 15.6 0.659 
Drink more than 10 drinks/week n(%) 11  (36) 10  (33) 0.782 
Past smokers n(%) 25  (81) 25  (83) 0.903 
Anthropometry               
Weight (kg) 101.0 ± 14.0 100.1 ± 18.0 0.827 
Body Mass Index (kg/m2) 32.9 ± 4.2 32.7 ± 5.5 0.881 
Neck circumference (cm) 42.9 ± 3.3 42.9 ± 2.9 0.946 
Mid-arm circumference (cm) 32.8 ± 2.5 33.7 ± 3.5 0.250 
Waist circumference (cm) 112.0 ± 11.6 109.7 ± 13.3 0.481 
Hip circumference (cm) 108.7 ± 10.1 109.5 ± 11.6 0.790 
Mid-Thigh circumference (cm) 51.9 ± 4.6 52.8 ± 7.9 0.602 
Values are mean ± standard deviation or number (percentage). p-value calculated by Students t-test 
or Fishers exact test. ^as diagnosed prior entry into the study.  
(Continued over) 
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Table 4.1 Baseline Characteristics (continued) 
 
CPAP       
(n=31) 
Sham CPAP  
(n=30) p-value 
Sleep and Breathing                 
Total Sleep Time (minutes) 364.9 ± 54.8 330.6 ± 93.4 0.084   
Sleep Efficiency (%) 80.4 ± 11.1 75.3 ± 20.9 0.236   
REM (% of total sleep time) 16.9 ± 6.4 16.2 ± 7.8 0.700   
Arousal index (/hour) 34.1 ± 20.9 34.1 ± 19.6 0.999   
Apnoea Hypopnoea Index (AHI) 48.2 ± 26.9 44.0 ± 24.9 0.527   
NREM AHI 50.0 ± 28.5 44.6 ± 26.3 0.453   
REM AHI 50.9 ± 24.3 45.2 ± 26.4 0.399   
Minimum SpO2 77.3 ± 10.1 74.6 ± 11.2 0.336   
Time SaO2 below 90% (min) 11.9 ± 15.7 12.9 ± 14.7 0.815   
Oxygen Desaturation (3%) Index  43.7 ± 30.9 44.5 ± 27.7 0.919   
Sexual Function & Relationship Parameters        
Relationship duration (years) 17.3 ± 13.5 17.2 ± 14.0 0.984   
Fathers n (%) 22 (71) 
(71) 
23 (77) 
 
(77) 
0.712   
Duration of erectile dysfunction (years) 6.0 ± 4.6 6.2 ± 5.5 0.857   
International Index of Erectile Function (IIEF) 39.0 ± 14.9 30.0 ± 16.3 0.029 
IIEF - Erectile Function 14.3 ± 7.3 10.7 ± 7.4 0.062 
IIEF - Intercourse Satisfaction 6.8 ± 3.7 4.8 ± 4.0 0.045 
IIEF - Orgasmic Function 6.8 ± 2.9 4.6 ± 3.5 0.011 
IIEF - Overall Satisfaction 4.9 ± 2.3 3.8 ± 2.0 0.045 
IIEF - Sexual Desire 6.2 ± 1.6 6.1 ± 2.4 0.909 
European Male Aging Study Questionnaire (EMAS) 33.1 ± 8.2 34.3 ± 7.2 0.531 
EMAS - Sexual Function related distress 9.3 ± 3.9 11.6 ± 5.7 0.069 
EMAS - Change in Sexual Functioning -3.3 ± 2.9 -3.1 ± 3.5 0.812 
EMAS - Overall Sexual Functioning 15.8 ± 5.2 15.0 ± 6.7 0.605 
EMAS - Masturbation 2.3 ± 1.8 2.2 ± 1.6 0.839 
Self Esteem and Relationship Questionnaire (SERS) 39.5 ± 11.0 37.4 ± 12.0 0.482 
SERS - Sexual Relationship Satisfaction 19.9 ± 6.8 17.8 ± 8.1 0.278 
SERS - Confidence 19.6 ± 5.6 19.2 ± 5.3 0.793 
SERS - Self Esteem 12.6 ± 4.1 12.1 ± 4.6 0.675 
SERS - Overall Relationship Satisfaction 7.0 ± 2.0 7.0 ± 2.0 0.898 
Nocturnal Penile Tumescence (n=43)               
Total number of erections 2.7 ± 1.9 2.5 ± 2.3 0.762 
Tip Rigidity Activation Units 26.5 ± 31.3 20.7 ± 17.8 0.473 
Tip Tumescence Activation Units 18.6 ± 20.1 20.6 ± 34.9 0.832 
Base Rigidity Activation Units 32.3 ± 35.6 34.2 ± 32.9 0.868 
Base Tumescence Activation Units 19.9 ± 21.8 27.7 ± 32.8 0.369 
Organic Erectile Dysfunction (%)* 13 (59) 14 (67) 0.754 
Note: Values are mean ± standard deviation. p-value calculated by Students t-test. * As defined in 
section 3.2.6 
(Continued over)  
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Table 4.1 Baseline Characteristics (continued)  
 
CPAP       
(n=31) 
Sham CPAP 
(n=30) p-value 
Quality of Life       
 Subjective Sleepiness (ESS)  10.3 ± 5.1 10.3 ± 4.4 0.987 
Functional Outcomes of Sleep Questionnaire (FOSQ)         
   FOSQ - Overall score 15.9 ± 3.0 14.9 ± 3.2 0.183 
FOSQ - Activity 3.1 ± 0.7 3.0 ± 0.7 0.569 
FOSQ - Vigilance 3.2 ± 0.6 3.1 ± 0.6 0.731 
FOSQ - Intimacy 2.8 ± 0.7 2.3 ± 1.0 0.041 
FOSQ - General Productivity 3.5 ± 0.5 3.4 ± 0.6 0.458 
FOSQ - Social Outcome 3.5 ± 0.8 3.6 ± 0.7 0.786 
Depression Anxiety Stress Scale (DASS) 
       
DASS - Depression 7.4 ± 7.3 11.4 ± 9.9 0.074 
DASS - Anxiety 6.6 ± 5.8 7.0 ± 5.8 0.763 
DASS - Stress 12.4 ± 7.1 13.2 ± 7.8 0.659 
Short Form 36 (SF-36)  
       
SF-36 - Physical Function 72.3 ± 21.8 72.0 ± 26.4 0.967 
SF-36 - Role - Physical 75.8 ± 29.2 67.2 ± 37.3 0.22 
SF-36 - Body Pain 74.9 ± 16.6 72.7 ± 25.9 0.701 
SF-36 - General Health 63.4 ± 18.3 59.6 ± 19.9 0.437 
SF-36 - Vitality 53.5 ± 21.8 49.8 ± 21.8 0.509 
SF-36 - Social Function 82.0 ± 23.8 77.6 ± 27.3 0.511 
SF-36 - Role Emotional 72.1 ± 34.6 66.7 ± 36.8 0.562 
SF-36 - Mental Health 75.0 ± 16.3 68.3 ± 20.0 0.157 
SF-36 - Physical Health 67.9 ± 15.1 64.8 ± 20.4 0.510 
SF-36 - Mental Health Dimension 76.4 ± 21.1 72.1 ± 23.3 0.462 
Note: Values are mean ± standard deviation. p-value calculated by Students t-test.  ESS = Epworth 
Sleepiness Score  
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4.4.1 Sleep and breathing 
At study entry, there were no differences between the CPAP and sham CPAP groups in 
terms of sleep and breathing parameters.  The baseline AHI was 46.1±25.8 with a minimum 
SaO2 of 76.0±10.6%.  Treatment with CPAP did not change total sleep time or REM 
percentage from baseline or between groups.  CPAP therapy, but not sham CPAP, reduced 
the severity of OSA (table 4.2).  CPAP reduced the AHI by 43.1 events per hour (p<0.001) to 
a mean of 7.3±6.6, while sham CPAP did not change AHI.  Similarly, the oxygen desaturation 
index (ODI) was reduced by 38.7 events per hour with CPAP to 7.2±8.7 and did not change 
for sham CPAP (table 4.2).    
4.4.2   Subjective Sexual functioning 
At baseline, of the 61 study participants, 11.4% had mild ED (IIEF-ED score 22-25), 21.3% had 
mild-moderate ED (IIEF-ED score 17-21), 26.2% had moderate ED (IIEF-ED score 11-16) and 
41% had severe ED (IIEF-ED score 6-10) [430, 544].    CPAP treatment improved overall 
satisfaction, as measured by the IIEF compared to sham CPAP, and trended toward an 
improvement in in both overall score and the overall sexual relationship satisfaction domain 
of the SERS questionnaire (p=0.06 and p=0.07 respectively). CPAP did not improve any other 
domain in the IIEF, EMAS or SERS questionnaires compared to sham CPAP (table 4.3).  
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 Table 4.2 Effect of CPAP on sleep disordered breathing  
 
CPAP (n=31) 
 
Sham CPAP (n=30) 
 
Difference between 
groups (95% CI)  
 
Baseline Week 12 p-value Baseline Week 12 p-value p-value 
TST (minutes) 364.9 ± 54.8 371.8 ± 50.1 .616 330.6 ± 93.4 352.5 ± 76.0 .358 -0.9 (-37.1 to 35.2) .959 
REM (% of TST) 16.9 ± 6.4 20.9 ± 10.2 .076 16.2 ± 7.8 17.7 ± 8.6 .502 3.2 (-2.0 to 8.4) .223 
Arousal Index  34.1 ± 20.9 14.4 ± 6.9 <.001 34.1 ± 19.6 38.2 ± 23.6 .484 -24.2 (-35.6 to -12.7) <.001 
AHI 48.2 ± 26.9 7.3 ± 6.6 <.001 44.0 ± 24.9 42.4 ± 27.1 .831 -41.6 (-54.7 to -28.4) <.001 
NREM AHI 50.0 ± 28.5 7.6 ± 7.2 <.001 44.6 ± 26.3 41.7 ± 29.3 .706 -39.9 (-54.1 to -25.7) <.001 
REM AHI 50.9 ± 24.3 10.0 ± 7.3 <.001 45.2 ± 26.4 45.3 ± 26.6 .997 -45.2 (-56.7 to -33.8) <.001 
Minimum SaO2 77.3 ± 10.1 89.2 ± 5.0 <.001 74.6 ± 11.2 77.4 ± 8.7 .332 8.9 (2.8 to 15.0) .005 
Time SaO2 
below 90% 
(min) 
11.9 ± 15.7 1.7 ± 2.1 0.001 12.9 ± 14.7 11.6 ± 12.0 .730 -8.0 (-15.9 to 0.2) .046 
ODI 43.7 ± 30.9 7.2 ± 8.7 <.001 44.5 ± 27.7 43.6 ± 28.4 .911 -37.4 (-52.4 to -22.4) <.001 
Note: Values are mean ± standard deviation. p-value calculated by Students t-test. Abbreviations:  AHI = Apnoea Hypopnea Index, NREM: Non Rapid Eye 
Movement sleep, ODI = Oxygen Desaturation (3%) Index, REM=Rapid Eye Movement Sleep, SaO2 = Oxygen saturation, TST = Total Sleep Time. 
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yTable 4.3 Effect of CPAP versus Sham CPAP on Sexual Function 
Variable Visit 
CPAP 
(n=31) 
Sham CPAP     
(n=30) 
Difference                      
Mean (95% CI) 
Effect 
size (d) 
p-value 
International Index of Erectile Function (IIEF)                 
Overall Score Week 4 43.00 ± 18.29 38.48 ± 19.38 4.52 (-5.67 to 14.71) 0.28 0.842 
  Week 8 42.78 ± 17.23 36.96 ± 22.18 5.82 (-5.34 to 16.97) 0.36 0.843 
  Week 12 43.31 ± 20.01 33.46 ± 20.08 9.85 ( -1.01 to 20.71) 0.61 0.342 
Erectile  Week 4 16.79 ± 8.68 14.96 ± 9.23 1.82 (-3.02 to 6.67) 0.24 0.866 
Function Week 8 16.30 ± 8.45 14.60 ± 10.46 1.70 (-3.64 to 7.03) 0.23 0.982 
  Week 12 16.28 ± 9.45 13.35 ± 9.43 2.93 (-2.18 to 8.04) 0.39 0.680 
Intercourse  Week 4 7.36 ± 4.59 5.96 ± 4.65 1.39 (-1.08 to 3.87) 0.36 0.852 
Satisfaction Week 8 7.07 ± 4.52 6.40 ± 5.22 0.67 (-2.01 to 3.36) 0.17 0.778 
  Week 12 7.52 ± 4.93 5.12 ± 4.67 2.40 (-0.20 to 5.01) 0.61 0.281 
Orgasmic  Week 4 7.07 ± 3.11 5.93 ± 3.92 1.15 (-0.77 to 3.06) 0.34 0.839 
Function Week 8 6.93 ± 3.22 5.32 ± 3.77 1.61 (-0.32 to 3.54) 0.47 0.543 
  Week 12 6.76 ± 3.40 4.69 ± 3.71 2.07 (0.14 to 3.99) 0.61 0.286 
Overall  Week 4 5.57 ± 2.33 4.67 ± 2.34 0.90 (-0.36 to 2.17) 0.40 0.531 
Satisfaction Week 8 5.93 ± 2.18 4.52 ± 2.86 1.41 (-0.01 to 2.83) 0.63 0.106 
  Week 12 6.17 ± 2.65 4.35 ± 2.53 1.83 (0.42 to 3.23) 0.82 0.038 
Sexual Desire Week 4 6.21 ± 1.71 6.74 ± 2.10 -0.53 (-1.56 to 0.51) -0.26 0.397 
  Week 8 6.39 ± 1.91 6.12 ± 2.15 0.27 (-0.85 to 1.39) 0.13 0.716 
  Week 12 6.59 ± 2.08 5.96 ± 2.37 0.62 (-0.58 to 1.83) 0.31 0.284 
Note: Values are mean ± standard deviation. p-value calculated by mixed model analysis. Effect size (Cohen’s 
d) calculated by dividing difference between CPAP and sham by the standard deviation at baseline. 
          (Continued over) 
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Table 4.3 Effect of CPAP versus Sham CPAP on Sexual Function (continued) 
Variable Visit 
CPAP 
Mean ± SD 
Sham CPAP     
Mean ± SD 
Difference                      
Mean (95% CI) 
Effect 
size (d) p-value 
European Male Aging Study questionnaire (EMAS)                 
Overall Score Week 4 34.29 ± 8.89 33.96 ± 9.26 0.33 (-4.79 to 5.45) 0.04 0.227 
  Week 8 35.89 ± 7.84 35.57 ± 7.71 0.32 (-4.12 to 4.76) 0.04 0.331 
  Week 12 35.83 ± 8.73 34.83 ± 7.70 0.99 (-3.60 to 5.58) 0.13 0.226 
Sexual  Week 4 7.14 ± 4.42 8.78 ± 5.60 -1.63 (-4.36 to 1.09) -0.33 0.895 
 Function Week 8 7.21 ± 4.27 10.32 ± 7.23 -3.11 (-6.46 to 0.25) -0.63 0.201 
 Distress Week 12 6.45 ± 4.82 8.80 ± 6.26 -2.35 (-5.38 to 0.68) -0.47 0.384 
Change in  Week 4 -1.43 ± 4.31 -1.69 ± 5.18 0.26 (-2.27 to 2.79) 0.08 0.790 
 Sexual Week 8 -0.96 ± 3.99 -1.85 ± 5.51 0.88 (-1.73 to 3.49) 0.28 0.304 
 Function Week 12 -0.62 ± 4.36 -1.62 ± 4.46 0.99 (-1.39 to 3.38) 0.31 0.443 
Overall  Week 4 17.11 ± 5.67 15.77 ± 6.62 1.34 (-2.02 to 4.70) 0.23 0.393 
 Sexual Week 8 17.89 ± 5.35 16.52 ± 6.58 1.37 (-2.07 to 4.81) 0.23 0.075 
 Function Week 12 18.34 ± 5.91 16.83 ± 7.46 1.51 (-2.17 to 5.20) 0.26 0.147 
Masturbation Week 4 2.46 ± 1.57 2.15 ± 1.61 0.32 (-0.55 to 1.18) 0.18 0.301 
  Week 8 2.54 ± 1.71 2.12 ± 1.72 0.42 (-0.53 to 1.36) 0.25 0.372 
  Week 12 2.41 ± 1.74 2.24 ± 1.74 0.17 (-0.78 to 1.13) 0.10 0.876 
Self-Esteem and Relationship Satisfaction (SERS)           
 
  
  Overall Score Week 4 44.11 ± 10.40 39.31 ± 14.31 4.80 (-2.00 to 11.6) 0.42 0.186 
  Week 8 44.07 ± 9.59 40.59 ± 16.29 3.48 (-4.5 to 11.46) 0.30 0.480 
  Week 12 46.79 ± 12.60 40.04 ± 14.18 6.75 (-0.64 to 14.14) 0.59 0.066 
Sexual  Week 4 22.75 ± 6.58 19.81 ± 8.93 2.94 (-1.29 to 7.16) 0.40 0.405 
 Relationship Week 8 22.79 ± 6.61 19.67 ± 10.02 3.12 (-1.73 to 7.97) 0.42 0.443 
 Satisfaction Week 12 24.66 ± 8.43 19.40 ± 9.00 5.26 (0.49 to  10.02) 0.71 0.059 
Confidence Week 4 21.36 ± 5.26 19.23 ± 6.33 2.13 (-1.05 to 5.30) 0.39 0.101 
  Week 8 21.29 ± 4.77 20.57 ± 6.65 0.72 (-2.62 to 4.06) 0.13 0.637 
  Week 12 22.14 ± 5.15 20.33 ± 6.91 1.80 (-1.52  to 5.13) 0.33 0.186 
Self Esteem Week 4 13.68 ± 4.17 12.26 ± 4.76 1.42 (-1.00 to 3.84) 0.33 0.230 
  Week 8 14.25 ± 3.04 12.96 ± 5.66 1.29 (-1.33 to 3.91) 0.30 0.301 
  Week 12 14.69 ± 3.66 12.68 ± 5.33 2.01 (-0.54 to 4.56) 0.46 0.090 
Overall  Week 4 7.68 ± 2.13 6.63 ± 2.48 1.05 (-0.20 to 2.30) 0.53 0.077 
 Relationship Week 8 7.04 ± 2.46 7.26 ± 2.20 -0.23 (-1.55 to 1.10) -0.11 0.524 
 Satisfaction Week 12 7.45 ± 2.13 7.33 ± 2.37 0.11 (-1.13 to 1.36) 0.06 0.818 
                      
Note: Values are mean ± standard deviation.  p-value calculated by mixed model analysis. Effect size 
(Cohen’s d) calculated by dividing difference between CPAP and sham by the standard deviation at 
baseline. 
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4.4.3 Hormonal Analysis 
At study commencement, testosterone levels spanned the lower part of the normal young 
adult reference range (10.2±3.7 nmol/L). CPAP therapy did not increase testosterone levels.  
There was an increase in testosterone from baseline to week 12 in those allocated to sham 
CPAP (12.4±4.3, p=0.04) which was not different than CPAP.   There was no change in 
luteinizing hormone, follicular stimulating hormone, or sex hormone binding globulin.  
4.4.4 Nocturnal Penile Tumescence 
Twenty eight participants (46%) were agreeable to undertake, and completed nocturnal 
penile tumescence (NPT) monitoring both prior treatment and study completion.  Of these, 15 
were on CPAP, 13 were on sham CPAP. Participants who agreed to take part in this monitoring 
did not differ from those who declined in terms of age, severity of ED, sleepiness, 
testosterone or weight.  However, those who did NPT monitoring had less severe OSA 
compared to those who did not (AHI:  41.5±22.7 vs 56.9±29.9, p=0.033; Minimum SaO2: 
78.5±9.0% vs 70.1±12.0, p=0.004; Oxygen Desaturation Index 37.9±25.1 vs 58.4±33.4, 
p=0.011).   Results for NPT monitoring are given in table 4.4. Data shown is from one night, 
that of the night of polysomnography at each visit.  At baseline, there were no differences in 
any NPT parameter between the CPAP and sham groups (table 4.1).  At Week 12, those who 
were allocated to CPAP had an increased number of erections compared to sham CPAP but 
did not show any improvement in any other parameter of NPT (table 4.4).  Nocturnal 
erections recorded occurred during periods of REM sleep, as well as some periods either side 
of those epochs designated as REM sleep.  An example of an individual NPT recording with 
concurrent sleep staging and pulse oximetry is shown for Baseline and Week 12 for a 
participant allocated to CPAP treatment (figure 4.2). 
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Table 4.4 Effect of CPAP on Sleep Related Erections 
 Baseline Week 12   
 All           
(n=38) 
CPAP         
(n=15) 
Sham CPAP 
(n=13) 
Effect 
size (d) 
p-value 
Number of erections per night 2.6 ± 2.1 4.1 ± 2.0 2.4 ± 1.8 0.81 <0.001 
Tip Rigidity Activation Units 24.0 ± 24.3 45.7 ± 45.2 47.0 ± 54.7 -0.05 0.713 
Tip Tumescence Activation Units 19.6 ± 19.4 33.6 ± 34.3 36.4 ± 47.0 -0.14 0.395 
Base Rigidity Activation Units 39.7 ± 48.2 68.2 ± 58.5 57.0 ± 58.6 0.23 0.974 
Base Tumescence Activation Units 30.9 ± 36.9 41.6 ± 39.9 49.2 ± 67.8 -0.21 0.101 
Note: Values are mean ± standard deviation. p-value calculated by mixed model analysis. Effect size (Cohen’s 
d) calculated by dividing difference between CPAP and sham by the standard deviation at baseline. 
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Note: (A) Baseline recording with no treatment.  Several erectile episodes are seen during some but 
not all of the REM sleep periods. (B) Recording at Week 12 for the same participant, using CPAP. 
Erectile episodes are seen during all REM sleep periods.  The number of episodes of erection increased 
however there has not been a change in quality.  
A 
B 
A 
Figure 4.2: Sleep staging, pulse oximetry & NPT recording for a patient allocated to CPAP  
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4.4.5  Quality of Life  
Allocation to CPAP therapy, compared to sham CPAP, did not change levels of sleepiness, 
depression, anxiety or stress (data not shown). Improvements were seen only in the domains 
of Vitality, in the SF-36 questionnaire, and in Vigilence in the FOSQ questionnaire, for those 
randomised to CPAP versus sham CPAP (mean difference, 95% CI: 11.05(-0.49 to 22.60), 
p=0.03, and 0.36(-0.05 to 0.77), p=0.01 respectively) at the Week 12 timepoint.   
4.4.6  CPAP adherence  
Adherence rates to CPAP therapy are listed in Table 4.5.  During the treatment period there 
was no significant difference between the usage of CPAP and sham CPAP, as measured by 
average hours used per intended days of use.  The average usage was 3.7 ± 2.5 hours and 2.6 
±2.2 hours per night for CPAP and sham CPAP groups respectively (p=0.092).  Adherence to 
therapy, defined by CPAP usage for more than 4 hours per night, was achieved by 46% of 
those randomised to real CPAP and 29% of those allocated to sham CPAP.  There appeared to 
be a bimodal distribution of low usage and high usage in the CPAP group, split at the 
commonly used definition of adherence, 4 hours per night minimum usage, but not in the 
placebo group (figure 4.3).  
Those participants adherent to treatment used the device for 6.2±0.9 hours per night for the 
CPAP group and 5.1±1.2 hours per night for the sham CPAP group (p=0.146).   Apart from 
relationship duration and a trend toward erectile dysfunction duration and pre-exisiting 
hypercholesterolemia, there was no other identifiable difference between those who did and 
did not adhere to CPAP therapy (table 4.6). 
Hereafter those participants who used CPAP or sham CPAP for more or less than 4 hours per 
night are referred to as “adherers” and “non-adherers” respectively.  The baseline 
characteristics of these two groups are described in table 4.7.  Apart from prevalence of a 
 - 156 - 
diagnosis of diabetes, the treatment two groups exhibited no differences at baseline.  There 
were a higher percentage of those with diabetes in the adherent CPAP group, compared to 
the adherent sham CPAP group (p=0.02).   
yTable 4.5 CPAP Adherence (hours of use per night) for study completers 
 CPAP Sham p-value 
 (n=26)
#
 (n=28)^  
Hours / intended days of use (mean ± SD) 3.7 ± 2.5 2.6 ±2.2 0.092 
Hours / days used (mean ± SD) 4.5 ± 2.0 4.0 ± 1.9 0.422 
Adherent to therapy (>4hours) n (%) 12 (46) 8 (29) 0.683 
Values are mean ± standard deviation.  p-value calculated using students t-test 
 
NOTE: #Although 31 participants were allocated to CPAP, data is only available for 26.  Data 
missing for 3 participants due to technical failure of CPAP recording cards and 2 withdrew 
before treatment commenced.  ^Although 30 participants were allocated to sham CPAP, data 
is only available for 28. Data missing for 1 participant due to technical failure of CPAP 
recording card and 1 withdrew before treatment commenced. 
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Figure 4.3: CPAP and Sham CPAP usage per night for all participants.   
Note: Histogram data shows the average usage of CPAP / sham CPAP in terms of number of participants who 
used CPAP (top row) or sham CPAP (bottom row) device in 20 minute epochs from no usage to 8 hours. The 
dashed vertical line represents the cut off mark of 4 hours per night, allocating patients to the adherent and 
non-adherent groups. Participants who withdrew after commencing treatment are indicated by the darker 
dashed squares. 
 
 - 158 - 
yTable 4.6 Characteristics of participants adherent and not adherent to CPAP treatment 
 
Non adherers                 
(<4 hrs CPAP 
usage)                 
(n=34) 
Adherers                             
(>4 hrs CPAP 
usage)            
(n=20) p value 
General Health 
       Hypertension n (%) 20 (59) 10 (50) 0.581 
Hypercholesterolemia n (%) 6 (18) 9 (45) 0.056 
Diabetes n (%) 6 (18) 4 (20) 0.998 
Body Mass Index (kg/m2) 33.7 ± 5.2 31.6 ± 4.7 0.143 
Erectile function 
       Duration of Erectile Dysfunction (years) 7.4 ± 5.7 4.2 ± 3.9 0.059 
International Index of Erectile Function 
(IIEF) 
33.9 ± 16.2 33.2 ± 17.5 0.885 
IIEF Erectile Dysfunction 11.9 ± 7.7 12.3 ± 8.0 0.857 
IIEF Intercourse Satisfaction 5.6 ± 4.2 5.7 ± 4.1 0.964 
IIEF Orgasmic Function 5.8 ± 3.5 5.3 ± 3.6 0.643 
IIEF Overall Satisfaction 4.3 ± 2.2 4.0 ± 2.1 0.630 
IIEF Sexual Desire 6.3 ± 2.4 6.0 ± 1.6 0.490 
Testosterone (nmol/L) 9.3 ± 3.0 10.4 ± 4.2 0.545 
Sleep and Breathing parameters 
       
Total Sleep Time 348.6 ± 91.6 337.8 ± 52.9 0.631 
Sleep Efficiency 78.8 ± 20.0 76.0 ± 12.2 0.576 
REM proportion (%) 17.5 ± 6.9 15.1 ± 8.0 0.261 
Arousal Index (per hour) 33.3 ± 20.0 38.5 ± 22.2 0.381 
Apnoea Hypopnoea Index (AHI) 47.0 ± 25.7 50.6 ± 27.7 0.636 
REM AHI 48.1 ± 27.8 52.5 ± 28.7 0.590 
NREM AHI 51.6 ± 23.9 48.1 ± 26.8 0.626 
Minimum SaO2 73.3 ± 10.0 78.0 ± 11.5 0.122 
Time below SaO2 90% 13.0 ± 13.1 14.1 ± 19.7 0.798 
Oxygen desaturation Index (per hour) 45.3 ± 28.0 48.4 ± 33.1 0.716 
Social & Lifestyle Factors 
       Alcoholic drinks per week 10.9 ± 15.1 8.3 ± 10.0 0.496 
Age (years) 52.7 ± 9.5 56.1 ± 9.1 0.208 
Relationship length (years) 12.3 ± 12.3 21.6 ± 13.6 0.013 
Fathers n (%) 24.0 (71) 14.0 (70) 0.990 
Site: Sydney based (versus Melbourne) n 
(%) 
29.0 (85) 16.0 (80) 0.179 
Past smoker 28.0 (83) 16.0 (80) 0.990 
Characteristics of those who did and did not adhere to CPAP/sham therapy, according to adherence 
definition of 4 hours minimum per night.  Values are mean ± standard deviation. p-value calculated using 
students t-test. CPAP adherence data missing for 4 participants due to technical difficulties (3 from CPAP 
group, 1 from sham CPAP).  No CPAP adherence data for 3 participants who withdrew before CPAP 
treatment commenced (2 from CPAP group, 1 from sham) 
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Table 4.7 Baseline Characteristics of participants adherent to CPAP / Sham CPAP 
 
CPAP           
(n=12) 
Sham CPAP       
(n=8) p-value 
Age (years) 56.9 ± 6.7 54.9 ± 12.3 0.636 
Medical History               
Hypertension n (%)^  4 (33)  2 (25) 0.999 
Using antihypertensives n (%)  4 (33)  1 (4) 0.603 
Hypercholesterolemia n (%)^  7 (58)  3 (38) 0.650 
Using statins n (%)  7 (58)  1 (13) 0.070 
Diabetes n (%)^  9 (75)  1 (13) 0.020 
Using diabetic medications (%)  9 (75)  1 (13) 0.020 
Lifestyle Factors               
Number of drinks per week 8.0 ± 11.1 8.8 ± 8.6 0.871 
Past smokers n(%)   9 (75)   7 (88) 0.619 
Anthropometry               
Weight (kg) 99.7 ± 16.2 88.4 ± 16.6 0.148 
Body Mass Index (kg/m2) 32.9 ± 4.4 29.7 ± 4.6 0.132 
Neck circumference (cm) 42.7 ± 3.4 41.4 ± 3.3 0.418 
Mid-arm circumference (cm) 32.1 ± 2.1 31.9 ± 2.8 0.897 
Waist circumference (cm) 111.4 ± 12.3 101.3 ± 9.9 0.069 
Hip circumference (cm) 109.7 ± 10.3 103.4 ± 6.9 0.148 
Mid-Thigh circumference (cm) 51.0 ± 5.3 51.2 ± 5.7 0.954 
Note: Values are mean ± standard deviation or number (percentage). p-value calculated by Students t-test or 
Fishers exact test. ^as diagnosed prior entry into the study.  
(Continued over)  
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Table 4.7 Baseline Characteristics of participants’ adherent to CPAP/Sham CPAP (continued) 
 
CPAP                     
(n=20) 
Sham CPAP                              
(n=8) 
p-value 
Sleep and Breathing               
Total Sleep Time (minutes) 341.0 ± 37.6 333.0 ± 73.1 0.783 
Sleep Efficiency (%) 77.6 ± 9.0 73.5 ± 16.4 0.478 
REM (% of total sleep time) 13.6 ± 7.3 17.4 ± 8.9 0.305 
Arousal index (/hour) 43.6 ± 25.2 30.9 ± 15.1 0.216 
Apnoea Hypopnoea Index (AHI) 59.1 ± 28.5 37.8 ± 22.4 0.093 
NREM AHI 61.7 ± 29.1 38.6 ± 23.2 0.076 
REM AHI 55.5 ± 22.9 37.8 ± 29.9 0.162 
Minimum SpO2 77.1 ± 10.8 79.4 ± 13.1 0.675 
Time SaO2 below 90% (min) 17.9 ± 21.6 8.5 ± 16.0 0.306 
Oxygen Desaturation (3%) Index  53.0 ± 36.4 41.7 ± 28.5 0.469 
Sexual Function & Relationship Parameters 
    
  
  
Relationship duration (years) 21.6 ± 12.3 21.6 ± 16.3 0.995 
Duration of erectile dysfunction (years) 5.1 ± 4.7 3.1 ± 2.4 0.330 
International Index of Erectile Function (IIEF)        
IIEF – Overall Score 38.4 ± 15.0 25.4 ± 18.9 0.103 
IIEF - Erectile Function 14.3 ± 7.5 9.1 ± 8.1 0.157 
IIEF - Intercourse Satisfaction 7.0 ± 3.5 3.8 ± 4.2 0.078 
IIEF - Orgasmic Function 6.5 ± 2.9 3.5 ± 3.9 0.062 
IIEF - Overall Satisfaction 4.2 ± 2.1 3.8 ± 2.3 0.680 
IIEF - Sexual Desire 6.4 ± 1.2 5.3 ± 1.8 0.105 
European Male Aging Study Questionnaire (EMAS)        
EMAS – Overall Score 33.4 ± 8.4 30.3 ± 3.9 0.344 
EMAS - Sexual Function related distress 9.0 ± 3.2 10.9 ± 5.6 0.355 
EMAS - Change in Sexual Functioning -3.6 ± 3.2 -2.6 ± 3.2 0.521 
EMAS - Overall Sexual Functioning 15.8 ± 5.0 12.0 ± 6.7 0.157 
EMAS - Masturbation 2.6 ± 1.7 1.5 ± 1.7 0.183 
Self Esteem and Relationship Questionnaire (SERS)        
SERS – Overall Score 38.7 ± 10.9 36.4 ± 14.5 0.707 
SERS - Sexual Relationship Satisfaction 19.6 ± 6.7 17.0 ± 9.4 0.494 
SERS - Confidence 19.1 ± 5.0 18.1 ± 7.2 0.730 
SERS - Self Esteem 12.1 ± 3.5 11.3 ± 6.1 0.735 
SERS - Overall Relationship Satisfaction 7.0 ± 2.0 6.9 ± 2.2 0.895 
       
Note: Values are mean ± standard deviation. p-value calculated using students t-test. 
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4.4.7  Interactions between treatments for adherers 
In order to assess any treatment interactions with Vardenafil in those participants adherent to 
CPAP or sham CPAP, interactions were tested in this sub-analysis, in the same manner as 
described in section 3.2.4, and presented in table 4.8.  No 3 way interactions between 
treatments were found in any parameter.  Since no interactions were seen in the 3 way 
analysis, a 2 way analysis of interactions was performed.  When analysed in a 2-way interaction, 
having removing visit from the model, there were no interactions found in any sexual function 
parameter.  However, four quality of life parameters were found to have an interaction – the 
Epworth Sleepiness Scale, and in the SF-36 questionnaire domains of Role Physical, General 
Health and Physical Health.  These parameters are presented in figure 4.4, presented by visit.   
No synergistic effects were found in any of these parameters.  
  
 - 162 - 
Table 4.8: Interaction between treatments for adherent CPAP/sham CPAP users. 
 
  
3 way p-value 
  
2 way p-value 
International Index of Erectile Function (IIEF)     
IIEF - Overall Score 0.7667 0.8673 
IIEF - Erectile Function 0.6414 0.5361 
IIEF - Intercourse Satisfaction 0.6018 0.6629 
IIEF - Orgasmic Function 0.1862 0.8600 
IIEF - Overall Satisfaction 0.3365 0.6296 
IIEF - Sexual Desire 0.9637 0.1507 
European Male Aging Study questionnnaire (EMAS) 
  
EMAS - Overall Score 0.3574 0.7761 
EMAS - Sexual Function Distress 0.5092 0.7518 
EMAS - Change in Sexual Function 0.9576 0.4318 
EMAS - Overall Sexual Function 0.7031 0.3858 
EMAS - Masturbation 0.9091 0.7384 
Self-Esteem and Relationship Satisfaction (SERS) 
  
SERS - Overall Score 0.9496 0.2741 
SERS - Sexual Relationship Satisfaction 0.7008 0.8099 
SERS - Confidence 0.7995 0.0787 
SERS - Self Esteem 0.9913 0.1625 
SERS - Overall Relationship Satisfaction 0.2571 0.2844 
Epworth Sleepiness Score (ESS) 
  
ESS - Overall Score 0.3062 0.0029 
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) 
 
EDITS - Overall Score 0.3165 0.9239 
Functional Outcomes of Sleep (FOSQ) 
  
FOSQ - Activity 0.9102 0.7010 
FOSQ - Vigilance 0.5846 0.0611 
FOSQ - Intimacy 0.8148 0.4865 
FOSQ - Productivity 0.8071 0.6796 
FOSQ - Social Outcomes 0.2179 0.2389 
Short-form 36 (SF-36) 
  
SF-36 Physical Function 0.5608 0.3733 
SF-36 Role Physical 0.3804 0.0124 
SF -36 Body Pain 0.0506 0.0660 
SF-36 General Health 0.5941 0.0188 
SF-36 Vitality 0.5068 0.8819 
SF-36 Social Function  0.4115 0.3719 
SF-36 Role Emotional 0.1655 0.1395 
SF-36 Mental Health Scale 0.6753 0.7350 
SF-36 Physical Health 0.2216 0.0100 
SF36 Mental Health Dimension 0.1253 0.3042 
Depression Anxiety Stress Scale (DASS) 
  
DASS Depression 0.0742 0.6527 
DASS Anxiety 0.4511 0.0694 
DASS Stress 0.7453 0.7871 
Note: Interaction terms presented as 3 way (CPAP/shamCPAP*Vardenafil/Placebo*time) and 2 way analysis 
(CPAP/sham CPAP*Vardenafil/Placebo).  p-value determine via mixed model analysis.  
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NOTE: Values shown are mean change from baseline, shown with standard error, for variables shown to 
have a statistical interaction between the two treatments.                                          
                                                                                                                                                                 (Continued over)  
y Figure 4.4 Change from baseline for variables with treatment interactions 
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Figure 4.4 Change from baseline for variables with treatment interactions (Continued)  
NOTE: Values shown are mean change from baseline, shown with standard error, for variables shown to have 
a statistical interaction between the two treatments.    
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4.4.8  Effect of adherence to CPAP therapy 
Due to the disparity regards adherence to therapy between participants, results were 
stratified into two groups:  adherent and non-adherent users. Baseline characteristics of these 
participants are shown in table 4.6.  Participants adherent to therapy comprise the per-
protocol analysis.  Whereas only overall satisfaction was seen to occur in the intend-to-treat 
analysis of those allocated to CPAP versus sham CPAP, several more changes were found in 
the per-protocol analysis.  At Week 4, no improvements were seen in any parameter.  At week 
8, overall satisfaction, as measured by the IIEF, had improved with CPAP compared to sham 
CPAP.  At week 12, CPAP improved erectile function, sexual desire, distress due to sexual 
dysfunction, overall sexual function, self-esteem, sexual relationship satisfaction and overall 
score in the SERS questionnaire compared to sham CPAP (table 4.9).  Clinical improvement in 
erectile function, as defined as an improvement by more than 4 points in the IIEF-ED domain 
was seen in 7 participants (58%), whereas no participants adherent to sham CPAP improved 
by more than 4 points.  Graphic representations of the effects of CPAP therapy compared to 
sham CPAP for some of the parameters of sexual function and relationship over the 12 week 
treatment period for adherent users are shown in figure 4.5 and figure 4.6.   
Several quality of life measurements in the ESS, DASS, SF-36 and FOSQ questionnaires showed 
improvements with CPAP compared to sham CPAP for adherent users.  CPAP usage, compared 
to sham CPAP decreased levels of sleepiness, stress and depression (table 4.10).  
Improvements in several parameters of mental health were seen with CPAP compared to 
sham CPAP (figure 4.7). Quality of life domains of Vigilance in the FOSQ, and Social Function 
and Physical Function of the SF-36 questionnaire also improved with CPAP compared to sham 
CPAP (figure 4.8).     
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Nocturnal penile tumescence was performed on the night of Week 12 polysomnography.  On 
this night, all patients, regardless of adherence to therapy throughout the study, used 
CPAP/sham CPAP.  Per-protocol analysis for this data did not differ from the original intention 
to treat analysis.  
Table 4.9 Effect of adherent CPAP use on sexual function and relationship parameters 
Variable Visit 
CPAP                     
(n=12) 
Sham CPAP     
(n=8) 
Difference                      
Mean (95% CI) 
Effect
size (d) 
p-value 
International Index of Erectile Function (IIEF)                   
Overall  Week 4 47.50 ± 14.85 37.50 ± 23.87 10.00 (-9.24 to 29.24) 0.57 0.827 
 Score Week 8 47.83 ± 14.26 30.00 ± 24.28 17.83 (-0.66 to 36.33) 1.02 0.264 
  Week 12 48.58 ± 19.44 24.25 ± 17.28 24.33 (6.47 to 42.20) 1.39 0.031 
Erectile  Week 4 19.00 ± 6.61 14.33 ± 10.31 4.67 (-3.76 to 13.09) 0.59 0.640 
Function Week 8 19.17 ± 7.12 11.14 ± 11.13 8.02 (-0.75 to 16.80) 1.01 0.182 
  Week 12 18.67 ± 9.00 8.50 ± 8.26 10.17 (1.80 to 18.53) 1.28 0.037 
Intercourse  Week 4 8.75 ± 3.67 5.57 ± 5.44 3.18 (-1.22 to 7.57) 0.78 0.633 
Satisfaction Week 8 8.33 ± 3.82 6.00 ± 5.63 2.33 (-2.22 to 6.89) 0.57 0.999 
  Week 12 9.00 ± 4.31 3.63 ± 3.58 5.38 (1.50 to 9.25) 1.32 0.068 
Orgasmic  Week 4 7.67 ± 2.93 5.17 ± 4.71 2.50 (-2.47 to 7.47) 0.70 0.775 
Function Week 8 7.42 ± 2.71 3.86 ± 4.10 3.56 (0.28 to 6.84) 1.00 0.325 
  Week 12 7.58 ± 3.34 3.63 ± 3.70 3.96 (0.62 to 7.30) 1.11 0.144 
Overall  Week 4 5.33 ± 2.06 4.83 ± 2.99 0.50 (-2.03 to 3.03) 0.24 0.626 
Satisfaction Week 8 6.17 ± 1.90 3.71 ± 2.93 2.45 (0.13 to 4.78) 1.16 0.020 
  Week 12 6.25 ± 2.70 3.38 ± 2.07 2.88 (0.50 to 5.25) 1.35 0.006 
Sexual  Week 4 6.75 ± 1.29 6.67 ± 1.37 0.08 (-1.31 to 1.48) 0.05 0.882 
Desire Week 8 6.75 ± 1.54 5.29 ± 2.06 1.46 (-0.29 to 3.21) 0.93 0.146 
  Week 12 7.08 ± 1.62 5.13 ± 1.96 1.96 (0.27 to 3.65) 1.24 0.031 
Note: Values are mean ± standard deviation.  p-value calculated using mixed model analysis. Effect size 
(Cohen’s d) calculated by dividing difference between CPAP and sham by the standard deviation at 
baseline. 
(Continued over) 
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Table 4.9 Effect of adherent CPAP use on sexual function and relationship parameters (continued)   
Variable Visit 
CPAP                     
(n=12) 
Sham CPAP     
(n=8) 
Difference                      
Mean (95% CI) 
Effect 
size (d) p-value 
European Male Aging Study questionnaire (EMAS)                 
Overall Score Week 4 34.58 ± 8.12 30.17 ± 9.13 4.42 (-4.54  to 13.37) 0.64 0.314 
  Week 8 36.82 ± 7.49 31.50 ± 5.61 5.32 (-2.17 to 12.81) 0.77 0.336 
  Week 12 36.67 ± 8.91 30.43 ± 4.12 6.24 (-1.36 to 13.83) 0.91 0.158 
Sexual 
Function  
Week 4 6.67 ± 4.52 9.00 ± 5.03 -2.33 (-7.06 to 2.39) -0.54 0.798 
Distress Week 8 5.75 ± 3.44 10.29 ± 7.11 -4.54 (-11.19 to 2.12) -1.05 0.114 
  Week 12 4.67 ± 2.42 10.00 ± 5.78 -5.33 (-10.25 to -0.42) -1.24 0.017 
Change in 
Sexual  
Week 4 -0.42 ± 5.45 -1.75 ± 4.23 1.33 (-3.47 to 6.14) 0.42 0.469 
Function Week 8 0.08 ± 5.02 -2.13 ± 4.22 2.21 (-2.32 to 6.74) 0.70 0.265 
  Week 12 0.25 ± 5.46 -2.00 ± 1.77 2.25 (-1.98 to 6.48) 0.71 0.257 
Overall Sexual  Week 4 17.17 ± 5.11 14.29 ± 5.85 2.88 (-2.52 to 8.29) 0.49 0.655 
Function Week 8 18.58 ± 4.83 14.00 ± 6.78 4.58 (-1.26 to 10.43) 0.78 0.118 
  Week 12 19.50 ± 5.96 12.57 ± 6.27 6.93 (0.84 to 13.02) 1.18 0.024 
Masturbation Week 4 2.67 ± 1.67 1.43 ± 1.40 1.24 (-0.35 to 2.82) 0.71 0.220 
  Week 8 2.75 ± 1.66 1.88 ± 1.46 0.88 (-0.64 to 2.39) 0.50 0.705 
  Week 12 2.58 ± 1.24 1.50 ± 1.69 1.08 (-0.29 to 2.46) 0.62 0.442 
Self-Esteem and Relationship Satisfaction (SERS)                   
Overall Score Week 4 42.75 ± 13.18 41.67 ± 16.15 1.08 (-13.94 to 16.11) 0.09 0.655 
  Week 8 45.92 ± 10.41 37.29 ± 17.33 8.63 (-4.68 to 21.94) 0.72 0.118 
  Week 12 48.50 ± 12.50 37.29 ± 14.19 11.21 (-1.95 to 24.38) 0.93 0.033 
Sexual  Week 4 22.25 ± 7.57 21.83 ± 9.97 0.42 (-8.48 to 9.31) 0.05 0.957 
Relationship  Week 8 24.50 ± 6.02 17.71 ± 11.76 6.79 (-4.25 to 17.82) 0.89 0.089 
Satisfaction Week 12 25.83 ± 7.02 18.14 ± 8.63 7.69 (0.04 to 15.34) 1.00 0.045 
Confidence Week 4 20.50 ± 6.71 19.83 ± 8.21 0.67 (-6.98 to 8.31) 0.11 0.260 
  Week 8 21.42 ± 5.05 19.57 ± 6.48 1.85 (-3.77 to 7.46) 0.32 0.270 
  Week 12 22.67 ± 5.69 19.14 ± 7.73 3.52 (-2.99 to 10.03) 0.60 0.055 
Self Esteem Week 4 13.00 ± 4.84 11.57 ± 6.35 1.43 (-4.01 to 6.87) 0.31 0.281 
  Week 8 14.25 ± 3.25 12.00 ± 5.83 2.25 (-2.80 to 7.30) 0.49 0.257 
  Week 12 15.08 ± 3.85 11.50 ± 6.05 3.58 (-1.73 to 8.90) 0.78 0.039 
Overall  Week 4 7.50 ± 2.20 7.00 ± 2.53 0.50 (-1.94 to 2.94) 0.25 0.322 
Relationship Week 8 7.17 ± 2.37 6.57 ± 2.30 0.60 (-1.76 to 2.95) 0.30 0.371 
 Satisfaction Week 12 7.58 ± 2.27 6.71 ± 2.36 0.87 (-1.44 to 3.18) 0.44 0.218 
Note:  Values are mean ± standard deviation.  p-value calculated using mixed model analysis. Effect size 
(Cohen’s d) calculated by dividing difference between CPAP and sham by the standard deviation at 
baseline. 
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Figure 4.5 Effect of CPAP on sexual function, as measured by the IIEF in adherers 
Note:  Adherence defined as greater than 4hours use per night. All values shown are change from 
baseline. Data are mean and standard error of the mean of the change from baseline. (A) IIEF Overall 
score (B) IIEF Erectile Function (C) Overall Satisfaction (D) Sexual Desire 
      Arrow indicates direction of improvement. *p<0.05 as determined by mixed model analysis.          
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Figure 4.6. Effect of CPAP on sexual function & relationship satisfaction in adherers 
Note: Adherence defined as greater than 4hours use per night. (A)  SERS Overall Score  (B) SERS Sexual 
Relationship Satisfaction (C), EMAS Overall Sexual Function (D) EMAS Sexual Function Distress.  All 
measurements are mean change from baseline and one standard error of the mean. 
       Arrows represent direction of improvement.  *p<0.05 as determined by mixed model analysis  
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Table 4.10 Effect of adherent CPAP use on quality of life parameters 
Variable Visit 
CPAP                 
(n=12) 
Sham CPAP     
(n=8) 
Difference                      
Mean (95% CI) 
Effect 
size (d) p-value 
Epworth  Week 4 5.75 ± 3.67 10.57 ± 6.02 -4.82 (-9.48 to -0.17) -1.08 0.001 
Sleepiness  Week 8 5.42 ± 2.84 11.00 ± 4.24 -5.58 (-9.00 to -2.17) -1.24 <0.001 
 Scale Week 12 4.92 ± 3.26 8.75 ± 5.73 -3.83 (-8.80 to 1.14) -0.86 0.004 
Functional Outcomes of Sleep (FOSQ)  
 
 
Activity Week 4 3.58 ± 0.41 3.20 ± 0.61 0.38 (-0.11 to 0.87) 0.64 0.101 
  Week 8 3.67 ± 0.32 3.18 ± 0.40 0.49 (0.15 to 0.83) 0.83 0.102 
  Week 12 3.67 ± 0.44 3.26 ± 0.60 0.40 (-0.09 to 0.89) 0.69 0.209 
Vigilance Week 4 3.73 ± 0.31 3.00 ± 0.79 0.73 (0.06 to 1.39) 1.59 0.003 
  Week 8 3.71 ± 0.29 3.29 ± 0.35 0.42 (0.12 to 0.72) 0.92 0.211 
  Week 12 3.78 ± 0.30 3.10 ± 0.92 0.68 (-0.10 to 1.46) 1.48 0.006 
Intimacy Week 4 3.57 ± 0.52 2.92 ± 0.83 0.65 (-0.05 to 1.35) 0.83 0.245 
  Week 8 3.69 ± 0.54 2.74 ± 0.99 0.95 (0.22 to 1.68) 1.21 0.083 
  Week 12 3.59 ± 0.64 2.90 ± 1.00 0.69 (-0.12 to 1.51) 0.88 0.099 
Productivity Week 4 3.85 ± 0.26 3.44 ± 0.54 0.41 (-0.05 to 0.88) 0.88 0.064 
 
Week 8 3.88 ± 0.20 3.59 ± 0.27 0.29 (0.07 to 0.51) 0.63 0.243 
  Week 12 3.78 ± 0.37 3.57 ± 0.46 0.21 (-0.22 to 0.63) 0.45 0.448 
Social  Week 4 3.88 ± 0.31 3.56 ± 0.62 0.31 (-0.22 to 0.85) 0.60 0.412 
   Outcomes Week 8 3.96 ± 0.14 3.75 ± 0.46 0.21 (-0.18 to 0.60) 0.39 0.940 
  Week 12 3.92 ± 0.29 3.50 ± 0.53 0.42 (-0.05 to 0.88) 0.79 0.122 
Depression Anxiety Stress Scale (DASS)                   
 Depression Week 4 3.17 ± 14.50 14.50 ± 16.41 -11.33 (-25.11 to 2.45) -0.99 0.014 
  Week 8 4.50 ± 15.50 15.50 ± 20.33 -11.00 (-28.12 to 6.12) -0.96 0.019 
  Week 12 4.00 ± 14.50 14.50 ± 15.70 -10.50 (-23.89 to 2.89) -0.91 0.028 
Anxiety Week 4 1.83 ± 8.29 8.29 ± 7.43 -6.45 (-13.33 to 0.43) -1.19 0.049 
  Week 8 2.83 ± 7.75 7.75 ± 11.39 -4.92 (-14.51 to 4.68) -0.90 0.079 
  Week 12 2.73 ± 5.75 5.75 ± 6.54 -3.02 (-7.86 to 1.81) -0.55 0.341 
Stress Week 4 5.33 ± 15.75 15.75 ± 12.85 -10.42 (-21.33 to 0.49) -1.22 0.007 
  Week 8 7.00 ± 15.75 15.75 ± 13.75 -8.75 (-20.47 to 2.97) -1.02 0.032 
  Week 12 8.73 ± 17.25 17.25 ± 10.02 -8.52 (-16.95 to -0.09)  - 1.00 0.031 
Note: Values are mean ± standard deviation.  p-value calculated using mixed model analysis.  Effect size 
(Cohen’s d) calculated by dividing difference between CPAP and sham by the standard deviation at 
baseline. 
 
                                                              (Continued over) 
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 Table 4.10 Effect of adherent CPAP use on quality of life parameters (continued) 
Variable Visit 
CPAP                 
(n=12) 
Sham CPAP     
(n=8) 
Difference                      
Mean (95% CI) 
Effect 
size (d) 
p-value 
Short-form 36 (SF-36)                       
Physical  Week 4 85.83 ± 12.40 62.14 ± 34.62 23.69 (-8.48 to 55.86) 1.25 0.006 
 Function Week 8 86.67 ± 11.35 79.29 ± 22.25 7.38 (-13.50 to 28.26) 0.39 0.414 
  Week 12 89.17 ± 9.73 76.88 ± 23.59 12.29 (-7.76 to 32.34) 0.65 0.083 
Body Pain Week 4 79.17 ± 16.70 72.00 ± 32.74 7.17 (-16.07 to 30.41) 0.35 0.198 
  Week 8 76.67 ± 21.04 76.50 ± 24.61 0.17 (-21.40 to 21.74) 0.01 0.850 
  Week 12 79.33 ± 20.07 78.00 ± 25.29 1.33 (-20.00 to 22.66) 0.06 0.708 
General  Week 4 66.92 ± 16.26 63.00 ± 32.79 3.92 (-24.23 to 32.06) 0.19 0.680 
 Health Week 8 69.17 ± 16.57 67.00 ± 31.10 2.17 (-24.67 to 29.00) 0.11 0.929 
  Week 12 70.17 ± 19.17 69.50 ± 27.46 0.67 (-21.16 to 22.49) 0.03 0.851 
Vitality Week 4 68.75 ± 14.79 52.50 ± 29.88 16.25 (-9.39 to 41.89) 0.67 0.031 
  Week 8 71.67 ± 9.61 44.38 ± 24.41 27.29 (6.58 to 48.00) 1.13 <0.001 
  Week 12 75.42 ± 16.02 46.88 ± 24.34 28.54 (9.67 to 47.41) 1.18 <0.0001 
Social  Week 4 90.75 ± 15.02 65.75 ± 31.86 25.00 (-2.25 to 52.25) 1.04 0.003 
 Function Week 8 87.67 ± 14.93 84.50 ± 25.68 3.17 (-15.83 to 22.17) 0.13 0.519 
  Week 12 89.67 ± 17.47 72.00 ± 30.39 17.67 (-8.74 to 44.08) 0.73 0.027 
Role  Week 4 86.08 ± 26.53 52.43 ± 50.41 33.65 (-13.72 to 81.03) 1.00 0.014 
 Emotional Week 8 94.50 ± 12.85 87.50 ± 35.36 7.00 (-16.23 to 30.23) 0.21 0.502 
  Week 12 86.08 ± 26.53 66.63 ± 39.92 19.46 (-11.61 to 50.53) 0.58 0.127 
Mental  Week 4 82.67 ± 17.25 64.57 ± 33.97 18.10 (-13.78 to 49.97) 0.82 0.044 
  Health Week 8 82.00 ± 17.10 61.00 ± 28.59 21.00 (-0.37 to 42.37) 0.95 0.012 
  Scale Week 12 81.67 ± 17.76 59.50 ± 27.42 22.17 (1.05 to 43.29) 1.00 0.006 
Physical  Week 4 77.50 ± 11.02 62.00 ± 27.26 15.50 (-3.03 to 34.03) 1.11 0.155 
  Health Week 8 78.17 ± 12.26 66.29 ± 24.67 11.88 (-5.84 to 29.61) 0.85 0.423 
  Week 12 81.08 ± 12.24 69.88 ± 20.84 11.21 (-4.26 to 26.68) 0.80 0.265 
Mental  Week 4 86.42 ± 18.44 64.17 ± 36.99 22.25 (-16.52 to 61.02) 0.99 0.007 
 Health Week 8 88.17 ± 11.72 77.63 ± 28.24 10.54 (-8.49 to 29.58) 0.47 0.190 
 Dimension Week 12 85.83 ± 19.54 66.13 ± 30.27 19.71 (-3.58 to 42.99) 0.88 0.021 
Note: Values are mean ± standard deviation.  p-value calculated using mixed model analysis. Effect size 
(Cohen’s d) calculated by dividing difference between CPAP and sham by the standard deviation at 
baseline. 
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Figure 4.7 Effect of CPAP on mental health in adherers 
Note: Adherence defined as greater than 4 hours use per night.  (A) Self Esteem (B) Depression (C), 
Stress (D), Anxiety  and (E) SF-36 Mental Health Scale  and (F) Mental Health Dimension. All 
measurements are change of scores from baseline and one standard error of the mean for the 
change from baseline 
       Arrows indicates direction of an improvement. * p<0.05 as determined by mixed model analysis.         
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y Figure 4.8 Effect of CPAP on quality of life in adherers 
Note: Adherence defined as greater than 4 hours use per night.  (A) FOSQ Vigilance domain (B), 
Epworth Sleepiness Score, SF-36 domains of (C) Social Function  and (D) Vitality.  All measurements 
are change of scores from baseline for only those who used CPAP or sham CPAP for more than 4 
hours per night. Data are mean and standard error of the mean for the change from baseline. 
        Arrows indicates direction of an improvement. * p<0.05 as determined by mixed model analysis.  
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4.4.9  Non-sexual relationships 
Adherence to sham CPAP, compared to CPAP appeared to impair non-sexual relationships, 
as measured by the single EMAS question related to Non-Sexual Relationship satisfaction at 
all time points (figure 4.9).  Three other measured parameters included aspects of non-
sexual relationship, that of Social Function domain in the SF-36, the SERS Overall 
Relationship Satisfaction domain and the EMAS Overall Relationship Satisfaction single 
question. Overall Relationship satisfaction in the EMAS questionnaire showed both an 
increase with CPAP, and a decrease with sham CPAP, which was significantly different at 
week 12 (p=0.005). In the SERS questionnaire, all scores decreased for sham CPAP and 
increased for CPAP, however, there was no significance difference (figure 4.9). Similarly 
social function in the SF-36 both increased with CPAP and decreased with sham CPAP, 
leading to a significant difference at Weeks 4 & 12 (figure 4.8C). 
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Figure 4.9 Effect of sham CPAP on relationship factors in adherers 
Note: Adherence defined as greater than 4 hours use per night. (A) Change in non-sexual 
relationship question of the European Male Aging Study questionnaire. Non-sexual 
relationship declined for sham CPAP users compared to no change or a slight improvement 
in this domain for CPAP users. All time points differed between sham CPAP and CPAP. (B) 
Change in Overall Sex Life Satisfaction: An increase was seen at Week 12 with CPAP, 
accompanied by a slight decrease with sham CPAP, leading to a statistical difference. (C) 
Change in overall relationship satisfaction in the Self-Esteem and Relationship Satisfaction 
questionnaire. Sham CPAP showed a decline at all time points compared to no change or a 
slight improvement in CPAP users, however, no there was no statistical difference.  
        Arrows indicate direction of improvement. * p<0.05   
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4.4.10 Non-adherence to therapy   
In participants not adherent to CPAP / sham CPAP, those who used the device less than 4 
hours per night or not at all, several differences were noted between the CPAP (n=14) and 
sham CPAP (n=20) groups at Week 12.  All differences were due to decrements in CPAP 
group and improvements in sham CPAP group, opposite to that of participants’ adherent to 
therapy.  There was a worsening in the CPAP group, compared to improvements with sham 
CPAP, in the depression domain of the DASS (change from baseline: CPAP 2.14±3.46, sham 
CPAP -4.35±6.17, p=0.002), the SF36 Role Emotional domain (CPAP -16.64±33.93, sham 
CPAP 13.77±29.06, p=0.012) and the SF36 Mental Health Dimension (CPAP -6.38±18.46, 
sham CPAP 8.94±17.81, p=0.026).      
4.4.11 Treatment Satisfaction 
After 4, 8 and 12 weeks of CPAP/sham CPAP, participants were asked about their 
satisfaction with treatment as it referred to erectile function using the Erectile Dysfunction 
Inventory of Treatment Satisfaction (EDITS) questionnaire.   Participants allocated to CPAP 
were more satisfied with treatment, as it related to erectile function, than those allocated 
to sham CPAP at the week 12 time point (table 4.10A).  This difference became more 
apparent for adherent users of CPAP treatment (table 4.10B). At all time points, over 70% of 
those allocated to CPAP were satisfied with treatment, as defined by a score greater than 
50, compared to less than 60% of those allocated to sham CPAP.  For adherent users, 100% 
of participants allocated to CPAP were satisfied with treatment at Week 12 compared with 
37% of adherent sham CPAP users (p=0.005) (figure 4.10).  Given the factorial nature of the 
study, the effects of Vardenafil may influence this result.  Satisfaction rates with Vardenafil 
versus placebo (Vardenafil 67-72% vs placebo 46-51%) were very similar to that of CPAP 
versus sham CPAP.  In the assessment of those men who had received placebo medication, 
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55-60% were satisfied with CPAP versus 39-40% of men allocated to sham CPAP.  This was 
significantly different at weeks 8 & 12 (p=0.016 and p =0.041 respectively)  
 
Table 4.11 Treatment satisfaction scores for CPAP  
A    
 
CPAP                        
(n=28) 
Sham CPAP                        
(n=27) p-value 
Week 4 65.4 ± 19.4 56.6 ± 24.7 0.190 
Week 8 64.1 ± 20.2 55.3 ± 26.0 0.199 
Week 12 67.4 ± 22.8 53.6 ± 24.5 0.041 
 
 
B 
       
 
Adherent CPAP     
(n=12) 
Adherent Sham CPAP 
(n=8) p-value 
Week 4 68.4 ± 18.7 71.8 ± 20.1 0.711 
Week 8 76.3 ± 13.6 52.0 ± 26.6 0.016 
Week 12 78.8 ± 14.5 54.4 ± 19.4 0.012 
Note: (A) All participants; (B) CPAP Adherers only. Values are mean ± standard 
deviation.   p-value calculated using mixed model analysis. 
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Figure 4.10 Percentage of participants satisfied with treatment for erectile function 
Note: Satisfaction defined as a score of more than 50 in the EDITS questionnaire (A) CPAP versus 
sham CPAP, (B) Adherent users of CPAP versus adherent users of sham CPAP. * p<0.05 
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4.5 DISCUSSION 
This is the first randomised sham controlled study to investigate the effect of CPAP on 
sexual function.  Using a factorial 2x2 randomised controlled trial, this study confirms that 
CPAP improves sexual satisfaction and increases the number of sleep related erections, 
without increases in tumescence or rigidity, but does not improve subjective erectile 
function on an intention-to-treat basis.  However, for those men who adhered to treatment, 
(per-protocol analysis) both erectile function and sexual desire improved. There were 
significant improvements in several aspects of sexual functioning and relationship 
parameters.  Additionally, those participants who were adherent to CPAP also had reduced 
sleepiness, improved levels of mood and several parameters related to quality of life, and 
were satisfied with treatment compared to sham treatment.  
4.5.1 Subjective Erectile Function 
This study has demonstrated that CPAP treatment, under an intention to treat basis does 
not improve subjective erectile function compared to that of sham CPAP. However, for 
those men who are adherent to CPAP, there was a statistical (p=0.037) and clinically 
meaningful improvement in erectile function (IIEF-ED increase by at least 4 points) [545] 
compared to those adherent to sham CPAP.  Response to CPAP treatment differed between 
participants.  A little over half of men adherent to CPAP treatment had clinically significant 
improvements in erectile function. This finding is in contrast to previous uncontrolled 
studies which have found little improvement in erectile function when OSA is treated.  In 
one such study,  no improvement from baseline was found in erectile function in 16 men 
with OSA who had used CPAP for 7 months, as measured via the Korean version of the IIEF 
[483].  Similarly, another study also found no improvement in erectile dysfunction in 27 men 
with 10 weeks of adequate CPAP usage respectively [408].  Two studies have reported that 4 
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in 5 patients with OSA and ED did not report an improvement in erectile function with 3 
months and 1 year of CPAP usage [484, 546].  Likewise, in another study, 2 out of 3 patients 
did not find an improvement in ED with one year of CPAP usage [474].  A long term (3 year) 
observational study of CPAP users and non-users found that overall there was no 
improvement in erectile function, however, only those with moderate-severe ED improved 
with CPAP therapy [412]. A shorter study of 2-3 months similarly found a greater 
improvement only in those with significant ED, but not overall [408]. However, like the 
present study, several others have reported improvements in erectile function overall.  In 
one of the few other studies specifically targeting men with both OSA and ED, a group of 15 
men who were all treated with CPAP for 12 weeks in an observational study, an 
improvement in erectile dysfunction was found, as well as all other domains in the IIEF 
except sexual desire [473].  A small (n = 27) randomised no-treatment controlled study 
showed a significant improvement in ED after 1 month of CPAP [481], however this should 
be interpreted with caution, given the short period of treatment, and the lack of placebo 
control. A prospective randomised study, using an anti-depressant as a comparator 
treatment, found that one month of CPAP treatment in those with severe sleep apnoea was 
sufficient to increase IIEF scores from 15 to 19.  Although this study was described as 
placebo controlled, the placebo was an anti-depressant medication, which may negatively 
impact on erectile function [417, 482]. An interim report of a longer study not yet 
completed reported that 23 patients treated with either CPAP, surgery or oral device found 
an increase in IIEF scores after 3 months of treatment [475].  The increase in sexual function 
in this study was not accompanied by any changes in testosterone levels, suggesting there 
may be an alternative mode of action. 
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The current data found a significant improvement in erectile function with CPAP compared 
to sham CPAP, but only in those who adhered to treatment.  The absence of a placebo 
control in previous studies has clearly been a limitation. A notable placebo effect was seen 
in the current study, particularly with those who were adherent to treatment, with 
participants allocated to sham CPAP reporting an increase in erectile function at week 4, 
with a decline at week 8, and an eventual return to baseline at Week 12 in the sham control 
group.  
4.5.2 Objective Erectile Function 
The number of sleep related erections (SRE’s) increased with CPAP treatment. This 
improvement in the number of erections overnight with CPAP use suggests that by 
abolishing airway obstruction and thus disruption from sleep, erections in REM sleep were 
no longer inhibited. The disruption of REM sleep due to OSA may reduce SRE’s, which 
normally occur during each REM sleep period [30]. The first study to report impaired SRE’s 
with patients with OSA was in 1981 which found that 7 of 15 patients in the study with 
apnoea or hypoventilation showed abnormal NPT determined via visual inspection of the 
recording [433].  Likewise, a review of 31 patients in 1986 being investigated for ED with 
NPT, found that 10 of these patients had sleep apnoea, resulting in disturbed nocturnal 
erections, and concluded that full sleep studies should be performed in conjunction with 
NPT to ensure that there is not an incorrect diagnosis of an abnormal NPT, namely, OSA 
[434].  There was no comment that this may be a contributor to ED.  In 1989, a small 
correlation was found between apnoea index and penile rigidity in a study of 285 patients 
[437].   The earliest study regarding the effect of CPAP on nocturnal erections reported that 
one night of CPAP usage was sufficient to improve nocturnal erections for some men when 
measured using mercury strain gauges [438].   Of the 22 OSA patients presenting with ED for 
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this study, 15 had impaired NPT recordings on a night without CPAP, defined as penile 
rigidity less than 500 grams and a tip circumference change of less than 16 millimetres.  
Overall, there was no change in NPT parameters when CPAP was used, however, as with 
subjective erectile function, there was individual variation.  There were 5 individuals who no 
longer had an impaired reading on the next night using CPAP.  This interpretation of this 
result is limited, however.  Depending on the criterion used to assess abnormality of NPT, 
there can be considerable night-to-night variability [472]. In the only other study assessing 
the impact of CPAP on nocturnal erections, after 3 months of treatment which included 
participants using CPAP as well as those who had undergone surgery for OSA, the only 
parameter reported was of percentage rigidity greater than 80%, which showed an 
improvement from 13.8% to 40%.  Duration of erection, rigidity activation units and 
tumescence activation units were not reported. In a review of the current methodology 
using the Rigiscan device parameters of RAU and TAU compared with traditional cut-offs of 
normal and abnormal recordings, the diagnostic accuracy of the device did not go above 
75% in any of the parameters, due to a large overlap in the RAU and TAU in that of men 
considered to have normal and abnormal erectile function, however, the authors recognised 
its utility in a research context and in documenting treatment efficacy in a clinical setting 
[105].   In this regard, changes in NPT are a more useful measurement of treatment efficacy.  
The current study showed no improvement with CPAP in the quality of nocturnal erections, 
only the quantity.  Since erections occur in REM sleep, it is important to consider the 
quantity of this sleep stage, which may change due to the treatment of OSA.  No such 
change was seen in this study between the percentage of REM sleep at baseline and Week 
12.  Visual inspection of NPT recordings shows that while at baseline some participants did 
not have erections during all episodes of REM sleep, these were more common at the Week 
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12 visit, as shown in the example given.  Unfortunately, in the current study, only 16 
participants were both agreeable to NPT monitoring and adherent to CPAP (n=10) /sham 
CPAP (n=6), which limits full investigation of the effect of CPAP on NPT in this population.      
Although NPT measurements may be able to distinguish the cause of ED as being either 
physiological or psychological in origin, there is controversy regarding the distinct bimodal 
categorization of aetiology, as well as the accuracy of device itself.  However, to fully 
investigate the current data using previously defined criteria was considered useful.  By 
analysing baseline data for the subset of patients, whom were agreeable to NPT monitoring, 
approximately one third would be considered to have a psychological basis of their erectile 
dysfunction using traditional criteria.   If these men do have purely psychological erectile 
dysfunction, the additional of physical treatments such as CPAP, may not address the 
underlying issue.   Given the association of OSA with depression [547], and the bidirectional 
relationship between ED and negative mood, self-esteem and life satisfaction [37], this 
complex relationship may play an important role in response to treatment.  Prior to the 
1990’s, ED was thought to be completely psychological in origin [101], and in a complete 
turnaround, it has now been suggested that sexual dysfunction has been increasingly 
attributed to medical causes and overlooks the contribution of psychological and social 
factors [11].  Indeed none of the studies aforementioned in regards to the association 
between OSA & ED have mentioned the possibility of a psychological influence.  In the 
present study, at baseline, half of all participants scored at least moderate depression on 
the Depression Anxiety Depression Scores [548].  With the presence of emotional problems 
or stress increasing the likelihood of ED by 3.5 [1], the possibility that there may be a 
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psychological influence on ED in this study cannot be ignored, however, the small numbers 
of participants agreeable to NPT monitoring limits further investigation.   
4.5.3 Non-Erectile Sexual Function 
The effect of CPAP on sexual function other than erectile function has not previously been 
studied in a randomised controlled study.  In this study, satisfaction with sexual function, as 
determined by the overall satisfaction domain of the IIEF was found to be improved with 
CPAP.  Likewise, a previous observational study of 1 year of CPAP treatment, in which all 
participants used CPAP for more than 4 hours, showed improvements in sexual satisfaction 
in men with OSA [474], however, this was not seen in a shorter 2-3 month study of CPAP in 
which all participants were included, with adherence self-reported to be over 6 hours per 
night [408]. Both of these previous studies were in men with OSA, not specifically included 
on the basis of erectile dysfunction.  The improvement in sexual satisfaction seen in the 
longer term study thus may not necessarily relate to improvements in erectile function.  The 
current study showed improvements in sexual satisfaction occurred in the absence of 
statistical improvements in erectile function.  This suggests there may be other factors, such 
as sleepiness, mood or relationship factors which improve with CPAP, and contribute to 
sexual satisfaction.  
An increase in sexual desire was seen in this study for participants adherent to CPAP 
treatment. Only two other studies have reported the influence of CPAP on libido.  Unlike the 
current study, three months of CPAP treatment did not change libido in 15 men with OSA 
and ED [473]. A long term observation study of 3 years of CPAP use found a change in libido 
between those who did and did not use CPAP, in that a slight improvement in those who 
used CPAP, compared to an equal decline in those who did not use CPAP resulted in a 
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significant difference [412], suggesting that CPAP treatment may prevent a decline in libido 
with the progression of time, rather than increase it.  CPAP did not change orgasmic 
function in this study.  Effects of CPAP on orgasmic function has been previously reported 
only in one study, and was shown only to decline in those men with OSA who do not use 
CPAP compared to those who did [412].   
4.5.4 Sleepiness and Sexual Function 
Studies reporting aspects of sexual function affected by sleepiness, and the effect of CPAP 
thereof have been limited.  The Intimacy and Sexual Relationships domain of the FOSQ 
questionnaire provides an opportunity to evaluate how sleepiness can affect intimacy and 
sexual relationships, in regard to sexual desire, ability to become aroused and the ability to 
have an orgasm.  The current study, did not find an improvement in this domain of the 
FOSQ due to CPAP compared to sham CPAP either when analysed under intend-to-treat or 
per-protocol analysis. Several other studies have also not found any improvement in this 
domain with CPAP treatment [366, 549-551].  In contrast, some observational studies have 
found an improvement.  In a large (n=123) study using this questionnaire, at least 3 months 
of CPAP treatment improved in this domain with an effect size of 0.44 for all subjects 
compared to baseline (p<0.001), however when stratified on the basis of severity of OSA, 
only those with the most severe apnoea (AHI greater than 60) had significant improvement, 
with an effect size of 0.77 [410].  Similarly, the FOSQ Intimacy domain improved with CPAP 
use by 0.57 points in men in a study investigating the efficacy of a hypnotic agent on CPAP 
adherence [476].  The lack of control group in these studies limits the interpretation of the 
improvement seen, due to the subjective nature of sexual functioning.  In the current study, 
both CPAP and sham CPAP improved from baseline to week 12 in the per-protocol analysis 
in this domain but there was no statistical difference between the two.    
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4.5.5 Relationship Factors 
The detriment in non-sexual relationships and social function with adherence to sham CPAP 
is a novel finding.  No other study has reported decrements with adherent use of sham 
CPAP.  Participants, who diligently persevere with treatment, without receiving benefit, may 
have a decrement in relationship quality for a number of reasons.  Potentially, both patient 
and partner have high expectations and devote energy to successful use of treatment, and 
experience discomfort from the addition of the sham CPAP mask to the bedroom, without 
receiving the rewards, thereby creating disappointment and potentially conflict. For the 
partner, both the snoring and the sound of the sham CPAP machine and mask could also 
contribute to continuing poor sleep quality.  
4.5.6 Quality of Life 
For those men adherent to treatment, but not overall, significant improvements were seen 
in several parameters of psychological wellbeing, including stress, depression in the DASS 
questionnaire, as well as the mental health domains in the SF-36. Previous studies have 
shown improvements in depression scores even with low usage of CPAP (<3 hours) 
compared to an oral placebo [361].  The current study was not able to show such an 
increase in the intention to treat analysis, which yielded a higher adherence rate (3.7hours), 
however, there was a significant improvement in depression levels at all timepoints for 
those who adhered (>4hours) to CPAP treatment. Adherent CPAP users exhibited several 
improvements in quality of life, specifically in regards to reduced sleepiness, vigilance and 
vitality.  A reduced level of sleepiness may have some impact upon mood, which may also 
have impacts on quality of life.  Of all the sub-scores in the quality of life measurement tool 
SF-36, that of vitality is said to be the most affected in those with OSA, and has been 
reported as the only domain sensitive to clinical categories of sleep disordered breathing 
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[330, 337]. This study did show an improvement in vitality, but only for those who were 
adherent to treatment.  Improvements in other parameters of quality of life have also been 
noted in CPAP use, particularly for those who experience more symptoms pre-treatment 
[346]. Improvements in domains of the SF-36 have been shown in several studies, with 
particular improvements in the field of mental health and vitality, more so with those who 
adhere to treatment [361, 363, 552].  Improvements in all except one domain (intimacy and 
social function) of the FOSQ were found in a sham CPAP controlled study of 45 patients 
[364].  In contrast, in another oral placebo randomised controlled study of those with mild-
moderate (AHI 5-30) OSA, no change was seen in any parameter of the SF-35 or FOSQ 
questionnaire by the use of CPAP [368].  Limitations in interpreting this result include low 
usage of CPAP (3.5±2.1 hours/night) and a placebo effect was noted in the control arm, 
[368].  However, a sub analysis of those whom were adherent to CPAP treatment (>4hours) 
also showed no improvement in any domain of the SF36 or FOSQ questionnaires in this mild 
OSA group [368]. Potentially this may be due to lower symptomatology in this group.   
4.5.7 Adherence to CPAP 
CPAP use in this study (mean 3.7 hours, 48% using more than 4 hours per night) is similar to 
a number of other studies of men with severe OSA [542, 553, 554].  Other studies have 
found AHI, BMI, and ESS to have effects on CPAP adherence [357, 555, 556], however this 
study found no such difference.  The only statistical difference between the those who 
adhered and did not adhere to CPAP treatment was that of relationship length, in that those 
who were adherent had been in a relationship for an average of 21.6 years, compared to 
those 12.3 years for non-adherent users.  Previous studies have also found partner influence 
to be influential in CPAP usage.  One study showed that those patients whom were living 
with a partner tended to have a higher adherence rate to treatment, with an odds ratio of 
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1.5 of being adherent (>4hours/night) with CPAP treatment [357]. In a small, 2 week study, 
the number of nights in which a man with OSA slept in the same bed as his wife was 
positively correlated with CPAP adherence [195].  In a longer term (6 month) sham 
controlled study, those who were more adherent to treatment, in both active and placebo 
arms, were more likely to be married [359]. Indeed having a partner at home has been 
identified as being a predictor in adherence to treatment [557]. This study required that all 
participants be in a stable relationship for at least 6 months prior to entry to ensure that 
there was ample opportunity to assess erectile function. For couples in which erectile 
dysfunction is present, relationship quality can be detrimentally affected [558]. This 
relationship quality can have an influence on CPAP adherence, with levels of conflict in the 
relationship, as well as perceived pressure from partners, having an inverse relationship 
with hours of CPAP use [355, 356]. In another study, patients whom had sought treatment 
for OSA due to their spouse rather than being self-referred were less adherent to CPAP 
treatment [537].  The presence of ED may have effects on CPAP adherence, both 
detrimental and beneficial, depending on relationship quality.  Potentially, there may be a 
bidirectional relationship regarding relationship quality and CPAP adherence in this 
population.  Trending towards a difference but not reaching statistical significance was the 
duration of erectile dysfunction with those adherent to treatment having ED for a shorter 
time (p=0.059).  In a study of men seeking medical assistance for their erectile function from 
their GP, the majority were those who had experienced ED for a shorter time frame (<1 
year) [559].  These men may be more receptive to treatment options than those who have 
had the condition for a longer period, and is an important consideration in the clinical 
setting.   
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Adherence to CPAP treatment in previous trials in men with OSA and ED has been addressed 
using differing methodologies. Several studies did not report adherence [438, 484, 485] 
while in other studies, those not adherent to CPAP were either excluded [414], allocated to 
surgery as an alternative treatment [354] or used as controls [412]. In a study of CPAP 
versus an anti-depressant, all patients were reported to use CPAP 7 hours a night every 
night, and another study comparing oral appliance with CPAP reported CPAP usage of 6.8 
hours per night [408, 417].  Neither of these studies report on how such a high adherence 
rate was achieved or determined.   
In men adherent to CPAP treatment in this study, 100% were satisfied with treatment as it 
pertained to erectile function.  In the only other similar study reporting treatment 
satisfaction with CPAP, only 20% of all participants reported satisfaction with CPAP 
compared with 53% satisfied with Sildenafil [484].  This study, however, did not report on, 
nor stratify by adherence to CPAP.  Potentially, the perceived positive effects of CPAP may 
reinforce CPAP use, with those finding benefit from treatment more likely to persist with 
treatment.   
When data was stratified by adherence, there were four parameters in which a significant 
interaction between CPAP and Vardenafil was found in those who used CPAP greater than 4 
hours per night - ESS, SF-36 domains Role Physical, General Health, and Physical Health. 
When these parameters were investigated further, there were no synergistic effects, that is, 
receiving both treatments did not produce an effect greater than the sum of the two.  
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4.5.8 Strengths and Limitations 
One of the strengths of this study is the randomised control design.  Given the reliance on 
subjective outcomes in relation to sexual function and quality of life parameters, a placebo 
component is imperative to correctly verify the impact of treatment.  Additionally, the 
duration of the study being twelve weeks allowed changes which take time to occur to 
become apparent, as well as extricating a placebo effect for many parameters which 
declined with time.  A longer period of treatment may have further quantified the effect of 
treatment or a lack of decline in functionality as seen in other long term studies [412, 546]. 
Limitations to the study include a low adherence to CPAP treatment overall which limits 
findings, and low patient numbers who adhered to treatment may not have provided 
sufficient power to clearly document the effect of CPAP on sexual function. The intervention 
at week 4 to enhance adherence may not have been early enough to be effective.   CPAP did 
not completely eliminate OSA, with participants falling into the mild range (AHI 7) at study 
completion, which may limit treatment effects seen.  Additionally, low overall numbers may 
have been insufficient to detect interactions between the two treatment arms.   
4.6 CONCLUSION 
This data provides evidence that CPAP is able to improve sexual function, erectile function 
and increase sexual desire when used as prescribed.  Reduction in scores of rates of 
depression, stress, anxiety and sleepiness due to CPAP use may contribute to overall 
satisfaction in sexual relationships, and improve several aspects of quality of life.  Sham 
CPAP may not be an ideal control device due to decrements in relationship quality. CPAP 
treatment of more than 4 hours per night may be an effective treatment for improving 
overall sexual health as well as quality of life, however, a little over a third of patients are 
able to adhere to this treatment. 
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5 The effects of Vardenafil on sleep disordered breathing, 
sexual functioning and quality of life in men with OSA 
5.1 CHAPTER SUMMARY 
Introduction:  Erectile dysfunction and obstructive sleep apnoea occur together in 
approximately 10-15% of community dwelling men. PDE-5 administration, the current 
treatment of choice for ED, has been shown to improve erectile function and sleep related 
erections in otherwise healthy men; however uncontrolled studies have reported PDE-5 
inhibitors to be less effective in men with OSA than that of other populations. High dose PDE-5 
inhibitors when used on-demand have been shown to increase nasal obstruction, making those 
susceptible to airway collapse at higher risk of obstructed breathing.  Men with OSA are 
reported to have impaired sleep related erections. The efficacy of PDE-5 inhibitors on sleep 
related erections in men with OSA has not been investigated.  This study aims to determine if a 
low daily dose of 10mg Vardenafil is effective in improving subjective erectile function and 
sleep related erections, as well as self-esteem, relationship, quality of life and treatment 
satisfaction without worsening sleep disordered breathing in men with OSA and ED. 
Methods:  Sixty-one men with erectile dysfunction (ED) and obstructive sleep apnoea (OSA) 
were randomised to receive either daily 10mg Vardenafil or placebo as part of a 2x2 factorial 
study also investigating the efficacy of continuous positive airway pressure (CPAP), for a period 
of 12 weeks.  Subjective measures of sexual function, mood, relationship factors and quality of 
life were assessed prior to, and after 4, 8 and 12 weeks of allocated treatment.  Objective 
measures of sleep, breathing, and sleep related erections were recorded at baseline and after 
12 weeks.  
Results:   Vardenafil did not worsen any parameter of sleep disordered breathing for those 
allocated to sham CPAP treatment.  Subjective erectile function improved initially at Week 4 & 
Week 8, but was not different than that of placebo at Week 12. Nocturnal erection quality 
improved with Vardenafil in regards to rigidity and tumescence. Vardenafil reduced distress due 
to sexual dysfunction and improved self-esteem and relationship satisfaction but had little 
impact on any other measurement in quality of life. Treatment satisfaction scores were higher 
for those taking Vardenafil than placebo throughout the study; however, in terms of being 
satisfied with treatment, this was only apparent at Week 4.   
Conclusion:   Although an improvement in sleep related erections was seen, a daily dosage of 
10mg Vardenafil may not be sufficient to completely improve erectile function in all men with 
OSA and ED, however, sufficient improvements in self-esteem and relationship satisfaction may 
warrant clinical application.  This dose did not worsen sleep disordered breathing.  
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5.2 INTRODUCTION 
Erectile dysfunction (ED) and obstructive sleep apnoea (OSA) often co-exist.  As well as OSA 
being male predominant, these conditions have common risk factors such as obesity and 
increasing age, and co-morbidities such as diabetes, hypertension, depression and 
cardiovascular disease [62, 313, 560-564].  Current literature suggests a high overlap between 
the two conditions, with rates ranging from 30-70% of OSA clinic based patients having ED [404, 
409, 414, 422, 431], with similar rates of ED clinic patients having OSA [415, 424, 434, 437].  
Men with OSA and ED thus represent a large population for whom effective treatments exist; 
however, these treatments have not been fully investigated in the presence of the other 
condition.  
The current treatment of choice for erectile dysfunction is the class of medication known as 
prosphodiesterase type 5 (PDE-5) inhibitors, used when needed (i.e. on-demand).  These act by 
increasing cyclic quanosine monophosphate (cGMP) in the corpus cavernosum.  As a result, 
there is a relaxation of the previously contracted smooth muscle and an inflow of blood, leading 
to an erection. This action enhances the normal response to sexual stimulation, which is a 
release of nitric oxide in the corpus cavernosum. Nitric oxide activates an enzyme, guanylate 
cyclise, which in turn increases cGMP [565].  
PDE-5 administration has been shown to increase nasal obstruction, both subjectively and 
objectively, in the nasal mucosa [460, 461]. For those susceptible to sleep disordered breathing, 
this creates a theoretical risk of further impaired airway patency due to engorgement of upper 
airway tissues, which may result in a reduction of nasal cross-sectional area and increase the 
tendency for relaxation of the soft tissue in the pharyngeal muscles [460-462] thus increasing 
the  risk of obstructive sleep apnoea. Indeed, a recent randomised placebo-controlled study of 
 - 193 - 
13 men with severe OSA showed that a 50mg dose of Sildenafil prior to sleep increased the 
apnoea hypopnoea index (AHI) from 32.3±11.3 to 48.1±20.8 (p=0.01), oxygen desaturation 
index from 18.5±9.1 to 30.3±14.5 (p<0.01), and amount of time hypoxic while asleep from 
7.9%±3.3%, to 15.6% ±9.6% (p<0.01) [463, 464]. This small study requires further investigation 
to determine if a lower dose of PDE-5 inhibitors is safe for those with OSA.  
Sleep related erections (SRE’s) occur during REM sleep, and have been shown to be impaired in 
men with OSA, potentially due to sleep fragmentation or hypoxaemia [22, 434]. SRE’s have 
been described in the scientific literature since the 1940’s [23, 24].  These were confirmed to be 
associated with REM sleep some thirteen years after the discovery of this stage of sleep [25, 
26].  During the sleep period, approximately 1-2.5 hours are spent in REM sleep [566].  
Erections occur during approximately 90% of this time [7].  Although the function of nocturnal 
erections is unknown, these episodes of penile blood engorgement increase corporeal 
oxygenation and may function to protect the morphological integrity of the penis [30, 31]. 
Without regular oxygenation, fibrosis of the smooth muscle may occur leading to atrophy of the 
corpora cavernosa [567]. PDE-5 administration has been shown to improve sleep related 
erections in otherwise healthy males [130, 132, 568, 569], however, this has not been 
investigated in the presence of OSA.  Potentially, the administration of PDE-5 inhibitors can 
assist SRE’s and may be useful in the prevention of deterioration in the cavernosal smooth 
muscle [569]. The efficacy of PDE-5 inhibitors in men with OSA has been reported in one 
uncontrolled study to be less than that of the general male population [484].  Given this report, 
together with the lack of placebo controlled studies in men with OSA and the widespread use of 
this medication, further investigation into the effects of PDE-5 inhibitors on breathing during 
sleep and its efficacy in this population are required.  This study aims to investigate if a low 
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dose of 10mg Vardenafil, administered daily, is effective in improving subjective erectile 
function and sleep related erections, without worsening sleep disordered breathing in men 
with OSA and ED.   
5.3 METHODS 
This was a multisite study, performed in Sydney at the Woolcock Institute of Medical Research, 
Glebe, New South Wales and in Melbourne at the Department at Respiratory and Sleep 
Medicine, Monash Medical Centre, Clayton, Victoria, as described in section 3.2.  
This study was performed as part of a 2x2 factorial study, investigating the effects of 12 weeks 
of Vardenafil and CPAP in men with OSA and ED.  Sample size was determined as described in 
section 3.2.4.  After baseline data collection, eligible participants at each site (Sydney and 
Melbourne) were randomised using two separate lists via computer generated random blocks 
of four to either 10mg Vardenafil or placebo in a 1:1 ratio. Participants were also allocated to 
either CPAP or sham CPAP concurrently, in equal numbers between the two groups. Subjective 
measurements were assessed before, as well as after 4, 8 and 12 weeks of treatment.  Once 
treatment was commenced, subjective efficacy of treatment was assessed at all following visits.  
Objective measurements were performed at baseline, prior treatment and week 12, when the 
allocated treatment was used.  
5.3.1 Participants 
Sixty one men aged between 18 and 65 years who had both obstructive sleep apnoea and 
erectile dysfunction were recruited into the study, as described in section 3.2.2.  Briefly, 
participants were required to have at least moderate obstructive sleep apnoea, defined as an 
apnoea-hypopnoea index (AHI) measured by polysomnogram, of greater than 20 events per 
hour, with an oxygen desaturation of 3 % or greater (ODI3) of at least 15 events per hour, as 
 - 195 - 
well as erectile dysfunction, defined as a score of less than 26 in the erectile function domain of 
the International Index of Erectile Function (IIEF) questionnaire.    
5.3.2 Vardenafil & Placebo  
Participants were randomised to receive either 10 milligrams of Vardenafil hydrochloride 
trihydrate (product name Levitra) or placebo (Bayer Schering Berlin, Germany).  Peak 
concentration of Vardenafil is reached in around one hour (minimum being around 15 minutes), 
with a half-life of around 4 hours [570]. Participants were instructed to take one tablet daily 
one hour before attempting to fall asleep, regardless of their intention to attempt sexual 
activity.  Medication sufficient for a four week period was dispensed at baseline, week 4 and 
week 8 with any remaining tablets returned at the next visit.  Returned tablets were counted 
manually to assess adherence with treatment.          
5.3.3 Statistical Analysis 
Statistical analysis was performed using SAS statistical package version 9.2 (SAS Institute, Cary, 
North Carolina, USA), as described in section 3.2.4. Student t-tests, or Fishers exact tests, were 
first used to compare groups at baseline.   The outcome variables were the mean values at 
weeks 4, 8 and 12 weeks as appropriate, with week 12 being the visit of interest. Data was 
analysed using intention-to-treat principles, performed as per established methods for factorial 
studies [517, 518].  Mixed model analysis was first used to test the hypothesis there was no 
interaction between the treatments used in the 2x2 factorial study. The interaction between 
the two treatments, as well as time, was assessed. If interaction terms were not significant, a 
secondary analysis of treatment effects, in the absence of time was assessed.  If no interaction 
was found, the effect of each treatment was assessed in separate models of treatment, time 
and the interaction term treatment*time, taking baseline values into consideration.  The raw 
mean, standard deviation, and between-group difference at each time point was 
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reported.  Normality of residuals of the final model was confirmed. Where no baseline data was 
present (ie for treatment efficacy), mixed model analysis was used, in the absence of any 
baseline considerations.  Student t-tests were used to compare the number of participants 
satisfied with treatment at each time point.  
5.3.4 Subjective Assessment of Sexual Function 
Subjective measurements of sexual function, relationship quality and quality of life were 
assessed at baseline and after 4, 8 and 12 weeks of treatment using self-administered 
computerized or paper based questionnaires, which was consistent for individual patients as 
described in section 3.2.5.  Briefly, participants sexual function was primarily assessed using the 
International Index of Erectile Function (IIEF) questionnaire [89].  Additional measures of sexual 
function were obtained from the European Male Aging Study (EMAS)  [84, 85] and the Self-
Esteem And Relationship Satisfaction (SERS) questionnaires [519]. Quality of life was assessed 
using the Short-Form Medical Outcomes Survey (SF-36) [333, 334, 520],  the Depression Anxiety 
Stress Scale (DASS) [521-523] and the Functional Outcomes of Sleep Questionnaire (FOSQ) 
[339]. Levels of sleepiness were assessed using the Epworth Sleepiness Score (ESS) [324, 524].  
Satisfaction with treatment was assessed at Week 4, Week 8 and Week 12 using the Erectile 
Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire [93].   
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5.3.5 Nocturnal Penile Tumescence (NPT) 
Sleep related erections were measured on a subset of participants who agreed to take part, 
using nocturnal penile tumescence (NPT) monitoring prior to treatment and at study 
completion using a Rigiscan Plus monitor [102] as described in section 3.2.6. 
5.3.6 Blood Parameters 
A single early morning fasted blood sample was collected after the overnight sleep study at 
baseline and at Week 12. Parameters assessed included reproductive hormones and routine full 
blood examination for safety.   
5.3.7 Polysomnography    
Overnight polysomnography was performed at baseline, prior treatment, and at Week 12 using 
the allocated treatment, in an attended laboratory setting and analysed using a Sandman Elite 
system and software (Sandman Elite v9.2, Tyco Healthcare, Denver, Colorado) at the Sydney 
site, or Compumedics Profusion 2 (Melbourne, Australia) at the Melbourne site.  A description 
of polysomnographic methods and analysis can be found in section 3.2.7. 
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5.4 RESULTS 
The flow of participants through the study is shown in figure 5.1.  Sixty-one men were 
randomized into the study, of these, 49 were from the Sydney site and 12 were from 
Melbourne. Of these participants, 30 were allocated to receive Vardenafil, and 31 to placebo. 
Six participants withdrew from the study after randomisation. Four participants were from the 
Sydney site, while two were from Melbourne.  Of these, two withdrew from the study due to 
being unhappy with the CPAP/sham treatment and four withdrew due to personal reasons.  
Four of the six withdrawals were randomised to placebo medication. There was no difference in 
any demographic, sleep or erectile function parameter between those who withdrew and those 
who completed the study (data not shown). Fifty five men completed the study. 
Participants were aged 54.1±9.1 years, had severe OSA (AHI 46.1±25.8) and moderate ED (IIEF-
ED 12.5±7.5).  Baseline characteristics of sleep and breathing parameters, medical history and 
degree of erectile dysfunction between those who were randomised to Vardenafil and placebo 
are shown in table 5.1.  There were no differences between the groups in regard to 
demographic variables or disease severity, with the only exception being duration of sleep and 
neck circumference, which were longer/larger in the Vardenafil group.  
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Figure 5.1 Study Flow 
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Table 5.1 Baseline characteristics 
 
Vardenafil  
(n=30) 
Placebo       
(n=31) p-value 
Age (years) 54.5 ± 9.5 53.8 ± 8.9 0.770 
        
Medical History               
Duration of erectile dysfunction (years) 6.0 ± 4.8 6.2 ± 5.4 0.853 
Hypertension n (%)^ 17  (57) 15  (48) 0.492 
Using antihypertensives n (%) 13  (43) 12  (39) 0.731 
Hypercholesterolemia n (%)^ 9  (30) 7  (23) 0.454 
Using statins n (%) 7  (23) 4  (13) 0.187 
Diabetes n (%)^ 6  (20) 5  (16) 0.523 
        
Lifestyle Factors               
Relationship duration (years) 17.1 ± 14.0 17.4 ± 13.5 0.938 
Number of drinks per week 8.4 ± 9.6 11.2 ± 15.5 0.398 
Drink more than 10 drinks/week n(%) 10  (33) 11  (36) 0.782 
Past smokers n(%) 25  (83) 25  (81) 0.903 
Fathers n(%) 24   (80) 21 (68) 0.448 
        
Anthropometry               
Weight (kg) 100.7 ± 15.6 100.4 ± 16.5 0.944 
Body Mass Index (kg/m2) 32.7 ± 4.6 32.9 ± 5.2 0.860 
Neck circumference (cm) 43.9 ± 3.0 42.0 ± 2.8 0.012 
Mid-arm circumference (cm) 33.3 ± 2.7 33.1 ± 3.3 0.817 
Waist circumference (cm) 111.6 ± 11.8 110.1 ± 13.1 0.635 
Hip circumference (cm) 109.7 ± 9.3 108.5 ± 12.1 0.664 
Mid-Thigh circumference (cm) 52.3 ± 6.5 52.5 ± 6.6 0.951 
        
Note: Values are mean ± standard deviation or number (percentage).  p-value calculated by Students t-
test or Fishers exact test. ^as diagnosed prior entry into the study. kg=kilograms, kg/m2= kilograms per 
metre squared. cm=centimetres 
(Continued over) 
. 
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Table 5.1 Baseline Characteristics (continued) 
 
 
Vardenafil 
(n=30) 
Placebo   
(n=31) p-value 
Sleep and Breathing               
Total Sleep Time (minutes) 369.4 ± 50.8 327.4 ± 93.0 0.033 
Sleep Efficiency (%) 82.5 ± 9.5 73.4 ± 20.7 0.031 
REM (% of total sleep time) 16.3 ± 7.7 16.8 ± 6.6 0.797 
Arousal index (/hour) 39.0 ± 23.3 29.1 ± 15.1 0.056 
Apnoea Hypopnoea Index (AHI) 48.9 ± 26.8 43.4 ± 24.9 0.410 
NREM AHI 49.6 ± 28.4 45.1 ± 26.5 0.527 
REM AHI 49.3 ± 23.2 46.9 ± 27.6 0.722 
Minimum SpO2 74.8 ± 11.0 77.2 ± 10.3 0.387 
Time SpO2 below 90% (min) 12.6 ± 15.5 12.2 ± 14.9 0.905 
Oxygen Desaturation (3%) Index  47.7 ± 30.6 40.4 ± 27.7 0.341 
Subjective Sexual Function & Relationship  
              
International Index of Erectile Function (IIEF) 34.5 ± 16.2 34.6 ± 16.3 0.978 
IIEF - Erectile Function 12.7 ± 7.5 12.3 ± 7.7 0.808 
IIEF - Intercourse Satisfaction 6.0 ± 3.8 5.7 ± 4.1 0.786 
IIEF - Orgasmic Function 5.7 ± 3.3 5.7 ± 3.5 0.991 
IIEF - Overall Satisfaction 4.2 ± 2.2 4.5 ± 2.2 0.545 
IIEF - Sexual Desire 5.9 ± 1.9 6.4 ± 2.1 0.317 
European Male Aging Study  (EMAS) 34.7 ± 6.7 32.8 ± 8.5 0.344 
EMAS - Sexual Function related distress 11.2 ± 5.2 9.7 ± 4.7 0.245 
EMAS - Change in Sexual Functioning -3.0 ± 3.0 -3.4 ± 3.5 0.703 
EMAS - Overall Sexual Functioning 15.7 ± 5.2 15.2 ± 6.6 0.782 
EMAS - Masturbation 2.2 ± 1.6 2.3 ± 1.8 0.839 
Self Esteem and Relationship  (SERS) 38.1 ± 12.0 38.9 ± 11.1 0.792 
SERS - Sexual Relationship Satisfaction 19.2 ± 8.0 18.6 ± 6.9 0.783 
SERS - Confidence 18.6 ± 5.5 20.3 ± 5.3 0.237 
SERS - Self Esteem 11.7 ± 4.5 13.0 ± 4.1 0.276 
SERS - Overall Relationship Satisfaction 6.9 ± 1.9 7.1 ± 2.1 0.608 
Nocturnal Penile Tumescence (n=43)               
Tip Rigidity Activation Units 20.4 ± 17.1 26.0 ± 30.2 0.503 
Tip Tumescence Activation Units 17.1 ± 15.0 21.3 ± 34.5 0.642 
Base Rigidity Activation Units 35.1 ± 34.9 31.9 ± 33.8 0.767 
Base Tumescence Activation Units 24.2 ± 25.8 23.3 ± 29.4 0.912 
Organic erectile dysfunction# (%) 11 (55%)^  16 (70%)@  0.323 
Note: Values are mean ± standard deviation. p-value calculated by Students t-test or Fishers 
exact test.  #Organic erectile dysfunction as determined using criteria specified in section 3.2.6.  
^subset (n=20), @ Subset (n=23), SpO2= Oxygen saturation   
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Table 5.1 Baseline Characteristics (continued)        
  
Vardenafil 
(n=30) 
Placebo    
(n=31) p-value 
Quality of Life 
 
 
  
 
  Subjective Sleepiness (ESS)  10.4 ± 4.6 10.2 ± 5.0 0.818 
Functional Outcomes of Sleep Questionnaire (FOSQ)               
FOSQ - Overall score 15.3 ± 2.8 15.5 ± 3.5 0.873 
FOSQ - Activity 3.1 ± 0.6 3.1 ± 0.8 0.646 
FOSQ - Vigilance 3.2 ± 0.5 3.1 ± 0.6 0.781 
FOSQ - Intimacy 2.6 ± 0.9 2.6 ± 1.0 0.985 
FOSQ - General Productivity 3.5 ± 0.5 3.4 ± 0.6 0.689 
FOSQ - Social Outcome 3.5 ± 0.7 3.6 ± 0.8 0.557 
Depression Anxiety Stress Scale (DASS) 
       
DASS - Depression 9.5 ± 9.3 9.2 ± 8.5 0.916 
DASS - Anxiety 5.9 ± 4.7 7.7 ± 6.6 0.213 
DASS - Stress 13.3 ± 7.2 12.3 ± 7.7 0.581 
Short Form 36 (SF-36)  
       
SF-36 - Physical Function 76.7 ± 15.7 67.7 ± 29.5 0.148 
SF-36 - Role - Physical 76.7 ± 27.5 66.9 ± 37.9 0.263 
SF-36 - Body Pain 75.0 ± 19.6 72.7 ± 23.5 0.677 
SF-36 - General Health 63.0 ± 20.8 60.1 ± 17.4 0.551 
SF-36 - Vitality 49.5 ± 22.2 53.9 ± 21.4 0.437 
SF-36 - Social Function 81.8 ± 22.9 78.0 ± 28.0 0.565 
SF-36 - Role Emotional 70.0 ± 34.3 68.9 ± 37.1 0.903 
SF-36 - Mental Health 72.9 ± 18.6 70.5 ± 18.4 0.602 
SF-36 - Reported Health 67.3 ± 14.9 65.5 ± 20.4 0.694 
SF-36 - Mental Health Dimension 74.9 ± 21.3 73.7 ± 23.3 0.836 
        
Note: Values are mean ± standard deviation.  p-value calculated by Students t-test .  ESS = 
Epworth Sleepiness Score. 
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5.4.1 Sleep and breathing 
Despite randomization, at baseline, there was a difference in sleep duration, and thus sleep 
efficiency, by more than 40 minutes between the Vardenafil and placebo groups, however 
as this was not a primary endpoint, this was not considered detrimental to the analysis. 
There was no difference in the change of any sleep or breathing parameters between 
Vardenafil and placebo overall.  Half of the study population was allocated to CPAP 
treatment, who should be effectively treated for their sleep disordered breathing.  The 
other half who received sham CPAP thus had untreated sleep apnoea.  In this group of 
participants (allocated to sham CPAP) there was no difference at baseline between the 
Vardenafil and placebo groups in regard to sleep and breathing parameters. When 
measured at 12 weeks, Vardenafil did not change any parameter of sleep or sleep 
disordered breathing including total sleep time, REM sleep duration, AHI or ODI between 
baseline and Week 12 (table 5.2). 
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Table 5.2 Effect of Vardenafil on sleep disordered breathing  
 
Vardenafil (n=14) 
 
Placebo (n=16) 
 
Difference between 
groups (95% CI)  
 
Baseline Week 12 p-value Baseline Week 12 p-value p-value 
TST (minutes) 365.3 ± 53.0 375.6 ± 78.5 0.694 300.3 ± 111.1 329.4 ± 68.9 0.432 -2.2 (-48.4 to 44.1) 0.923 
REM (% of TST) 15.7 ± 9.0 15.7 ± 8.0 0.990 16.6 ± 6.9 19.8 ± 9.0 0.306 -0.5 (-6.3 to 5.3) 0.863 
Arousal Index  39.3 ± 24.4 42.5 ± 29.6 0.768 29.2 ± 12.8 34.0 ± 15.7 0.385 -8.5 (-24.4 to 7.3) 0.274 
AHI 47.1 ± 24.5 46.7 ± 31.1 0.969 41.0 ± 25.8 38.2 ± 23.1 0.767 -8.5 (-25.9 to 8.8) 0.317 
NREM AHI 47.1 ± 26.9 46.6 ± 33.8 0.967 42.3 ± 26.6 36.8 ± 24.4 0.586 -1.4 (-20.3 to 17.5) 0.882 
REM AHI 47.5 ± 22.1 48.6 ± 21.0 0.905 43.1 ± 30.6 42.2 ± 31.5 0.943 -8.8 (-22.8 to 5.2) 0.203 
Minimum SpO2 71.1 ± 11.3 74.9 ± 10.5 0.390 77.9 ± 10.5 79.8 ± 6.0 0.570 2.9 (-5.6 to 11.4) 0.487 
Time SpO2 
below 90% 
(min) 
15.8 ± 19.3 15.1 ± 15.0 0.917 10.3 ± 8.9 8.1 ± 7.1 0.481 -4.8 (-24.2 to 14.6) 0.611 
ODI 47.5 ± 27.7 49.4 ± 32.0 0.874 41.6 ± 28.3 37.8 ± 24.3 0.714 -0.2 (-9.7 to 9.2) 0.958 
Note: Only those participants allocated to sham CPAP (ie, untreated OSA) are presented here. Values are mean ± SD. TST = Total Sleep Time, 
REM = Rapid Eye Movement Sleep, AHI = Apnoea Hypopnea Index, ODI = Oxygen Desaturation (3%) Index, SpO2=Oxygen saturation, 
min=minutes. p-value determined by students t-test. 
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5.4.2  Subjective Sexual functioning 
At baseline, of the 61 study participants, 11.4% had mild ED (IIEF-ED score 22-25), 21.3% had 
mild-moderate ED (IIEF-ED score 17-21), 26.2% had moderate ED (IIEF-ED score 11-16) and 41% 
had severe ED (IIEF-ED score 6-10) [430, 544].    
Vardenafil, compared to placebo, improved the overall score of the International Index of 
Erectile Function (IIEF) at the Week 8 timepoint by 11 points (p=0.024). An increase was seen at 
Week 4 and Week 12 by 10 and 8 points respectively but this did not reach statistical 
significance over placebo (p=0.09 and p=0.07 respectively) (Table 5.3 and Figure 5.2). 
Contributing to this overall improvement at week 8 was the improvement seen in the erectile 
function and intercourse satisfaction domains; however no improvements were seen in the 
domains of orgasmic function, overall satisfaction, and sexual desire.  Increases in the IIEF-ED 
domain by more than 4 points are considered clinically meaningful [545] which were seen at 
weeks 4 & 8 (5.3±6.7 and 5.4±7.5 points respectively), while there was only a borderline 
improvement at week 12 (increase by 4.0±7.7 points) which was not statistically different than 
placebo.  At week 12, 25% of those allocated to Vardenafil reported normal erectile function, 
compared to 7% of those allocated to placebo, which when analysed using Fishers exact test, 
was not different (figure 5.3).  At Week 12, there were no differences in any domain, or the 
overall score of the IIEF between Vardenafil and placebo.  
Significant improvements were seen with Vardenafil compared to placebo in the European 
Male Aging Study questionnaire (table 5.4).  At all timepoints there was a reduction in distress 
caused by sexual dysfunction, and there was also consistent improvement in the domain 
related to change in sexual function throughout the study (figure 5.4). No changes were seen in 
the overall score, or the domains of overall sexual function or masturbation.  
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Vardenafil improved the overall score in the Self Esteem and Relationship Satisfaction 
questionnaire at week 4 and week 12. At week 4, there was an improvement in the Sexual 
Relationship Satisfaction domain with Vardenafil compared to placebo (figure 5.4).  No other 
improvements in other domains were seen (table 5.4).  Stratification into initial severity groups 
on the basis of IIEF-ED domain did not show any group to respond to Vardenafil moreso than 
placebo in any domain measured.  
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Table 5.3 Effect of Vardenafil on Sexual Function: International Index of Erectile Function 
Variable Visit 
Vardenafil       
(n=30) 
Placebo               
(n=31) 
Difference                      
Mean (95% CI) 
Effect 
  size (d) 
p-value 
International Index of Erectile Function (IIEF)     
Overall  Week 4 44.39 ± 19.15 37.04 ± 18.01 7.36 (-2.71 to 17.42) 0.46 0.088 
 Score Week 8 45.04 ± 19.76 34.92 ± 18.84 10.12 (-0.64 to 20.87) 0.63 0.024 
  Week 12 42.89 ± 21.91 34.26 ± 18.23 8.63 (-2.29 to 19.56) 0.53 0.067 
Erectile  Week 4 18.14 ± 8.84 13.56 ± 8.54 4.59 (-0.12 to 9.29) 0.61 0.038 
 Function Week 8 18.12 ± 9.50 12.85 ± 8.73 5.27 (0.19 to 10.35) 0.70 0.024 
  Week 12 17.11 ± 9.92 12.59 ± 8.56 4.51 (-0.50 to 9.53) 0.60 0.069 
Intercourse  Week 4 7.43 ± 4.69 5.89 ± 4.52 1.54 (-0.93 to 4.00) 0.39 0.194 
 Satisfaction Week 8 8.31 ± 4.43 5.26 ± 4.80 3.05 (0.50 to 5.60) 0.78 0.010 
  Week 12 7.46 ± 4.82 5.26 ± 4.85 2.21 (-0.41 to 4.82) 0.56 0.100 
Orgasmic  Week 4 6.75 ± 3.47 6.26 ± 3.68 0.49 (-1.44 to 2.42) 0.14 0.636 
 Function Week 8 6.35 ± 3.57 6.00 ± 3.59 0.35 (-1.63 to 2.32) 0.10 0.537 
  Week 12 6.18 ± 3.72 5.37 ± 3.63 0.81 (-1.18 to 2.80) 0.24 0.291 
Overall  Week 4 5.46 ± 2.52 4.78 ± 2.17 0.69 (-0.59 to 1.96) 0.31 0.116 
 Satisfaction Week 8 5.81 ± 2.64 4.74 ± 2.49 1.07 (-0.35 to 2.48) 0.48 0.061 
  Week 12 5.82 ± 3.16 4.78 ± 2.12 1.04 (-0.42 to 2.51) 0.47 0.074 
Sexual  Week 4 6.61 ± 1.91 6.33 ± 1.94 0.27 (-0.77 to 1.32) 0.14 0.296 
 Desire Week 8 6.46 ± 1.86 6.07 ± 2.16 0.39 (-0.73 to 1.50) 0.19 0.124 
  Week 12 6.32 ± 2.06 6.26 ± 2.43 0.06 (-1.15 to 1.28) 0.03 0.381 
Note: Values are mean ± standard deviation. * p-value calculated by mixed model analysis. 
Effect size (Cohen’s d) calculated by dividing difference between CPAP and sham by the standard 
deviation at baseline. 
 
 
 
y Figure 5.2 Effect of Vardenafil on erectile function over time 
A B 
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Note: (A) IIEF Overall Score, (B) IIEF Erectile Function domain. Values shown are change from baseline means 
plus standard error.  *p<0.05 as calculated by mixed model analysis.  Arrows indicate direction of 
improvement. 
 
 
Figure 5.3 Distribution of Erectile Dysfunction Categories 
Note:  ED category defined by IIEF ED scores:  No ED: >26; Mild ED: 22-26; Mild-Moderate ED: 17-21; 
Moderate ED:11-16; Severe ED: 6-10  [430]. Number displayed is percentage of participants at each 
visit.   
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Table 5.4 Effect of Vardenafil on Sexual function and Relationship: EMAS & SERS 
Variable Visit 
Vardenafil       
(n=30) 
Placebo               
(n=31) 
Difference                      
Mean (95% CI) 
Effect 
size 
(d) p-value 
European Male Aging Study questionnaire (EMAS)         
Overall Score Week 4 36.04 ± 8.96 31.83 ± 8.61 4.21 (-0.77 to 9.19) 0.55 0.052 
  Week 8 36.84 ± 7.20 34.64 ± 8.17 2.20 (-2.18 to 6.58) 0.29 0.423 
  Week 12 37.52 ± 7.16 33.15 ± 8.78 4.36 (-0.05 to 8.78) 0.57 0.060 
Sexual  Week 4 7.36 ± 5.19 8.56 ± 4.93 -1.20 (-3.94 to 1.54) -0.24 0.004 
Function Week 8 7.38 ± 6.54 9.93 ± 5.25 -2.54 (-5.81 to 0.72) -0.51 <0.001 
  Distress Week 12 6.89 ± 5.88 8.23 ± 5.32 -1.34 (-4.41 to 1.73) -0.27 0.007 
Change in  Week 4 0.48 ± 4.90 -3.68 ± 3.52 4.16 (1.89 to 6.43) 1.29 0.001 
  Sexual Week 8 0.04 ± 4.55 -2.81 ± 4.60 2.85 (0.35 to 5.35) 0.89 0.013 
  Function Week 12 0.68 ± 4.55 -2.93 ± 3.43 3.60 (1.42 to 5.79) 1.12 0.005 
Overall  Week 4 17.21 ± 6.37 15.60 ± 5.83 1.61 (-1.75 to 4.96) 0.27 0.299 
Sexual Week 8 17.85 ± 6.14 16.68 ± 5.74 1.17 (-2.18 to 4.51) 0.20 0.249 
  Function Week 12 18.85 ± 6.82 16.42 ± 6.33 2.43 (-1.20 to 6.06) 0.41 0.089 
Masturbation Week 4 2.32 ± 1.59 2.30 ± 1.61 0.03 (-0.84 to 0.89) 0.01 0.826 
  Week 8 2.19 ± 1.64 2.50 ± 1.79 -0.31 (-1.26 to 0.63) -0.18 0.622 
  Week 12 2.11 ± 1.45 2.58 ± 1.98 -0.47 (-1.41 to 0.47) -0.28 0.322 
      
Self-Esteem and Relationship Satisfaction (SERS)      
Overall  Week 4 44.04 ± 14.53 39.38 ± 9.72 4.65 (-2.15 to 11.45) 0.41 0.029 
  Score Week 8 44.08 ± 14.23 40.88 ± 11.45 3.20 (-4.18 to 10.58) 0.28 0.235 
  Week 12 46.56 ± 14.91 40.81 ± 11.75 5.75 (-1.67 to 13.17) 0.50 0.040 
Sexual  Week 4 23.50 ± 8.95 19.04 ± 5.95 4.46 (0.34 to 8.59) 0.60 0.025 
   Relationship  Week 8 22.88 ± 9.05 19.81 ± 7.60 3.08 (-1.58 to 7.73) 0.41 0.273 
   Satisfaction Week 12 24.56 ± 9.77 19.89 ± 7.67 4.67 (-0.13 to 9.46) 0.63 0.055 
Confidence Week 4 20.54 ± 6.52 20.12 ± 5.14 0.42 (-2.80 to 3.64) 0.08 0.146 
  Week 8 21.19 ± 6.22 20.72 ± 5.10 0.47 (-2.73 to 3.68) 0.09 0.301 
  Week 12 22.00 ± 6.66 20.62 ± 5.31 1.38 (-1.95 to 4.71) 0.25 0.085 
Self Esteem Week 4 13.07 ± 4.80 12.88 ± 4.21 0.18 (-2.27 to 2.64) 0.04 0.166 
  Week 8 13.56 ± 4.85 13.76 ± 4.06 -0.20 (-2.71 to 2.30) -0.05 0.468 
  Week 12 14.25 ± 4.90 13.23 ± 4.24 1.02 (-1.49 to 3.53) 0.23 0.059 
Overall  Week 4 7.14 ± 2.53 7.19 ± 2.18 -0.04 (-1.32 to 1.24) -0.03 0.667 
   Relationship  Week 8 7.31 ± 2.48 6.96 ± 2.19 0.35 (-0.97 to 1.67) 0.18 0.430 
   Satisfaction Week 12 7.41 ± 2.41 7.38 ± 2.06 0.02 (-1.21 to 1.26) 0.02 0.768 
                        
Note: Values are raw mean ± standard deviation at each visit.  p-value obtained using mixed model 
analysis. Effect size (Cohen’s d) calculated by dividing difference between CPAP and sham by the 
standard deviation at baseline. 
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Figure 5.4 Changes from baseline, SERS and EMAS Sexual Functioning. 
Note:  (A) EMAS Sexual function distress (B) EMAS Change in sexual functioning (C) Self-Esteem and 
Relationship Satisfaction overall score (D) SERS Sexual Relationship satisfaction. Values are mean change 
from baseline with one standard error.  *p<0.05.  Arrows indicate direction of improvement 
  
A B 
C D 
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5.4.3  Sleep Related Erections 
Forty three participants (70%) were agreeable to undertake nocturnal penile tumescence (NPT) 
monitoring to assess sleep related erections. Of these, only 36 (59%) completed a successful 
recording (>4 hours) on the baseline PSG night. Five men chose not to use the device on this 
night after using the device at home the prior two nights of acclimitisation and two did not 
have sufficient data on PSG night due to dislocation of the loops during sleep. At Week 12, only 
28 (46%) successful recordings occurred, due to withdrawal of participants (n=5), participant 
decision not to use the device at this visit (n=2) and technical difficulties (n=1). Of these, 15 
were allocated to Vardenafil and 13 were on placebo. Participants who completed both 
Rigiscan recordings did not differ from those who declined in terms of age, severity of ED, 
sleepiness, testosterone or weight.  However, those who did NPT monitoring had less severe 
OSA compared to those who did not (AHI:  41.5±22.7vs 56.9±29.9, p=0.033; Minimum SpO2: 
78.5±9.0% vs 70.1±12.0, p=0.004; Oxygen Desaturation Index 37.9±25.1 vs 58.4±33.4, p=0.011).    
Results for NPT monitoring are given in table 5.5. Data shown is from the night of 
polysomnography.  At baseline, there were no differences in any NPT parameter between the 
Vardenafil or placebo groups (table 5.1).  Vardenafil increased all parameters of NPT quality 
(base and tip tumescence and rigidity), but not number of erections compared to placebo 
(table 5.5).  An example NPT recording for one participant, allocated to Vardenafil and sham, 
with concurrent sleep staging and pulse oximetry at baseline and week 12, is shown in figure 
5.5. 
Using predefined parameters (section 3.2.6) to categorise participants into those with ED of 
either organic and psychological origin, using the PSG night for those whom completed it, or 
the best at-home recording for those who did not,  16 (37%) of participants were categorised 
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as having ED of psychological origin.  These participants did not differ from those categorised as 
having organic ED in terms of age, BMI, severity of OSA or blood parameters.  However, there 
was a significant difference in terms of subjective ED severity, as measured by the IIEF 
questionnaire. Men who were classified as having psychological ED by the traditional criteria 
had less severe subjective ED (IIEF-ED 15.8±7.4 vs 10.5±7.9, p=0.036).  Of all mood and quality 
of life parameters measured, only those related to mental health differed between men 
classified as having psychological versus organic ED.  Those men with organic ED were more 
depressed (12.44±10.9 vs 5.6±4.4, p=0.022), and scored lower in the domain of mental health 
(65.3±22.7 vs 80.7±12.15, p=0.016) and the mental health dimension (69.04±25.2 vs 84.3±14.1, 
p=0.033) in the SF-36 questionnaire.  A trend toward being more stressed (14.8±8.6 vs 
10.1±4.9, p=0.054) was also noted.  
 
Table 5.5 Effect of Vardenafil on Sleep Related Erections 
 Vardenafil Placebo   
 
Baseline 
(n=17) 
Week 12 
(n=15) 
Baseline 
(n=20) 
Week 12 
(n=13) 
Effect 
size (d) 
p-value 
Number of 
Erections 3.00 ± 2.09 3.40 ± 2.10 2.24 ± 2.10 3.23 ± 2.13 
 
 
0.08 
 
 
0.495 
Tip RAU 25.18 ± 22.60 58.87 ± 58.05 22.95 ± 26.19 31.77 ± 31.85 1.12 0.010 
Tip TAU 20.18 ± 17.84 48.47 ± 48.57 19.10 ± 21.10 19.23 ± 18.48 1.51 0.010 
Base RAU 49.00 ± 63.74 82.73 ± 66.79 31.85 ± 29.08 40.23 ± 35.34 0.88 0.003 
Base TAU 30.53 ± 31.33 63.87 ± 65.29 31.30 ± 41.86 23.54 ± 23.94 1.09 0.010 
Note: Values given are mean ± standard deviation.  *p-value obtained using mixed model analysis, 
RAU = Rigidity Activity Units, TAU = Tumescence Activity Units. Effect size (Cohen’s d) calculated by 
dividing difference between CPAP and sham by the standard deviation of all participants at baseline. 
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NOTE:  (A) Baseline recording with no treatment.  Several erectile episodes are seen mostly 
during REM sleep.   (B) Recording at Week 12 using Vardenafil. The number of episodes has not 
changed, however the total duration and quality has increased. SaO2 = Oxygen saturation 
B 
A 
Figure 5.5 Sleep staging, pulse oximetry and NPT for a patient allocated to Vardenafil. 
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5.4.4 Hormonal Analysis 
At study commencement, testosterone levels were borderline low (10.2±3.7 nmol/L).  Those 
allocated to Vardenafil had a minor increase in testosterone levels from baseline to Week 12 
(12.3±3.0, p=0.023) although this was no different than the change with placebo (11.1±4.5, 
p=0.384).  There was no change in luteinizing hormone, follicular stimulating hormone, or 
thyroid stimulating hormone.  
5.4.5 Quality of Life  
Very little change was found with Vardenafil on quality of life compared to placebo.  There was 
no change in levels of sleepiness in the ESS, anxiety or stress in the DASS questionnaire or any 
parameter in the FOSQ questionnaire (Table 5.6).  Only at week 8 were two domains improved 
with Vardenafil compared to placebo, firstly the SF-36 domain of vitality (p=0.01) and secondly, 
the depression domain in the DASS questionnaire, due to a worsening of depression with 
placebo (p=0.01).    
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Table 5.6 Effect of Vardenafil on quality of life  
Variable Visit 
Vardenafil  
(n=30) 
Placebo  
(n=31) 
Difference                      
Mean (95% CI) 
Effect 
size (d) p-value 
            
Epworth  Week 4 9.1 ± 5.4 8.9 ± 5.3 0.3 (-2.6 to 3.1) 0.04 0.663 
 Sleepiness  Week 8 9.3 ± 5.3 8.5 ± 5.0 0.8 (-2.1 to 3.6) 0.17 0.516 
 Score Week 12 8.0 ± 4.6 8.5 ± 5.1 -0.5 (-3.1 to 2.2) -0.10 0.625 
    
Functional Outcomes of Sleep (FOSQ)       
Overall  Week 4 97.4 ± 14.2 97.0 ± 14.6 0.4 (-7.5 to 8.2) 0.02 0.813 
 Score Week 8 98.4 ± 16.2 97.3 ± 15.0 1.1 (-7.5 to 9.7) 0.06 0.628 
  Week 12 98.5 ± 17.5 97.9 ± 17.2 0.6 (-9.2 to 10.4) 0.03 0.706 
Activity Week 4 3.4 ± 0.4 3.3 ± 0.6 0.0 (-0.3 to 0.3) 0.14 0.675 
  Week 8 3.4 ± 0.5 3.4 ± 0.6 0.0 (-0.3 to 0.3) 0.00 0.911 
  Week 12 3.4 ± 0.6 3.4 ± 0.7 -0.1 (-0.4 to 0.3) 0.00 0.611 
Vigilance Week 4 3.3 ± 0.7 3.3 ± 0.6 0.0 (-0.4 to 0.4) 0.00 0.408 
  Week 8 3.4 ± 0.6 3.4 ± 0.6 0.0 (-0.3 to 0.3) 0.00 1.000 
  Week 12 3.3 ± 0.8 3.3 ± 0.8 0.0 (-0.4 to 0.4) 0.00 0.941 
Intimacy Week 4 3.0 ± 0.1 3.0 ± 0.6 0.0 (-0.4 to 0.5) 0.00 0.657 
  Week 8 3.1 ± 0.8 3.2 ± 0.9 -0.1 (-0.6 to 0.3) -0.11 0.653 
  Week 12 3.2 ± 0.8 3.0 ± 1.1 0.2 (-0.6 to 0.7) 0.22 0.525 
Productivity Week 4 3.6 ± 0.4 3.6 ± 0.5 0.0 (-0.3 to 0.2) 0.00 0.889 
  Week 8 3.6 ± 0.4 3.7 ± 0.4 -0.1 (-0.3 to 0.2) -0.18 0.828 
  Week 12 3.5 ± 0.6 3.6 ± 0.5 -0.1 (-0.4 to 0.3) -0.18 0.888 
Social  Week 4 3.7 ± 0.6 3.8 ± 0.5 0.1 (-0.4 to 0.2) -0.13 0.756 
 Outcomes Week 8 3.8 ± 0.4 3.9 ± 0.4 0.1 (-0.3 to 0.2) -0.13 0.778 
  Week 12 3.6 ± 0.6 3.7 ± 0.7 0.0 (-0.4 to 0.3) -0.13 0.794 
        
Depression Anxiety Stress Scale (DASS)             
Depression Week 4 6.6 ± 9.3 8.5 ± 10.4 -1.9 (-7.1  to 3.4) -0.22 0.105 
  Week 8 6.4 ± 10.0 9.0 ± 11.0 -2.7 (-8.4  to 3.1) -0.29 0.006 
  Week 12 6.8 ± 9.0 7.7 ± 10.1 -0.9 (-6.1 to 4.3) -0.10 0.066 
Anxiety Week 4 3.8 ± 3.9 6.4 ± 5.9 -2.6 (-5.3 to 0.0) -0.45 0.272 
  Week 8 3.3 ± 3.8 8.0 ± 7.7 -4.7 (-8.1 to -1.4) -0.82 0.167 
  Week 12 2.7 ± 3.6 6.0 ± 6.9 -3.3 (-6.3 to -0.3) -0.57 0.745 
Stress Week 4 9.4 ± 7.7 10.4 ± 9.1 -1.0 (-5.4 to 3.5) -0.14 0.255 
  Week 8 9.1 ± 8.7 11.3 ± 10.4 -2.2 (-7.4 to 3.1) -0.30 0.197 
  Week 12 9.9 ± 8.0 11.0 ± 11.2 -1.1 (-6.4 to 4.2) -0.15 0.388 
             
Note: Values are raw means ± standard deviation.  p-value determined using mixed model analysis. 
Effect size (Cohen’s d) calculated by dividing difference between CPAP and sham by the standard 
deviation at baseline. 
 
(Continued over) 
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Table 5.6 Effects of Vardenafil on quality of life (continued) 
Variable Visit 
Vardenafil 
(n=30) 
Placebo 
(n=31) 
Difference                      
Mean (95% CI) 
Effect 
size (d) 
p-value 
Short-form 36 (SF-36)             
Physical  Week 4 79.5 ± 19.8 73.2 ± 27.3 6.3 (-6.5 to 19.2) 0.26 0.694 
 Function Week 8 82.1 ± 21.1 79.4 ± 24.2 2.7 (-9.9 to 15.2) 0.11 0.823 
  Week 12 82.3 ± 15.2 82.4 ± 22.3 -0.1 (-10.4 to 10.2) 0.00 0.365 
Role  Week 4 74.2 ± 30.4 66.9 ± 37.9 7.2 (-10.4 to 24.9) 0.21 0.497 
 Physical Week 8 75.9 ± 29.5 66.9 ± 37.9 8.9 (-8.7 to 26.6) 0.26 0.359 
  Week 12 75.9 ± 29.5 66.9 ± 37.9 8.9 (-8.6 to 26.4) 0.26 0.632 
Body Pain Week 4 74.2 ± 21.9 70.8 ± 29.2 3.4 (-10.3  to 17.0) 0.16 0.773 
  Week 8 74.0 ± 22.7 69.0 ± 27.1 5.0 (-8.6 to 18.7) 0.23 0.421 
  Week 12 75.5 ± 20.1 75.8 ± 26.6 -0.3 (-13.0 to 12.4) -0.01 0.794 
General  Week 4 68.1 ± 19.9 58.6 ± 26.0 9.5 (-2.9 to 21.9) 0.50 0.447 
Health  Week 8 71.0 ± 19.4 66.1 ± 24.9 4.9 (-7.3 to 17.1) 0.26 0.588 
  Week 12 67.7 ± 20.7 67.2 ± 24.3 0.5 (-11.7 to 12.7) 0.03 0.128 
Vitality Week 4 59.3 ± 21.9 56.4 ± 21.7 2.9 (-8.7 to 14.5) 0.13 0.187 
  Week 8 63.3 ± 16.8 56.5 ± 24.7 6.9 (-4.7 to 18.4) 0.31 0.013 
  Week 12 61.6 ± 20.4 59.6 ± 23.6 2.0 (-10.0 to 13.9) 0.09 0.157 
Social  Week 4 81.2 ± 23.7 73.4 ± 26.1 7.8 (-5.4 to 21.0) 0.31 0.367 
Function  Week 8 84.8 ± 20.8 79.8 ± 26.8 5.0 (-8.1 to 18.1) 0.20 0.518 
  Week 12 84.5 ± 20.8 79.2 ± 25.9 5.3 (-7.4 to 18.0) 0.21 0.521 
Role  Week 4 79.8 ± 35.6 69.2 ± 40.3 10.6 (-9.9 to 31.1) 0.30 0.275 
 Emotional Week 8 81.5 ± 32.5 70.4 ± 39.6 11.1 (-8.7 to 30.9) 0.31 0.335 
  Week 12 71.4 ± 34.9 72.9 ± 37.0 -1.5 (-21.0 to 18.0) -0.04 0.658 
Mental  Week 4 76.3 ± 19.7 69.3 ± 20.3 7.0 (-3.8 to 17.8) 0.38 0.197 
 Health  Week 8 78.1 ± 18.7 71.0 ± 22.2 7.1 (-4.1 to 18.3) 0.39 0.271 
 Scale Week 12 78.3 ± 19.8 74.1 ± 21.3 4.2 (-6.9 to 15.3) 0.23 0.745 
Physical  Week 4 71.9 ± 17.1 67.2 ± 22.3 4.7 (-6.2 to 15.5) 0.26 0.275 
 Health Week 8 73.2 ± 17.1 67.6 ± 25.1 5.7 (-6.3 to 17.7) 0.32 0.215 
  Week 12 73.8 ± 14.9 71.8 ± 23.7 2.0 (-8.6 to 12.7) 0.10 0.696 
Mental  Week 4 80.3 ± 22.0 71.8 ± 25.5 8.6 (-4.4 to 21.6) 0.38 0.204 
 Health  Week 8 81.4 ± 19.0 73.7 ± 24.3 7.7 (-4.2 to 19.7) 0.35 0.330 
Dimension  Week 12 78.0 ± 23.8 75.4 ± 25.5 2.6 (-10.8 to 15.9) 0.12 0.959 
            
Note: Values are raw means ± standard deviation.  p-value determined using mixed model analysis.  
Effect size (Cohen’s d) calculated by dividing difference between CPAP and sham by the standard 
deviation at baseline. 
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5.4.6 Adherence to medication   
Medication adherence, defined as the proportion of tablets taken over a given period was 
assessed.   Despite requests, not all participants returned unused tablets at each visit.  
Although 30 participants were allocated to Vardenafil, data is only available for 21 as 8 
participants did not return medication bottles, and 1 withdrew before treatment commenced. 
For placebo, data is only available for 24 participants as 5 did not return medication bottles, 
data was missing for 2 participants and 2 withdrew before treatment commenced. 
On the basis of those for whom data was available, medication adherence was not different 
between Vardenafil (84.0%) and placebo (84.5%) (p=0.915).  Adherence to medication, defined 
as taking 80% or more prescribed tablets was achieved by 71% of those taking Vardenafil, and 
75% of those taking placebo (p=0.999).  
5.4.7  Treatment Satisfaction 
At Weeks  4, 8 and 12, participants were asked about their satisfaction with treatment as it 
referred to erectile function using the Erectile Dysfunction Inventory of Treatment Score 
(EDITS).  All items on the EDITS were scored from zero (no satisfaction or dissatisfaction) to four 
(high satisfaction). The mean satisfaction score for each patient was calculated. Each mean 
score was multiplied by 25 giving a range between 0 (extremely low treatment satisfaction) to 
100 (extremely high treatment satisfaction). At all timepoints, those who received Vardenafil 
were more satisfied overall than those who received placebo (table 5.7).   
A score of over 50 in the Erectile Dysfunction Inventory of Treatment Score (EDITS) is 
considered to represent satisfaction with treatment [525].  Figure 5.6 shows the percentage of 
participants satisfied with treatment for Vardenafil versus placebo. Only at Week 4 was there a 
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significant difference (p=0.0001) in the number of participants considered to be satisfied with 
treatment with Vardenafil over placebo.  
 
Table 5.7: Treatment Satisfaction Score for Vardenafil  
  
Vardenafil          
(n=28) 
Placebo                   
(n=27) 
p-value 
Week 4 72.4 ± 15.3 46.3 ± 21.7 <0.001 
Week 8 67.2 ± 21.5 51.0 ± 22.4 0.007 
Week 12 70.5 ± 19.9 50.4 ± 23.8 0.004 
Note: Values are mean ± standard deviation.  p-value determined using mixed model analysis 
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Figure 5.6: Percentage of participants satisfied with treatment for erectile function 
Note: Treatment satisfaction defined as a score of more than 50 in the EDITS questionnaire.  
*p<0.05 determined using Fishers exact test. 
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5.5 DISCUSSION 
This is the first randomised controlled trial to study the effects of daily low dose Vardenafil in 
men with OSA and ED on subjective sexual function, sleep related erections, and quality of life. 
We have studied 61 men with severe OSA and moderate ED. At Week 12, Vardenafil did not 
improve subjective erectile function more so than placebo, however, it did improve nocturnal 
erections, as well as self-confidence, reduced distress due to erectile dysfunction, and there 
was a higher degree of satisfaction, although there was no difference in the number of men 
satisfied with Vardenafil compared to placebo.  There were very minimal improvements in 
mood and quality of life with Vardenafil.   
5.5.1 Effect of Vardenafil on OSA 
The current study provided an opportunity to investigate the effect of a lower daily dose 
(10mg) of Vardenafil on breathing during sleep in untreated OSA by assessing the effect in 
those allocated to sham CPAP, that is, those who were untreated for their sleep apnoea.   
Unlike that of a previous study using an on-demand 50mg dose of Sildenafil [464], daily dose 
10mg Vardenafil did not show any worsening of OSA in terms of AHI, ODI, minimum oxygen 
saturation, nor time with oxygen levels below 90%, compared to placebo.   This difference may 
also be due to a different PDE-5 inhibitor, or a lower dose, both of which may reduce unwanted 
side effects in regards to unintentional upper airway muscle relaxation or other sleep apnoea-
worsening effects.  
5.5.2 Subjective Erectile Function 
The present study is the first to investigate the efficacy of low dose daily Vardenafil on 
subjective erectile function, specifically in patients with OSA. A low daily dose was used rather 
than a higher dose on-demand in an effort to obtain efficacy without the risk of worsening OSA.  
In a previous study of men with OSA status not reported, a 12 week daily dose 10mg versus on-
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demand 10mg use of Vardenafil showed no difference between the two in regards to 
treatment efficacy [119]. However, another study showed a reduced efficacy with daily dosage 
over on-demand administration of Vardenafil in men with after a prostatectomy [120]. This 
difference may be due to differing patient groups. The first study recruited patients with ED of 
unspecified cause; the other studied all patients undergoing prostatectomy who previously had 
normal erectile function.  The former more closely matches the present study population. In 
this OSA population, 12 weeks of a daily dose of 10mg Vardenafil did not improve subjective 
erectile function compared to placebo. These results support those found in a previous study of 
Sildenafil on-demand in men with OSA in which the efficacy was found to be reduced in men 
with OSA compared to other populations studied [485]. Potentially, the presence of OSA may 
limit the efficacy of Vardenafil.  One potential mechanism to explain this may be due to 
repetitive hypoxic episodes which may limit the amount of circulating nitric oxide, which is 
imperative to dilate vessels for erections to occur. Another may be due to the presence of 
psychological factors, such as depression, due to untreated OSA, influencing erectile function, 
which Vardenafil does not overcome.  
The majority of studies of PDE-5 inhibitor efficacy have mostly been conducted in non-OSA 
populations.  A meta-analysis of 9 non-OSA studies, comprising 6809 participants, found 
overall, an increase of 6.2 points in the IIEF-ED domain with at least 12 weeks of Vardenafil.  In 
the present study, at the end of the first and second months of treatment, Vardenafil improved 
erectile function compared to placebo by 5.4 and 5.3 points in the IIEF-ED domain respectively.  
However, the increase at study endpoint was 4.0 points, which was not statistically different 
from placebo. However, an increase of 4 points is considered clinically meaningful [412]. No 
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other study has reported a decline in responsiveness to Vardenafil or any other PDE-5 inhibitor 
over time; however, such regular assessments in the first 3 months have not been reported.   
The majority of previous studies have been performed using Vardenafil in an on-demand 
administration regime, rather than daily dose [571-573].  In previous studies, in men with OSA 
status undefined, the first multicentre randomised controlled trial in 580 patients using 
differing doses of Vardenafil on-demand showed an improvement of 8.8 points in the ED 
domain when 10mg was used [571].  None of these patients had diabetes and overall had less 
severe ED, were younger and thinner than the present study.  In a follow up study, a large 
multisite randomised controlled study of 760 patients, again using differing dosages of 
Vardenafil on-demand, the patient population was similar to that of the current study in terms 
of ED severity, age, proportion of patients with diabetes, hypertension, but were slightly less 
overweight (BMI 28.8 vs 32.9kg/m2) than the current study [572], but the status of OSA was 
unknown and not listed as an exclusion criteria.  In this latter study, the IIEF-ED domain 
increased by 7.2 points with 10mg Vardenafil used on demand.  The current study, using the 
same dosage, but more often, was only able to increase IIEF-ED domain by 4.4 points, 
suggesting there may be some inhibitory factor reducing efficacy in OSA patients.  
In the current study, only 44% of men of men allocated to Vardenafil (and sham CPAP, that is, 
being untreated for OSA) reported an improvement in ED, as measured by an increase by more 
than 4 points in the IIEF-ED domain.  This supports the results of the only other study 
investigating the effects of PDE-5 inhibitors in men with OSA, in which only 44% of men had an 
improvement in erectile function with 20mg Vardenafil  [431]. Similarly, a meta-analysis of 15 
studies showed that Vardenafil on-demand was found to improve erections in 77% of men 
(with OSA status undefined) compared to 27% of those on placebo [121].  A return to normal 
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erectile function, that is, an IIEF-ED score of greater than 26, was achieved by only 25% of those 
randomised to Vardenafil in the current study, compared to 7% of those allocated to placebo. 
Stratification by baseline ED severity did not show any differences with response to Vardenafil, 
perhaps due to insufficient power to detect such a change. In a study of a non-OSA population, 
6 months of Vardenafil 10mg on-demand was sufficient for 43% of men to return to a normal 
level of erectile function (compared to 12.6% with placebo), with severity of baseline ED 
significantly influencing this rate (89% for those with mild ED down to 25% of those with severe 
ED).   
The effect of Vardenafil on sexual function in the presence of other medical conditions has 
previously been explored in a small number of studies.  A prospective study investigating the 
effects of Vardenafil after nerve sparing prostatectomy, recruited 440 men with ED of similar 
age to that of the current study to take part in a dose comparison study [574].  In those 
allocated to take 10mg on-demand, an improvement in ED by 6 points in the IIEF-ED domain 
was seen.  In a study of men with diabetes and ED, those allocated to 10mg Vardenafil on-
demand also found an improvement in IIEF-ED of 6 points [573]. The population in this study all 
had diabetes and more severe ED than the current study, though they were of a similar age and 
BMI. The presence or absence of OSA was not reported, or excluded.  The current study found 
less efficacy, with an improvement by 4-5 points in the IIEF-ED domain. The reasons for this 
discrepancy may be due to a difference in ED severity, or that OSA may inhibit the efficacy of 
this medication through exposure to repetitive intermittent hypoxia, or an on-demand regime 
may be more effective in this population.     
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5.5.3 Sleep Related Erections 
Although subjective erectile function did not improve, significant improvements in objectively 
measured sleep related erections (SRE’s) were seen with Vardenafil compared to placebo in 
this OSA population. In two previous studies of young healthy men with normal erectile 
function, a dose of 100mg of Sildenafil increased SRE parameters as measured by Rigiscan [130, 
131]. Additionally, in a study of men with ED, 100mg of Sildenafil at bedtime also improved 
SRE’s in terms of Rigiscan tumescence activity units (TAU) and rigidity activity units (RAU) at 
both the base and the tip of the penis, without an increase in the number of episodes during 
sleep [569].  The current study mirrors these results. A study conducted in 1996, soon after the 
measurement units RAU and TAU were included in the assessment software, concluded that tip 
TAU was the best overall measurement correlating with the diagnosis of erectile dysfunction, 
closely followed by both base TAU and RAU [575].   In those allocated to Vardenafil, the current 
study found improvements in all four parameters,  suggesting that Vardenafil is effective in 
improving nocturnal erections in the presence of obstructive sleep apnoea. Normative values 
are not available for sleep related erections, which may have provided some insight into the 
extent of improvements with Vardenafil, given the finding that Vardenafil increases the 
tumescence and rigidity of sleep related erections in young healthy men without ED, as well as 
in older men with OSA with ED. Despite this increase in SRE’s, this did not translate to an 
improvement in subjective functioning, suggesting there may be another factor involved. The 
small numbers of participants monitored limit the interpretation of this result, which warrants 
further investigation.      
5.5.4 Quality of Life 
Several studies have shown that ED can have a negative impact on quality of life [530, 531, 558]  
however, many of the major studies in the efficacy of Vardenafil on erectile function do not 
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report on this aspect [119, 132, 571, 572].  In the current study of men with OSA, the only 
improvement in quality of life parameters seen was that of the domain of Vitality at the week 8 
time point, but this was no longer different at week 12. The change seen was an improvement 
between 9.5-13.5 points with Vardenafil at the different time points (compared to placebo 2.5-
5.5) which, using a definition of 7.5 as being clinically meaningful [576], suggests that the use of 
Vardenafil treatment in those with ED in OSA can improve quality of life in terms of Vitality. 
This supports the findings of a study in 121 Spanish men with ED, in which 12 weeks of flexible 
dose Vardenafil (administration method not described) improved the SF-36 domain of Vitality 
compared to placebo, but no other domain [577]. The domain of Vitality has been shown in 
several clinical trials to be sensitive to treatment effects in areas such as hypertension, AIDS 
and prostate disease, with a 5 point reduction associated with a significant risk of social 
consequences such as being unable to work and hospitalisation [576].  Unlike the present 
study, an uncontrolled study in 40 Japanese men with ED, but otherwise healthy, at least one 
month of on-demand Sildenafil showed improvements from baseline in physical function, 
general health and role emotional domains however there was no control group, making 
interpretation difficult [578].   
The majority of studies assessing the effect of PDE-5 inhibitors on quality of life have been in 
disease specific populations, with effects dependent upon the disease studied. In a randomised 
controlled study of male and female subjects (n=42) with tinnitus, 12 weeks of twice daily 
Vardenafil did not improve tinnitus levels, nor any domain of the SF-36 compared to placebo 
[579].   The use of Sildenafil in patients with pulmonary arterial hypertension has been shown 
to improve the domains of physical functioning, general health and vitality in the SF-36 
compared to placebo, which was attributed to a greater exercise capacity due to Vardenafil by 
 - 225 - 
the correlation with improvements in the 6-minute walk test [580, 581].  A study of patients 
with benign prostatic hyperplasia had an improved quality of life due to Vardenafil, compared 
to placebo, which may be due to its effect on lower urinary tract symptoms [582].  In an 
uncontrolled study of hemodialysis patients with ED, improvements in the two domains of 
physical and mental components of the SF-36 have been noted with 4 weeks of open label 
10mg on-demand Vardenafil [583].  Unlike these studies, Vardenafil does not appear to 
improve other non-erectile dysfunction facets of OSA, and as such, does not improve quality of 
life.  
5.5.5 Treatment Satisfaction 
Although the overall score regards treatment satisfaction was higher with Vardenafil compared 
to placebo, there was no difference between Vardenafil and placebo in the number of 
individuals who found the treatment satisfactory.  This suggests there was individual variability 
regards to treatment response.  Only 70% were satisfied with Vardenafil, compared to 48% of 
placebo.  This result, however, should be interpreted within the context of CPAP treatment also 
being concurrently used.  There was no distinction made when the questionnaire was asked, as 
to which treatment (CPAP or Vardenafil) the questionnaire referred.  Treatment satisfaction 
was similar (75% vs 48%) when CPAP and sham CPAP was compared.   
A recent large (n=7496) multicentre study of 12 months duration reported that 95% of 
participants were satisfied with the efficacy of Vardenafil [584].  This study used a variety of 
doses of Vardenafil, titrated for each patient, with the most common dose (66%) being 20mg.  
There is no detail regarding if administration regime was on demand or daily.   Potentially, this 
study may differ from the current study, since the dosage was customised to each patient, 
whereas this study was a standard dose.  Given the higher BMI in this study, 10mg may not be 
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sufficient.  A larger (n=73,946), older non-placebo controlled study, also found more than 90% 
of participants satisfied with Vardenafil [585].   The current study did not show such high 
satisfaction rates, which may be due to dilution by the influence of CPAP/sham CPAP or dosage.  
Given the lack of subjective improvement with Vardenafil, however, this level of treatment 
satisfaction may well be representative despite these differences.  
5.5.6 Strengths and Limitations 
This is the first placebo controlled study assessing the efficacy of daily dose Vardenafil in men 
with OSA and ED.  Placebo control is imperative in this area of research, given the subjective 
nature of the reporting of sexual function.  Additionally, the addition of the objective measure 
of erectile function, nocturnal penile tumescence, provides an insight into the physiological 
aspects of erectile function, which is often not measured in clinical trials.  A limitation of the 
study, however, is low patient numbers.  More participants may have revealed more 
information, and provided sufficient power to investigate more sub-analyses to further 
understand the influence of psychological factors and initial ED severity.   
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5.6 CONCLUSION 
This study showed that 10mg daily Vardenafil did not worsen sleep disordered breathing.  An 
improvement in sleep related erections occurred, however, this did not translate to an 
improvement in subjective erectile function in this group of men with OSA and ED. The 
physiological basis of sleep related erections is not completely understood, however, they may 
act to prevent fibrosis in the corpora cavernosa.  Vardenafil improved these erections, which 
may act to maintain erectile capacity. The efficacy of Vardenafil in men with OSA appears to be 
less effective than in that of the general population, the cause of which is unknown but may be 
due to repetitive hypoxia limiting nitric oxide, or psychological factors.  Clinically meaningful 
improvements may occur with Vardenafil use; however, this is not statistically different than 
placebo. Although distress caused by erectile dysfunction was alleviated by 10mg Vardenafil in 
this population, quality of life, overall, was not improved.  A low daily dose of Vardenafil may 
be of clinical benefit to some patients with OSA and ED, and can be used without risk of 
worsening sleep disordered breathing. 
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6. Overall Conclusions 
 
OSA and erectile dysfunction are frequently associated with each other. Currently, there is no 
high level evidence to inform decisions on how best to treat men with OSA and erectile 
dysfunction. This thesis investigated the relationship between the triad of OSA, sexual function, 
and testosterone using two randomised controlled trials.  
The first randomised controlled trial of compared exogenous testosterone administration with 
placebo in men with untreated OSA and obesity.  The second study, designed as a factorial 
study, assessed the impact of CPAP versus sham CPAP, as well as the PDE-5 inhibitor, Vardenafil 
versus placebo on sexual function and quality of life parameters.  
On an intention to treat basis, neither CPAP use, exogenous testosterone treatment nor a PDE-
5 inhibitor improved erectile function. In contrast, post-hoc analysis revealed that adherent 
CPAP use did improve erectile function over the same period. Similarly, sexual desire was 
increased by the adherent use of CPAP, as well as by testosterone treatment, but not by a PDE-
5 inhibitor.  Importantly, for a practical clinical point of view, only one third of participants 
were adherent with CPAP, leaving two-thirds of men with OSA inadequately treated, or not at 
all.   
This thesis also showed that efficacious use of CPAP treatment improves not only sexual health, 
but many other facets of quality of life.  The psychological factors related to ED have not been 
mentioned in previous literature related to OSA and ED.  Given the high rates of depression, 
sleepiness, and relationship breakdown with OSA, there may be a tri-directional relationship 
between OSA, psychological factors and erectile dysfunction.  Breaking this cycle by 
successfully treating OSA with CPAP has been shown in this study to improve rates of 
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sleepiness, depression, stress, as well as erectile function and sexual function.  Providing PDE-5 
inhibitors does not improve any psychological factors measured in this study and was not 
effective in increasing either erectile function or sexual desire.  Further research is required to 
investigate this potential causal pathway, in order to fully understand the mechanisms behind 
the association of OSA and ED.  
Detailed review of the literature reveals that the widely held belief that OSA is associated with 
reduced libido may not be the case.   Many papers do not cite a reference, and those that do 
often cite Guilleminault, et al 1977, as robust evidence that OSA is associated with low libido, 
with no current evidence to corroborate this assertion.  When this paper was written in 1977, 
there was no distinction made between libido and erectile dysfunction in the medical 
literature, which is apparent in the wording “Twelve patients reported impotence.  Abatement 
of sexual drive had progressed slowly…”.  At present, there is no evidence clearly 
demonstrating a robust independent link between OSA and reduced libido.  The research 
reported in this thesis, however, has been the first to clearly show, via a randomised controlled 
study that regular use of CPAP increases sexual desire.  This conclusion however, due to study 
inclusion criteria, applies only to men with erectile dysfunction.  Further studies are needed to 
widen this understanding to include men who do not present with erectile dysfunction.   
The importance that many men place on good sexual health should be used as an incentive to 
encourage regular CPAP use.  This thesis provides high quality evidence that the use of CPAP 
for more than four hours a night is able to improve erectile function and sexual desire. Given 
the poor adherence rates achieved not only in this study, but many others, the knowledge of 
the positive impact on sexual health by CPAP should be widely disseminated, in an effort to 
improve adherence with treatment, and reduce cardiovascular risk.  
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